The ethical aspects of biomedical research
in developing countries

(cid:1)(cid:2)(cid:3)(cid:4)(cid:5)(cid:5)(cid:6)(cid:7)(cid:8)(cid:9)(cid:10)(cid:11)(cid:3)(cid:12)(cid:11)(cid:13)(cid:14)(cid:5)(cid:11)(cid:15)(cid:3)(cid:16)(cid:8)(cid:6)(cid:11)(cid:17)(cid:18)(cid:19)(cid:20)(cid:5)(cid:11)(cid:21)(cid:5)(cid:19)(cid:18)(cid:13)(cid:5)(cid:27)

(cid:1)(cid:2)(cid:3)(cid:4)(cid:4)(cid:5)(cid:6)(cid:4)(cid:7)(cid:8)(cid:9)(cid:10)(cid:11)(cid:12)(cid:13)(cid:5)(cid:2)(cid:8)(cid:14)(cid:4)(cid:11)(cid:7)(cid:8)(cid:15)(cid:16)(cid:16)(cid:15)

Secretariat of the EGE

European Group on Ethics in Science and New Technologies to the European Commission

(cid:17)(cid:8)(cid:18)(cid:5)(cid:13)(cid:2)(cid:3)(cid:19)(cid:2)(cid:20)(cid:8)(cid:15)(cid:16)(cid:16)(cid:21)(cid:8)(cid:17)

*Report written by Katerina Sukovski, a trainee with the Secretariat of the European Group on Ethics in
Science and New Technologies to the European Commission  from October 1st , 2002 to Febuary 28th,
2003.

                                                
(cid:1)(cid:2)(cid:3)(cid:4)(cid:5)(cid:6)(cid:7)(cid:8)(cid:9)(cid:3)(cid:6)(cid:10)(cid:11)(cid:7)(cid:9)(cid:12)(cid:7)(cid:13)(cid:7)(cid:12)(cid:6)(cid:3)(cid:14)(cid:9)(cid:10)(cid:6)(cid:7)(cid:11)(cid:4)(cid:7)(cid:15)(cid:6)(cid:16)(cid:5)(cid:7)(cid:17)(cid:4)(cid:2)(cid:7)(cid:18)(cid:9)(cid:19)(cid:20)(cid:7)(cid:13)(cid:19)(cid:12)(cid:21)(cid:6)(cid:3)(cid:12)
(cid:11)(cid:4)(cid:7)(cid:17)(cid:4)(cid:2)(cid:3)(cid:7)(cid:22)(cid:2)(cid:6)(cid:12)(cid:11)(cid:9)(cid:4)(cid:19)(cid:12)(cid:7)(cid:13)(cid:23)(cid:4)(cid:2)(cid:11)(cid:7)(cid:11)(cid:15)(cid:6)(cid:7)(cid:1)(cid:2)(cid:3)(cid:4)(cid:5)(cid:6)(cid:13)(cid:19)(cid:7)(cid:24)(cid:19)(cid:9)(cid:4)(cid:19)

(cid:1)(cid:2)(cid:3)(cid:4)(cid:5)(cid:6)(cid:2)(cid:2)(cid:7)(cid:8)(cid:9)(cid:10)(cid:2)(cid:4)(cid:10)(cid:11)(cid:12)(cid:13)(cid:2)(cid:6)(cid:14)
(cid:15)(cid:15)(cid:4)(cid:16)(cid:15)(cid:15)(cid:4)(cid:17)(cid:4)(cid:18)(cid:4)(cid:16)(cid:4)(cid:19)(cid:4)(cid:20)(cid:15)(cid:4)(cid:20)(cid:20)

A great deal of additional information on the European Union is available on the Internet.
It can be accessed through the Europa server (http://europa.eu.int).

Cataloguing data can be found at the end of this publication.

Luxembourg: Office for Official Publications of the European Communities, 2003

ISBN 92-894-5064-9

© European Communities, 2003
Reproduction is authorised provided the source is acknowledged.

(cid:1)(cid:2)(cid:3)(cid:4)(cid:5)(cid:6)(cid:7)(cid:8)(cid:3)(cid:4)(cid:8)(cid:9)(cid:10)(cid:11)(cid:6)(cid:12)(cid:13)(cid:14)(cid:10)(cid:2)(cid:15)

PRINTED ON WHITE CHLORINE-FREE PAPER

(cid:22)(cid:19)(cid:13)(cid:6)(cid:5)(cid:8)(cid:12)(cid:23)(cid:8)(cid:24)(cid:12)(cid:25)(cid:11)(cid:5)(cid:25)(cid:11)(cid:4)

Introduction ................................................................................................................................ 1

Agenda....................................................................................................................................... 3

Moral Pluralism
Søren HOLM .............................................................................................................................. 7

Norms, Values and Trans-Cultural Medical Ethics
Monica KONRAD ..................................................................................................................... 11

Ethics of clinical collaboration with developing countries: controversial issues
Reidar K. LIE............................................................................................................................ 21

ICMR’s approach concerning the ethics of clinical research in India
Vasantha MUTHUSWAMY....................................................................................................... 27

HIV/AIDS clinical research in Africa: ethical aspects
Nicolas MEDA .......................................................................................................................... 33

Ethical issues in the pneumococcal conjugate vaccine clinical trials in the Philippines:
the ARIVAC experience
Hanna NOHYNEK .................................................................................................................... 43

Ethical aspects of conducting clinical trials in developing countries: Experiences of
GlaxoSmithKline (GSK).
Nadia TORNIEPORTH............................................................................................................. 51

Discussion................................................................................................................................ 59

Curriculum Vitae of the Speakers............................................................................................. 71

Participants............................................................................................................................... 87

Secretariat of the EGE ............................................................................................................. 95

(cid:26)(cid:25)(cid:11)(cid:2)(cid:12)(cid:27)(cid:3)(cid:10)(cid:11)(cid:28)(cid:12)(cid:25)

The  European  Group  on  Ethics  (EGE)1  is  an  independent,  pluralist  and  multidisciplinary  body,  which
advises  the  European  Commission on  ethical  aspects  of  science  and  new  technologies  in  connection
with the preparation and implementation of Community legislation or policies.

The Group is composed of twelve independent experts appointed by the Commission for their expertise
and personal qualities.

The Group is presently preparing its 17th Opinion on “(cid:1)(cid:2)(cid:3)(cid:4)(cid:3)(cid:1)(cid:2)(cid:5)(cid:6)(cid:7)(cid:8)(cid:4)(cid:7)(cid:9)(cid:10)(cid:3)(cid:6)(cid:1)(cid:9)(cid:4)(cid:11)(cid:12)(cid:4)(cid:13)(cid:5)(cid:11)(cid:14)(cid:3)(cid:15)(cid:5)(cid:6)(cid:7)(cid:8)(cid:4)(cid:16)(cid:3)(cid:9)(cid:3)(cid:7)(cid:16)(cid:6)(cid:2)(cid:4)(cid:5)(cid:17)
(cid:15)(cid:3)(cid:18)(cid:3)(cid:8)(cid:11)(cid:10)(cid:5)(cid:17)(cid:19)(cid:4) (cid:6)(cid:11)(cid:20)(cid:17)(cid:1)(cid:16)(cid:5)(cid:3)(cid:9)(cid:21).  This  reflection  work  has  been  requested  on  behalf  of  the  European
Commission.  The  EU  Sixth  Framework  Research  Program  (FP6),  adopted  on  the  3rd  of  June  2002,
defines thematic priority fields for 2002-2005, open to collaboration also for non-EU countries. Within the
FP6, a European and Developing Countries Clinical Trials Partnership aiming at joining efforts to combat
poverty  linked  diseases,  such  as  AIDS,  malaria  and  tuberculosis,  is  being  set  up  and  will  involve
developing countries.

In preparing its  opinions,  the  EGE  is  open to  broad  consultation,  involving  experts,  representatives  of
European institutions and other international institutions as well as representatives of civil society. The
objective  of  the  Round  Table  organized  by  the  Group  is  to  promote  transparency  dialogue  between
parties representing different interests.

The round table organized by the European Group on Ethics was held on October 1st, 2002, in order to
stimulate  dialogue  and  reflection  on  the  ethical  aspects  raised  by  clinical  research  in  developing
countries. The following report is a summary of the presentations and discussions which took place.

Christiane Bardoux
Secretary of the EGE

1 More information on the EGE is available on the website:
http://europa.eu.int/comm/european_group_ethics

1

                                                
(cid:29)(cid:29)(cid:9)(cid:9)(cid:30)(cid:30)(cid:31)(cid:31)  (cid:8)(cid:8)(cid:22)(cid:22)!!(cid:1)(cid:1)""##
#(cid:11)$(cid:28)(cid:10)(cid:19)(cid:6)(cid:8)(cid:19)(cid:4)%(cid:5)(cid:10)(cid:11)(cid:4)(cid:8)(cid:12)(cid:23)(cid:8)(cid:13)(cid:28)(cid:12)&(cid:5)(cid:27)(cid:28)(cid:10)(cid:19)(cid:6)(cid:8)(cid:2)(cid:5)(cid:4)(cid:5)(cid:19)(cid:2)(cid:10)$(cid:8)(cid:28)(cid:25)(cid:8)(cid:27)(cid:5)’(cid:5)(cid:6)(cid:12)%(cid:28)(cid:25)((cid:8)(cid:10)(cid:12)(cid:3)(cid:25)(cid:11)(cid:2)(cid:28)(cid:5)(cid:4)

(cid:22)(cid:3)(cid:5)(cid:4)(cid:27)(cid:19)(cid:20)(cid:8)(cid:14)(cid:4)(cid:11)(cid:8)(cid:9)(cid:10)(cid:11)(cid:12)(cid:13)(cid:5)(cid:2)(cid:7)(cid:8)(cid:15)(cid:16)(cid:16)(cid:15)(cid:7)(cid:8)(cid:1)(cid:2)(cid:3)(cid:4)(cid:4)(cid:5)(cid:6)(cid:4)

(cid:22)(cid:16)(cid:19)(cid:7)(cid:17)(cid:5)(cid:9)(cid:3)(cid:15)(cid:4)(cid:13)(cid:23)(cid:4)(cid:1)(cid:2)(cid:3)(cid:4)(cid:24)(cid:20)(cid:16)(cid:11)(cid:10)(cid:3)(cid:7)(cid:17)(cid:4)(cid:25)(cid:16)(cid:11)(cid:20)(cid:10)(cid:4)(cid:11)(cid:17)(cid:4)(cid:24)(cid:1)(cid:2)(cid:5)(cid:6)(cid:9)(cid:4)(cid:5)(cid:17)(cid:4)(cid:26)(cid:6)(cid:5)(cid:3)(cid:17)(cid:6)(cid:3)(cid:4)(cid:7)(cid:17)(cid:15)(cid:4)(cid:27)(cid:3)(cid:28)(cid:4)(cid:29)(cid:3)(cid:6)(cid:2)(cid:17)(cid:11)(cid:8)(cid:11)(cid:19)(cid:5)(cid:3)(cid:9)

(cid:1)(cid:2)(cid:3)(cid:4)(cid:5)(cid:1)

10:00 

(cid:1)(cid:2)(cid:3)(cid:4)(cid:5)(cid:6)(cid:2)(cid:7)(cid:8)(cid:9)(cid:7))*(cid:2)(cid:19)(cid:25)(cid:8)+#(cid:29),#(cid:29)-(cid:31), Vice-President of the European Group on Ethics
(cid:10)(cid:11)(cid:2)(cid:12)(cid:2)(cid:13)(cid:14)(cid:15)(cid:14)(cid:16)(cid:5)(cid:13)(cid:7)(cid:5)(cid:17)(cid:7)(cid:14)(cid:18)(cid:2)(cid:7)(cid:19)(cid:20)(cid:21)(cid:11)(cid:5)(cid:22)(cid:2)(cid:15)(cid:13)(cid:7)(cid:15)(cid:13)(cid:23)(cid:7)(cid:24)(cid:2)(cid:25)(cid:2)(cid:3)(cid:5)(cid:22)(cid:16)(cid:13)(cid:26)(cid:7)(cid:27)(cid:5)(cid:21)(cid:13)(cid:14)(cid:11)(cid:16)(cid:2)(cid:12)(cid:7)(cid:27)(cid:3)(cid:16)(cid:13)(cid:16)(cid:4)(cid:15)(cid:3)(cid:7)(cid:28)(cid:11)(cid:16)(cid:15)(cid:3)(cid:12)(cid:7)(cid:10)(cid:15)(cid:11)(cid:14)(cid:13)(cid:2)(cid:11)(cid:12)(cid:18)(cid:16)(cid:22)(cid:29)

(EDCTP) by (cid:9)(cid:10)(cid:11)(cid:19)’(cid:28)(cid:8).(cid:30)(cid:26)(cid:31)(cid:22)!(cid:31)!(cid:8)(cid:22)(cid:29)(cid:26)!/, Director, DG Research (Health)

10:15

/(cid:12)(cid:2)(cid:5)(cid:25)(cid:8)+(cid:12)(cid:6)&: “Moral pluralism” (Manchester, UK)

10:35

,(cid:12)(cid:25)(cid:28)(cid:10)(cid:19)(cid:8)0(cid:12)(cid:25)(cid:2)(cid:19)(cid:27): “Norms and values” (Cambridge, UK)

10:55

(cid:29)(cid:5)(cid:28)(cid:27)(cid:19)(cid:2)(cid:8)01(cid:8)"(cid:28)(cid:5): “Ethics of clinical collaboration with developing countries, controversial issues

and solutions” (Bergen, NO)

11:15

Discussion

(cid:14)(cid:21)2(cid:16)(cid:16)

3(cid:8)3(cid:8)3(cid:8)3(cid:8)3(cid:8)3(cid:8)3(cid:8)3(cid:8)3(cid:8)3(cid:8)3(cid:8)3(cid:8)3(cid:8)3(cid:8)3(cid:8)3(cid:8)3(cid:8)(cid:8)(cid:8)"(cid:8)(cid:30)(cid:8)(cid:31)(cid:8)(cid:24)(cid:8)+(cid:8)(cid:8)(cid:8)(cid:8)3(cid:8)3(cid:8)3(cid:8)3(cid:8)3(cid:8)3(cid:8)3(cid:8)3(cid:8)3(cid:8)3(cid:8)3(cid:8)3(cid:8)3(cid:8)3(cid:8)3(cid:8)3(cid:8)3

14:30

14:50

15:10

15:30

4(cid:19)(cid:4)(cid:19)(cid:25)(cid:11)$(cid:19)(cid:8),(cid:3)(cid:11)$(cid:3)(cid:4)5(cid:19)&(cid:20): “ICMR’s approach concerning the ethics of clinical research in India”
(New Delhi, India)

(cid:31)(cid:28)(cid:10)(cid:12)(cid:6)(cid:19)(cid:4)(cid:8),(cid:5)(cid:27)(cid:19): “HIV/AIDS clinical research in Africa: ethical aspects”
(Burkina Faso, West Africa)

+(cid:19)(cid:25)(cid:25)(cid:19)(cid:8)(cid:31)(cid:12)$(cid:20)(cid:25)(cid:5)6: “Pneumoccal vaccine clinical trials in Philippines: ethical aspects“
(Helsinki, FIN)

(cid:31)(cid:19)(cid:27)(cid:28)(cid:19)(cid:8)(cid:22)(cid:12)(cid:2)(cid:25)(cid:28)(cid:5)%(cid:12)(cid:2)(cid:11)$: “Ethical aspects of clinical trials in developing countries: concrete
experiences of GSK” (Rixensart, Belgium)

15:50

Discussion

17:00

End of the Round Table

3

(cid:30)(cid:16)(cid:3)(cid:9)(cid:3)(cid:17)(cid:1)(cid:7)(cid:1)(cid:5)(cid:11)(cid:17)(cid:9)

/7(cid:2)(cid:5)(cid:25)(cid:8)+(cid:9)",
Dr. Søren Holm
University of Manchester & University of Oslo

,(cid:12)(cid:2)(cid:19)(cid:6)(cid:8)8(cid:6)(cid:3)(cid:2)(cid:19)(cid:6)(cid:28)(cid:4)&

(cid:6)(cid:7)(cid:8)(cid:9)(cid:10)(cid:11)(cid:12)(cid:13)(cid:14)(cid:15)

This  presentation  represents  a  philosophical  perspective  on  the  ethical  implications
of  clinical  research  through  the  discussion  of  the  nature  of  moral  pluralism.  Moral
pluralism is the idea that moral values and/or moral judgements are not universal and
that moral nihilism is false. It is thus a rejection of moral universalism, but a rejection
that keeps open a space for moral discourse.

There are a number of different forms of moral pluralism. These differ with regard to
how  ‘deep’  the  pluralism  is  supposed  to  be.  The  most  common  form  of  moral
pluralism  is  the  so-called  ‘(cid:1)(cid:2)(cid:3)(cid:4)(cid:2)(cid:5)(cid:6)(cid:3)(cid:7) (cid:5)(cid:8)(cid:3)(cid:6)(cid:4)(cid:9)(cid:10)(cid:9)(cid:11)(cid:12)’  which  typically  claims  that  moral
values and moral judgements differ between cultures (as an empirical statement this
is fairly uncontroversial). It also implies that there is no deeper/higher level of moral
thinking that can show the moral values of a given culture to be wrong which entails a
rejection  of  foundationalism  in  ethics.  And  finally,  that  we  should  be  tolerant  of  the
moral values and judgements of other cultures.

According to cultural relativism moral discussion and criticism is thus possible within
a culture, but not between cultures except in the areas where they share values. This
concept  may  sound  attractive  because  it  seemingly  supports  cultural  tolerance  and
offers  a  platform  from  which  to  criticise  cultural  imperialism  of  a  moral  nature.  On
closer  analysis,  however,  it  is  easy  to  see  that  there  is  no  valid  argument  from
cultural  relativism  to  cultural  tolerance.  If  our  culture  values  intolerance,  then  we
would presumably be right when we were intolerant!

8(cid:2)(cid:12)(cid:13)(cid:6)(cid:5)&(cid:4)(cid:8)5(cid:28)(cid:11)$(cid:8)(cid:10)(cid:3)(cid:6)(cid:11)(cid:3)(cid:2)(cid:19)(cid:6)(cid:8)(cid:2)(cid:5)(cid:6)(cid:19)(cid:11)(cid:28)’(cid:28)(cid:4)&

Cultural  relativism  also  entails  other  problems.  First,  it  is  at  risk  of  collapsing  into  a
more  comprehensive  relativist  position,  where  moral  values  and  judgements  are
simply  seen  as  personal  expressions  of  taste  or  emotion.  There  is  no  argument  to
stop at cultures and not move to sub-cultures, groups, families, individual, etc.

Second,  it  potentially  undermines  the  idea  of  universal  human  rights,  and  the
possibility of rightful criticism of human rights breaches, at least as moral rights. We
might  claim  legal  rights,  but  if  cultural  relativism  were  really  true,  we  would  not  be
able to derive universal rights through a moral construct

And  finally,  cultural  relativism  follows  from  the  view  that  we  cannot  compare  the
“quality”  of  different  cultures,  but  we  can  perhaps  compare  the  features  of  those
cultures.  For  example,  some  countries  treat  people  with  mental  illness  “better”  than
others, without saying that that makes one culture universally “better”. Therefore, our
inability to compare cultures does not mean we can not compare their features.

9

This, however, requires that we can delimit “a culture”, and again we cannot say that
cultures are equivalent to countries. Who can make a rightful claim to be a culture?
Often  this  is  done  through  self-identification:  I  decide  whether  I  belong  to  a  given
culture. This, however, does not solve the problem. For example, imagine in Europe
that we had a culture making a living out of crime, and this culture managed to export
itself to other parts of the world. Those who identified with the feature of crime would
identify to the culture and not to the nation state or region they belonged to. One can
take this reasoning further: should we tolerate killing or stealing within a given cultural
grouping in our society if that is part of that group’s culture?

Moreover,  there  is  a  risk  of  marginalising  sub-cultures  within  the  culture.  Who
decides  what  the  culture  thinks?  What  moral  practices  are  right?  We  should  be
careful of reifying cultures: making them into things, which they are not.

!(cid:2)(cid:5)(cid:8)(cid:11)$(cid:5)(cid:2)(cid:5)(cid:8)(cid:19)(cid:25)(cid:20)(cid:8)&(cid:12)(cid:2)(cid:5)(cid:8)’(cid:28)(cid:19)(cid:13)(cid:6)(cid:5)(cid:8)(cid:23)(cid:12)(cid:2)&(cid:4)(cid:8)(cid:12)(cid:23)(cid:8)&(cid:12)(cid:2)(cid:19)(cid:6)(cid:8)%(cid:6)(cid:3)(cid:2)(cid:19)(cid:6)(cid:28)(cid:4)&9

First, we  have  what  could  be  called  “procedural  pluralism”. This  is the  idea that  the
moral goals and values are universal in some sense, but that the ways in which  we
try  to  reach  these  goals  are,  and  have  to  be  different  in  different  cultures.  For
example,  self-determination  may  be  agreed  upon  on,  but  the  methods  for
documenting this self-determination may differ in that the person has made a choice
for  himself  or  herself.  In  this,  values,  judgements,  goals  are  the  same,  but  the
methods for reaching them may differ in different cultures

Second,  is  what  could  be  called  “limited  pluralism”.  The  idea  that  there  are  a  few
universal moral values, but that most of morality is culturally determined. But here too
we  could  come  to  disagreement  about  what  these  Universal  values  are,  and  even
when there is agreement, we are then tempted  to  use  these  agreed  upon  universal
values (few and far between) to make derivative values such as human rights.

Finally,  “negotiated  universalism”  is  when  we  have  to  work  with  people  with  other
cultures, we negotiate the values we are going to build on. We do not try to convince
that our  values  are right,  but rather  we  negotiate  a  set  of  values/procedures for  the
given  context.  We  can  see  a  lot  of  different  types  of  human  rights  this  way.  For
example,  the  Bioethics  Convention  is  hardly  satisfying  from  a  moral  philosophical
point of view, but exemplifies a negotiated set of values that most member states of
the Council of Europe can agree to. So maybe we cannot get  any further than this,
but with partners we can negotiate for a set of shared values.

10

 (cid:2)1(cid:8),(cid:12)(cid:25)(cid:28)(cid:10)(cid:19)(cid:8)0(cid:9)(cid:31)(cid:29)! 
Cambridge, United Kingdom
School of Advanced Study
University of London

(cid:31)(cid:12)(cid:2)&(cid:4)(cid:7)(cid:8)4(cid:19)(cid:6)(cid:3)(cid:5)(cid:4)(cid:8)(cid:19)(cid:25)(cid:27)(cid:8)(cid:22)(cid:2)(cid:19)(cid:25)(cid:4)(cid:17)(cid:24)(cid:3)(cid:6)(cid:11)(cid:3)(cid:2)(cid:19)(cid:6)(cid:8),(cid:5)(cid:27)(cid:28)(cid:10)(cid:19)(cid:6)(cid:8)#(cid:11)$(cid:28)(cid:10)(cid:4)

,(cid:12)(cid:25)(cid:28)(cid:10)(cid:19)(cid:8)0(cid:9)(cid:31)(cid:29)! 

(cid:26)(cid:25)(cid:11)(cid:2)(cid:12)(cid:27)(cid:3)(cid:10)(cid:11)(cid:28)(cid:12)(cid:25)

Professor Vice-President and members of the EGE, thank you for the invitation to speak
at  today’s  Round  Table.  I  am  pleased  to  be  here  in  my  capacity  as  a  medical
anthropologist.  The  focus  of  today’s  discussion  is  of  direct  relevance  both  to  social
anthropological  concerns  and  to  medical  anthropology  more  specifically.  Let  me  briefly
preface my comments by saying a little about the kind of work medical anthropologists do.

Medical  anthropology  deals  with  the  relationship  between  culture,  taken  in  the  broadest
sense, and various aspects of health and illness. Medical anthropologists spend periods
of  field  research  in  settings  across  all  parts  of  the  world.  This  means  that  our  research
inevitably generates cross-cultural data, thereby creating opportunities for new knowledge
to be built up from comparative analysis.

Our  aim  always  --  as  trained  ’professional  strangers’  --  is  to  gain  an  in-depth
understanding  of  the  cultural  values,  beliefs  and  experiences  informing  the  local  health
practices  we  study.  At  times  this  may  also  include  analysis  of  the  cultural  processes  of
moral  action.  Increasingly  so,  anthropologists  are  turning  their  focused  attention  to  the
contextual  nature  of  moral  decision-making  and  the  cultural  embeddedness  of  moral
systems, including the field of bioethics.

(cid:22)(cid:12)5(cid:19)(cid:2)(cid:27)(cid:4)(cid:8)(cid:19)(cid:8)(cid:11)(cid:2)(cid:19)(cid:25)(cid:4)(cid:10)(cid:3)(cid:6)(cid:11)(cid:3)(cid:2)(cid:19)(cid:6)(cid:8)&(cid:5)(cid:27)(cid:28)(cid:10)(cid:19)(cid:6)(cid:8)(cid:5)(cid:11)$(cid:28)(cid:10)(cid:4)

So  the  question  of  how  biomedical  research  can  be  conducted  as  international
collaborations between different countries is of direct relevance to medical anthropology.
In  thinking  about  how  we  create  normative  and  regulatory  frameworks  with  broad
applicability,  it  is  important  to  consider  the  following:  What  is  a  ’trans-cultural  medical
ethics’  and  how  can  it  be  truly  effective  in  the  future  as  a  genuine  ’health  for  all’
development policy?

This question deserves attention for many reasons. There are today a number of health
priorities that were not at the fore of the thinking that shaped the original guidelines of the
[World  Medical  Association’s]  (cid:1)(cid:2)(cid:3)(cid:4)(cid:5)(cid:6)(cid:5)(cid:7)(cid:8)(cid:9)(cid:10)(cid:11) (cid:9)(cid:12)(cid:11) (cid:13)(cid:2)(cid:4)(cid:14)(cid:8)(cid:10)(cid:15)(cid:8)  in  the  1960s.  First,  the  effects  of
globalisation  and  the  changing  geopolitical  and  socio-economic  landscape.  This  is  of
direct  relevance  to  global  epidemics  and  emerging  drug-resistant  viruses;  to  the  health
effects  of  warfare  and  ethnic  genocide  on  migration  and  resettlement;  also  to  the
implications  of  the  new  biotechnologies,  especially  in  the  field  of  genetics  and  human
reproduction.  And  additionally  the  impact  of  the  new  information  and  communication
technologies with telemedicine delivery systems. Some of the close connections between
international  health  ethics  and  globalisation  were  brought  home  when  Tore  Godal,
Executive  Secretary  of  the  Global  Alliance  for  Vaccine  and  Immunisation  (GAVI)

13

commented  on  the  possible  diversion  of  funds  away  from  routine  vaccine  production  to
vaccine development against bioterrorism in the light of 9/11 (International AIDS Vaccine
Initiative  [IAVI]  Report  2002).  Also  of  relevance:  the  emergence  of  new  collaborative
partnerships  and  cross-regional  networks  set  up  specifically  to  combat  poverty-related
diseases  such  as  the  European  and  Developing  Countries  Clinical  Trials  Partnership
(EDCTP) that Octavi Quintana Trias will talk to us about later today. Initiatives such as the
Millennium Development Goals and the  network  ’clusters’  that  are  shaping  global  public
private partnerships deserve special mention too.

All  these  developments  indicate  why  a  trans-cultural  medical  ethics  now  seems
particularly  timely. We  currently  have  at  our  disposal  a  particular  conceptual  framework
that has underpinned much of Western-derived bioethics during the latter half of the 20th
century.  But,  as  moral  philosophers  and  ethicists  themselves  have  observed,  this
framework may not be sufficiently(cid:11)accommodating to pose a range of culturally inflected
questions, nor to secure certain desired-for solutions within a global context. Principlism
and  the  ’4-principles  approach’  developed  by  Beauchamp  and  Childress  (1994)  with  its
stress  on  the  respect  for  persons  through  (1)  autonomy  (2)  beneficence  (3)  non-
maleficence and (4) justice, including equity, was not originally formulated with the explicit
remit  of  tackling  the  socio-political  effects  of  multiculturalism  -  either  within  the  USA  or
elsewhere.  Nor,  in  its  founding  conceptualisation,  was  it  particularly  sensitive  to  the
challenges  facing  cross-cultural  field  research  in  international  health.  Nonetheless,  it  is
these  very  principles  that  have  provided  general  guidance  for  many  regulatory  bodies
involved  in  formulating  ethical  guidelines  for  biomedical  research.  And  it  is  these
principles that continue to inform the work programmes of various international agencies,
inter-governmental  and  non-governmental  bodies  (e.g.  WHO,  the  UN,  The  Council  for
International  Organisations  of  Medical  Sciences  (CIOMS),  Médecins  sans  Frontières
(MSF),  International  Red  Cross).  So,  we  need  to  ask  careful  and  non-hurried  questions
about the extent to which the framing conceptions and premises of Western bioethics can
continue  to  provide  a  primary(cid:11) source  of  ethics  evaluation  beyond  the  resource  rich
countries  for  which  they  were  originally  devised.  How  do  we  best  start  to  ask  these
questions?

If we say that a trans-cultural medical ethics may establish certain unconditional minimum
requirements  such  as  the  inalienability  of  'human  dignity',  it  does  not  (cid:10)(cid:2)(cid:3)(cid:2)(cid:14)(cid:14)(cid:5)(cid:6)(cid:8)(cid:4)(cid:16)  follow
that  such  a  position  is  homologous  with  moral  fundamentalism  or  absolutism  (cid:17)(cid:2)(cid:6)(cid:11) (cid:14)(cid:2)(cid:18)
Namely, the view that certain  ethical  principles  are  timelessly  and  universally  applicable
as  immutable  standards.  Nor  is  a  trans-cultural  medical  ethics  (cid:10)(cid:2)(cid:3)(cid:2)(cid:14)(cid:14)(cid:5)(cid:6)(cid:8)(cid:4)(cid:16)  exactly  the
same  as  the  critical  project  of  cross-cultural  (cid:5)(cid:10)(cid:7)(cid:19)(cid:6)(cid:9)(cid:17)(cid:9)(cid:4)(cid:9)(cid:20)(cid:8)(cid:3)(cid:5)(cid:4)  analysis.  And  if  we  do  not
(cid:10)(cid:2)(cid:3)(cid:2)(cid:14)(cid:14)(cid:5)(cid:6)(cid:8)(cid:4)(cid:16) equate cultural relativism with uncritical acceptance of the moral norms of any
given culture -- as Soren Holm has just outlined to us -- then we are also better placed to
see  how  a  trans-cultural  medical  ethics,  built  upon  (cid:2)(cid:7)(cid:19)(cid:8)(cid:3)(cid:5)(cid:4)(cid:11) (cid:17)(cid:4)(cid:21)(cid:6)(cid:5)(cid:4)(cid:8)(cid:14)(cid:22),  depends  upon
continuous dialogue, negotiation and reflection between different agents and parties.

Modulating between different varieties of fundamentalism and relativism to establish new
bioethics  models  with  global  relevance  is  demanding  conceptual  work.  It  requires
nuanced  thinking.  What  I  want  to  stress  today  is  that  these  important  conceptual

14

questions  have  no  instantly  accessible,  straightforward  answers.  Our  conceptual  efforts
need to be shaped by on-the-ground empirical investigation and guided by the weight of
specific  contexts  witnessed  in  real  time:  observing  real  situations,  real  people,  real
dilemmas. Adding another layer of collaborative networks to those I mentioned a moment
ago  would  seem  to  promise  a  constructive  way  forward.  A  global  bioethics  needs  a
multidisciplinary  taskforce.  Ethicists  and  moral  philosophers,  medical  anthropologists,
health-allied  professionals,  international  lawyers  and  human  rights  specialists:  shouldn’t
we  also  be  thinking  about  ways  of  working  creatively  alongside  each  other  on  specific
research projects? I believe something along these lines has been shaping up by way of
the informal partnerships of (cid:23)(cid:19)(cid:2)(cid:11)(cid:24)(cid:4)(cid:9)(cid:25)(cid:5)(cid:4)(cid:11)(cid:26)(cid:9)(cid:6)(cid:21)(cid:22)(cid:11)(cid:9)(cid:10)(cid:11)(cid:27)(cid:8)(cid:9)(cid:2)(cid:7)(cid:19)(cid:8)(cid:3)(cid:14)(cid:11)(cid:8)(cid:10)(cid:11)(cid:28)(cid:2)(cid:14)(cid:2)(cid:5)(cid:6)(cid:3)(cid:19).

Now various commentators have been critical of the existing international regulations on
biomedical  research.  It  has  been  said  that  they  are  too  complex,  over-general,
insufficiently  specific  and  cross-referenced.  (Tröhler  &  Reiter-Theil  1998).  Also  that  the
essentially  normative,  aspirational  and  decontextualised  frameworks  of  the  instruments
endow them with a rigid, non-proactive character (Christakis 1996:263; see also Tröhler &
Reiter-Theil  1998  on  medical  ethics  codification).  These  critiques  all  point  to  the
significance  of  the  gap  between  norms  as  idealistic  stipulations  and  their  actual
implementation  in  practice.  Which  in  turn  points  to  the  recognition  that  international
declarations need to be responsive to local needs and circumstances, rather than simply
'top-down' formulations of 'first principles'. 'Bottom-up' approaches, as I have been saying,
depend  upon  the  collection  of  fresh  empirical  data.  A  trans-cultural  medical  ethics  that
incorporates such grass-roots perspectives would have many agendas. One surely would
be to ask and document how what is learnt in practice can shape future ethics guidelines.
How does decision-making and problem-solving on the ground, especially during clinical
practice and across multi-site project-based partnerships, feed back into the modification
of new guidelines, norms and values?

Basically, this question amounts to a plea to consider the implementation of guidelines in
terms of a (cid:14)(cid:19)(cid:8)(cid:12)(cid:7) from contents based protocol to procedure based negotiations. To do this
within a joint sponsor-host collaborative framework, it may be helpful to bear in mind the
notion of 'procedural justice'. Bioethicist Ruth Macklin (1998:133) has advocated a version
of  procedural  justice  for  future  transcultural  research  in  human  subject  experimentation
that  is  based  on  '…a  different  yet  important  expression  of  fairness,  and  relat[ing]  to  the
(cid:17)(cid:6)(cid:9)(cid:3)(cid:2)(cid:14)(cid:14)(cid:11) (cid:5)(cid:3)(cid:3)(cid:9)(cid:6)(cid:29)(cid:8)(cid:10)(cid:20)(cid:11) (cid:7)(cid:9)(cid:11) (cid:30)(cid:19)(cid:8)(cid:3)(cid:19)  decisions  are  made  and  actions  are  carried  out'  (emphasis
added).  Macklin  and  colleagues  (Kahn  (cid:2)(cid:7)(cid:11) (cid:5)(cid:4)  1998)  identify  the  need  to  move  beyond
simply ensuring informed consent agreements to what they call a 'balancing conception of
justice'  ((cid:8)(cid:25)(cid:8)(cid:29):  4),  namely  one  as  preoccupied  with  benefits  as  it  is  with  concepts  of  risk,
burden and harm. Suggesting that the dilemmas facing the ethics of subject recruitment
can  be  conceptualised  in  terms  of  benefit  and  not  simply  according  to  risk  criteria,
(cid:17)(cid:6)(cid:9)(cid:3)(cid:2)(cid:29)(cid:21)(cid:6)(cid:5)(cid:4)(cid:11) (cid:31)(cid:21)(cid:14)(cid:7)(cid:8)(cid:3)(cid:2)  crucially  places  emphasis  on  processes  of  decision-making.  Let's
consider  this  notion  of  procedural  justice  by  introducing  some  points  about  informed
consent from the perspective of critical ethical pluralism.

15

#(cid:11)$(cid:28)(cid:10)(cid:19)(cid:6)(cid:8)%(cid:6)(cid:3)(cid:2)(cid:19)(cid:6)(cid:28)(cid:4)&(cid:8)(cid:19)(cid:25)(cid:27)(cid:8)%(cid:2)(cid:12)(cid:10)(cid:5)(cid:27)(cid:3)(cid:2)(cid:19)(cid:6)(cid:8):(cid:3)(cid:4)(cid:11)(cid:28)(cid:10)(cid:5)2(cid:8);(cid:3)(cid:5)(cid:4)(cid:11)(cid:28)(cid:12)(cid:25)(cid:28)(cid:25)((cid:8)(cid:19)(cid:3)(cid:11)(cid:12)(cid:25)(cid:12)&(cid:20)(cid:8)(cid:19)(cid:4)(cid:8)%(cid:19)(cid:2)(cid:19)(cid:27)(cid:12)<(cid:5)(cid:4)(cid:8)(cid:28)(cid:25)(cid:8)(cid:10)(cid:12)(cid:25)(cid:4)(cid:5)(cid:25)(cid:11)

Cultural  differences  in  beliefs  about  the  nature  of  personhood  and  the  location  of
decisional  authority  for  consent  have  been  problematic  for  some  recent  investigators
conducting  international  health  research.  In  some  settings,  the  internationally  agreed-
upon  standard  for  individual  informed  consent  that  derives  from  the  norm  of  autonomy
can  seem  inappropriate  since  important  decisions  are  often  made  in  conjunction  with
families or by entire communities. Patients asked to enrol in a medical study might then
be sceptical of an investigator who did not involve their immediate or extended kin in the
decision-making process. As one commissioned submission to the US National Bioethics
Advisory  Council  Report  (2001)  observes,  research  projects  may  need  to  adopt  a
’multistep  consent  process’.  For  research  involving  children,  this  might  begin  with
community consent followed by individual parental consent. Village elders might also be
invited  to  sit  in  on  sessions  with  juniors  because  of  community  suspicions  that  children
may be abducted and used as  servants,  or  subjected  possibly  to  organ  harvesting  (see
Sugarman (cid:2)(cid:7)(cid:11)(cid:5)(cid:4) 2001). The process of consent as the acquisition of community trust thus
takes place over several encounters. It is in this basic sense ’procedural’. And it may well
vary  in  its  specific  practice  between  different  rural  and  urban  settings  (requirements  for
community consent generally being stronger in rural areas).

However,  securing  study  approval  from  community  leaders,  tribal  elders,  or  household
heads is no (cid:14)(cid:21)(cid:25)(cid:14)(cid:7)(cid:8)(cid:7)(cid:21)(cid:7)(cid:2) for individual consent, regardless of the particular cultural setting.
This is the [minimum requirement] position adopted by The Nuffield Council of Bioethics
Report  (2002)  and  its  emphasis  on  the  importance  of  individual  autonomy  within  the
context  of  community  consent.  That  said,  we  need  to  know  more  about  how  different
members of communities really see themselves as genuinely involved in such decisions,
as well as how different communities think of themselves as inter-related and inter-relating
members.  This is  where  the  in-depth,  time-sensitive  and  detail-rich  work  of  cultural  and
anthropological  analysis  may  play  a  very  constructive  part  within  the  setting  of
epidemiological  and  other  collaborative  health  research.  For  example,  local  norms
associated  with  marriages  involving  multiple  wives  may  comprise  additional  cultural
factors  that  influence  recruitment  strategies  and  the  process  of  informed  consent
acquisition.  In  genetic  epidemiological  studies,  for  instance,  investigators  might  want  to
enrol  family  members  who  are  genetically  related  to  each  other.  When  a  man  has
conjugal relations with more than one wife, but researchers only want to recruit the wife
who  is  genetically  important  to  the  study  on  account  of  known  biologically  related
offspring, medical personnel must navigate the potentially disruptive social consequences
for  extended  family  households.  One  can  easily  anticipate  that  incoming  researchers
would not be hearing the whole story about intrahousehold disputes between the various
wives simply by talking to the husband in question. Nor for that matter could it always be
easy to obtain a full account from the tribal chief or head of the local council from whom
one 
’part’  of  a  multi-step  consent  may  already  have  been  obtained.  But  an
anthropologically  focused  research  study,  working  alongside  people  from  the  local
community,  would  aim  to  treat  these  different  viewpoints  as  culturally  significant  data  in
their own right.

16

The philosophical question here is this: how do we reconfigure a system of consent(s) not
predicated exclusively on the value of subject autonomy. To understand ethical pluralism
as  culturally  specific  forms  of  procedural  justice,  further  empirical  work  is  required  to
address  the  relevance  of  consent  procedures  in  the  light  of  non-western  cultural  norms
(for  instance,  taking  into  account  varying  local  understandings  relating  to  norms  of
personhood and other manifestations of personal identity).

In  its  Report  published  earlier  this  year,  the  Nuffield  Council  of  Bioethics  introduces  the
concept  of  ’genuine’  consent,  thereby  refining  further  the  previous  stipulations  in  the
CIOMS/WHO  guidelines  (1993) for  ’informed’  consent  (see Nuffield Council  of  Bioethics
2002:77).  But  what  exactly  is  ’genuine’  consent?  What  are  the  specific  criteria  for  its
evaluation?  How  do  we  take  on  board  issues  of  information  provision  during  clinical
sessions? Lines of miscommunication might be manifest as problems to do with language
barriers  and  translation,  such  as  the  introduction  of  terms  for  which  there  are  no
indigenous  concepts,  like  ’placebo’  or  ’randomisation’.  One  ’incoming’  (externally-
sponsored)  anthropological  researcher  from  North  America  notes  that  amongst  the
Yoruba-speaking  trial  participants  recruited  to  a  genetic  epidemiology  study  she  co-
conducted  in  Nigeria,  people  did  not  understand  the  terms  ’genotyping’  and  ’candidate
genes’  because  there  is  no  local  Yoruba  term  for  ’gene’  (Marshall  2001).  How  does
procedural  justice  unfold  here  as  ’fair’  strategies  for  risk  communication?  Behind  this
question lie numerous others, each of which requires further empirical analysis.

One of the basic principles of the Declaration of Helsinki (WMA 2000) states:

(cid:27)(cid:8)(cid:9)(cid:22)(cid:2)(cid:29)(cid:8)(cid:3)(cid:5)(cid:4)(cid:11) (cid:6)(cid:2)(cid:14)(cid:2)(cid:5)(cid:6)(cid:3)(cid:19)(cid:11) (cid:8)(cid:10) (cid:9)(cid:4) (cid:8)(cid:10)(cid:20)(cid:11) (cid:19)(cid:21)(cid:22)(cid:5)(cid:10)(cid:11) (cid:14)(cid:21)(cid:25)(cid:31)(cid:2)(cid:3)(cid:7)(cid:14)(cid:11) (cid:22)(cid:21)(cid:14)(cid:7)(cid:11) (cid:3)(cid:9)(cid:10)(cid:12)(cid:9)(cid:6)(cid:22)(cid:11) (cid:7)(cid:9)(cid:11) (cid:20)(cid:2)(cid:10)(cid:2)(cid:6)(cid:5)(cid:4)(cid:4)(cid:16)(cid:11) (cid:5)(cid:3)(cid:3)(cid:2)(cid:17)(cid:7)(cid:2)(cid:29)
(cid:14)(cid:3)(cid:8)(cid:2)(cid:10)(cid:7)(cid:8)(cid:12)(cid:8)(cid:3)(cid:11)(cid:17)(cid:6)(cid:8)(cid:10)(cid:3)(cid:8)(cid:17)(cid:4)(cid:2)(cid:14)(cid:11)(cid:5)(cid:10)(cid:29)(cid:11)(cid:14)(cid:19)(cid:9)(cid:21)(cid:4)(cid:29)(cid:11)(cid:25)(cid:2)(cid:11)(cid:25)(cid:5)(cid:14)(cid:2)(cid:29)(cid:11)(cid:9)(cid:10)(cid:11)(cid:5)(cid:29)(cid:2)!(cid:21)(cid:5)(cid:7)(cid:2)(cid:4)(cid:16)(cid:11)(cid:17)(cid:2)(cid:6)(cid:12)(cid:9)(cid:6)(cid:22)(cid:2)(cid:29)(cid:11)(cid:4)(cid:5)(cid:25)(cid:9)(cid:6)(cid:5)(cid:7)(cid:9)(cid:6)(cid:16)(cid:11)(cid:5)(cid:10)(cid:29)(cid:11)(cid:5)(cid:10)(cid:8)(cid:22)(cid:5)(cid:4)
(cid:2)"(cid:17)(cid:2)(cid:6)(cid:8)(cid:22)(cid:2)(cid:10)(cid:7)(cid:5)(cid:7)(cid:8)(cid:9)(cid:10)(cid:11)(cid:5)(cid:10)(cid:29)(cid:11)(cid:9)(cid:10)(cid:11)(cid:5)(cid:11)(cid:7)(cid:19)(cid:9)(cid:6)(cid:9)(cid:21)(cid:20)(cid:19)(cid:11)(cid:15)(cid:10)(cid:9)(cid:30)(cid:4)(cid:2)(cid:29)(cid:20)(cid:2)(cid:11)(cid:9)(cid:12)(cid:11)(cid:7)(cid:19)(cid:2)(cid:11)(cid:14)(cid:3)(cid:8)(cid:2)(cid:10)(cid:7)(cid:8)(cid:12)(cid:8)(cid:3)(cid:11)(cid:4)(cid:8)(cid:7)(cid:2)(cid:6)(cid:5)(cid:7)(cid:21)(cid:6)(cid:2)(cid:18)

On  the  face  of  it,  this  all  sounds  sensible.  But,  can  people  consider  themselves  as
(cid:20)(cid:2)(cid:10)(cid:21)(cid:8)(cid:10)(cid:2)  participants  in  trials  when  they  do  not  understand  the  defining  concepts  and
rationales  motivating  the  studies?  In  a  certain  sense  this  question  applies  to  all  human
experimental  studies  in  medicine,  but  it  has  additional  salience  in  the  context  of
international  collaborations.  Can  we  think  of  developing  country  recruits  as  real
in  a  genetic  study  when  subjects’  own  predominantly  a-genetic
participants 
understandings of ’inheritance’ mean that they also hold non-western notions of disease
transmission?  Or  to  turn  that  question  around.  How  do Western  researchers  working  in
developing  countries  themselves  respond  when  trial  participants  who  have  not  had
educational schooling in the germ theory of disease causation report that they can explain
the sudden death of a relative as the effects of witchcraft and evil spirits?

And another dimension: is it enough simply to say at recruitment stage that  ’this  clinical
trial might lead to a cure sometime in the future’ and leave it at that? How, if at all, is the
future  defined  in  consent  procedures?  What  specificity  of  information  is  given  about
delayed benefits and how are the different phases of trials explained? Is it understood --
implicitly or explicitly -- by the trial participant that a cure will impact during one’s lifetime,
or  that  direct  health  benefits  shall  only  accrue  at  some  unspecified  time  for  future

17

generations?  How  can  and  how  should  Western  researchers  ethically  ’explain’  the
rationale  of  their  research  and  seek  to  clarify  the  problem  of  so-called  ’therapeutic
misconception’  (see  Nuffield  Council  of  Bioethics  2002:46)?  Also,  how  is  the  sequential
relationship  in  real  time  to  expected  drug  development  made  explicit?  The  issue  of  the
financial  commitments  by  pharma  to  drug  manufacturing  for  diseases  that  offer  little
promise of large commercial return: how is this explained during the consent procedure,
indeed if at all? Given that such  issues  may  be  unknown  even  to  the  sponsor  and  host
researchers themselves both before, during and even after the completion of a successful
trial, what then is the basis of so-called ’genuine consent’?

Now  at  the  same  time  as  one  wants  to  ask  these  kinds  of  detailed  questions,  recent
evidence suggests that the detailed documentation of written consent forms may be (cid:7)(cid:9)(cid:9)
cumbersome  for  some  potential  trial  recruits.  For  those  unaccustomed  to  official
documentation, the requirement to make a personal signature or undergo thumb printing
as proof of voluntary consent are acts that may cause suspicion and intimidation because
they are seen as excessively legalistic. Persons with low literacy levels may be frightened
of the repercussions of signing a document because this may be associated with previous
police tactics (Sugarman (cid:2)(cid:7)(cid:11)(cid:5)(cid:4) 2001). Or it may be associated with past experiences that
resulted in forms of victimisation, such as loss of personal property or land, when ’legal’
documents  were  used  against  them  (Marshall  2001).  Also,  in  the  context  of  guerrilla
warfare,  the  use  of  written  informed  consent  might  pose  a  risk  to  participants  by  linking
them to particular institutions.

It is true that several of the recent national guidelines recommend that informed consent
documents be developed in collaboration with local colleagues, and that special attention
be paid to potential problems in translation of particular concepts. Also, that a degree of
flexibility be exercised with regards to written consent documents for those unaccustomed
to receiving documentation of any important transaction. These are constructive  starting
points.  But  we  need  to  go  still  deeper  than  this.  It  is  not  just  western  researchers  who
need to ’educate’ others in biomedical constructs and related scientific terminology. Such
educational attempts will be at best meaningless, and at worst seen as yet another form
of  ’health  ethics  imperialism’,  unless  a  genuinely  intercultural  and  multilateral  learning
process unfolds on the ground. Incoming researchers from developed countries need to
understand  and  respect(cid:11) how  cultural  beliefs  concerning  the  cause  and  treatment  of
disease may differ radically from Western views about disease aetiology, rather than see
alternative explanatory systems of ill-health as beliefs that simply threaten the viability of a
proposed biomedical research study. A positive extension of this would be the setting up
of  projects  aimed  at  the  effective  integration  of  different  health  knowledge  systems  and
traditions.  The  recent  debates  on  international  health  ethics  have  tended  to  forget  that
certain so-called ’developing’ countries have their own indigenous stocks of ancient health
wisdom.  In  terms  of  education  and  training,  India  has  one  of  the  largest  formally
recognised  traditional  medicine  sectors  in  the  world.  Currently,  the  Department  of  the
Indian  Systems  of  Medicine  &  Homeopathy  (2001)  is  seeking  to  promote  medical
pluralism so as to combine approaches from modern biomedicine with Ayurveda, Unani,
Siddha, Yoga & Naturopathy. And it’s worth noting also that several ingredients of Indian
medicines  have  found  application  in  many  allopathic  drugs  used  in  the  conventional

18

treatment  of  cancer,  blood  pressure,  heart  disease  and  diabetes  --  the  major  Western
killers.

Which brings me to my last point. Many of the issues I have mentioned bear directly upon
the collection of human biological samples and the problem of the  ownership  of  genetic
resources  in  the  context  of  the  Human  Genome  Diversity  project,  and  other  genomics
ventures. The ethics and equity of IPR claims relating to international ’bioprospecting’ can
be  taken  right  back  to issues  of  consent  and  information  provision  at  the  point  of  blood
and  other  tissue  sample  collection  from  various  indigenous  peoples.  Many  indigenous
groups  see  the  patenting  of  human  life  as  a  violation  of  their  integrity  and  against  their
own  traditions  and  norms.  So,  policies  are  required  to  protect  the  (cid:3)(cid:9)(cid:4)(cid:4)(cid:2)(cid:3)(cid:7)(cid:8) (cid:2)(cid:11) (cid:6)(cid:8)(cid:20)(cid:19)(cid:7)(cid:14)  of
indigenous  peoples,  as  proposed  for  instance  by  the  Indigenous  Peoples  Council  on
Biocolonialism and the [generically formulated] Indigenous Research Protection Act.

(cid:18)(cid:28)(cid:25)(cid:19)(cid:6)(cid:8)5(cid:12)(cid:2)(cid:27)(cid:4)

In  conclusion,  further  thinking  is  required  to  develop  interdisciplinary  collaborations
between  bioethics,  clinical  medicine,  medical  anthropology  and  human  rights.    With  the
objective  of  establishing  a  culturally  sensitive  and  plurally-inflected  bioethics  research
agenda for ’global health’. That way we can start to flesh out specific cases. And start to
show  how  a  shift  from  the  rigidity  of  pre-given,  content-based  international  ethical
standards to processes of negotiated settlement -- as procedure-based protocols -- may
not  only  change  the  language  in  which  we  talk  about  norms  and  values,  but  give  more
people better, healthier lives. Because ultimately it is the terrible health inequities between
rich and poor countries that we must work to eliminate. Thank you.

19

(cid:29)(cid:5)(cid:23)(cid:5)(cid:2)(cid:5)(cid:25)(cid:10)(cid:5)(cid:4)

Beauchamp, T.L. & Childress, J.F. (1994) (cid:1)(cid:2)(cid:7)(cid:8)(cid:4)(cid:7)(cid:25)(cid:20)(cid:5)(cid:10)(cid:11)(cid:3)(cid:12)(cid:11)(cid:28)(cid:7)(cid:3)(cid:29)(cid:5)(cid:6)(cid:7)(cid:4)(cid:18)(cid:20)(cid:11)(cid:24)(cid:13)(cid:14)(cid:7)(cid:4)(cid:10), Oxford: Oxford University Press.

Christakis,  N  (1996)  ’The  distinction  between  ethical  pluralism  and  ethical  relativism:  implications  for  the
conduct  of  transcultural  clinical  research’.  In  Harold  Y.  Vanderpool  (ed)  (cid:17)(cid:14)(cid:5)(cid:11) (cid:24)(cid:13)(cid:14)(cid:7)(cid:4)(cid:10)(cid:11) (cid:3)(cid:12)(cid:11) (cid:15)(cid:5)(cid:10)(cid:5)(cid:18)(cid:2)(cid:4)(cid:14)(cid:11) (cid:30)(cid:8)(cid:31)(cid:3)(cid:20)(cid:31)(cid:7)(cid:8)(cid:9)
 (cid:16)(cid:29)(cid:18)(cid:8)(cid:11)!(cid:16)(cid:19)"(cid:5)(cid:4)(cid:13)(cid:10)#(cid:11)$(cid:18)(cid:4)(cid:7)(cid:8)(cid:9)(cid:11)(cid:13)(cid:14)(cid:5)(cid:11)%&(cid:0)(cid:1)(cid:11)’(cid:5)(cid:8)(cid:13)(cid:16)(cid:2)(cid:23), Frederick, Maryland: University Publishing Group.

CIOMS/WHO  (1993)  (cid:30)(cid:8)(cid:13)(cid:5)(cid:2)(cid:8)(cid:18)(cid:13)(cid:7)(cid:3)(cid:8)(cid:18)(cid:20)(cid:11) (cid:24)(cid:13)(cid:14)(cid:7)(cid:4)(cid:18)(cid:20)(cid:11) (cid:26)(cid:16)(cid:7)(cid:6)(cid:5)(cid:20)(cid:7)(cid:8)(cid:5)(cid:10)(cid:11) (cid:12)(cid:3)(cid:2)(cid:11) (cid:28)(cid:7)(cid:3)(cid:29)(cid:5)(cid:6)(cid:7)(cid:4)(cid:18)(cid:20)(cid:11) (cid:15)(cid:5)(cid:10)(cid:5)(cid:18)(cid:2)(cid:4)(cid:14)(cid:11) (cid:30)(cid:8)(cid:31)(cid:3)(cid:20)(cid:31)(cid:7)(cid:8)(cid:9)(cid:11)  (cid:16)(cid:29)(cid:18)(cid:8)(cid:11) !(cid:16)(cid:19)"(cid:5)(cid:4)(cid:13)(cid:10),
available at: http://www.cioms.ch/frame_1993_texts_of_guidelines.htm

Department of Indian Systems of Medicine & Homeopathy (2001) (cid:21)(cid:2)(cid:18)(cid:12)(cid:13)(cid:11)((cid:18)(cid:13)(cid:7)(cid:3)(cid:8)(cid:18)(cid:20)(cid:11)(cid:1)(cid:3)(cid:20)(cid:7)(cid:4)(cid:23)(cid:11)(cid:3)(cid:8)(cid:11)(cid:30)(cid:8)(cid:6)(cid:7)(cid:18)(cid:8)(cid:11)!(cid:23)(cid:10)(cid:13)(cid:5)(cid:29)(cid:10)(cid:11)(cid:3)(cid:12)
)(cid:5)(cid:6)(cid:7)(cid:4)(cid:7)(cid:8)(cid:5),  Ministry  of  Health  &  Family  Welfare  Government  of 
India,  New  Delhi,  available  at
http://indianmedicine.nic.in

IAVI  Report  (2002)  ’New  models  for  vaccine  delivery:  an  interview  with  Tore  Godal,  International  AIDS
Vaccine Initiative, available at http://www.vaccinealliance.org/tg_interview.html

Kahn,  J.,  Mastroianna,  A.C.,  &  J.  Sugarman  (eds)  1998  (cid:28)(cid:5)(cid:23)(cid:3)(cid:8)(cid:6)(cid:11) ’(cid:3)(cid:8)(cid:10)(cid:5)(cid:8)(cid:13)*(cid:11) !(cid:5)(cid:5)+(cid:7)(cid:8)(cid:9)(cid:11) ,(cid:16)(cid:10)(cid:13)(cid:7)(cid:4)(cid:5)(cid:11) (cid:7)(cid:8)(cid:11) (cid:15)(cid:5)(cid:10)(cid:5)(cid:18)(cid:2)(cid:4)(cid:14),
Oxford: OUP.

Macklin, R. (1999) -(cid:9)(cid:18)(cid:7)(cid:8)(cid:10)(cid:13)(cid:11)(cid:15)(cid:5)(cid:20)(cid:18)(cid:13)(cid:7)(cid:31)(cid:7)(cid:10)(cid:29)*(cid:11)’(cid:16)(cid:20)(cid:13)(cid:16)(cid:2)(cid:18)(cid:20)(cid:11)(cid:21)(cid:7)(cid:31)(cid:5)(cid:2)(cid:10)(cid:7)(cid:13)(cid:23)(cid:11)(cid:18)(cid:8)(cid:6)(cid:11)(cid:13)(cid:14)(cid:5)(cid:11)!(cid:5)(cid:18)(cid:2)(cid:4)(cid:14)(cid:11)(cid:12)(cid:3)(cid:2)(cid:11)(cid:24)(cid:13)(cid:14)(cid:7)(cid:4)(cid:18)(cid:20)(cid:11).(cid:8)(cid:7)(cid:31)(cid:5)(cid:2)(cid:10)(cid:18)(cid:20)(cid:10)(cid:11)(cid:7)(cid:8)(cid:11))(cid:5)(cid:6)(cid:7)(cid:4)(cid:7)(cid:8)(cid:5),
Oxford: OUP.

Marshall. P. (2001) ’The relevance of culture for informed consent in US-funded international health research’
in National Bioethics Advisory Commission (US) Report: (cid:24)(cid:13)(cid:14)(cid:7)(cid:4)(cid:18)(cid:20)(cid:11)(cid:18)(cid:8)(cid:6)(cid:11)(cid:1)(cid:3)(cid:20)(cid:7)(cid:4)(cid:23)(cid:11)(cid:30)(cid:10)(cid:10)(cid:16)(cid:5)(cid:10)(cid:11)(cid:7)(cid:8)(cid:11)(cid:30)(cid:8)(cid:13)(cid:5)(cid:2)(cid:8)(cid:18)(cid:13)(cid:7)(cid:3)(cid:8)(cid:18)(cid:20)(cid:11)(cid:15)(cid:5)(cid:10)(cid:5)(cid:18)(cid:2)(cid:4)(cid:14)*
’(cid:20)(cid:7)(cid:8)(cid:7)(cid:4)(cid:18)(cid:20)(cid:11)(cid:17)(cid:2)(cid:7)(cid:18)(cid:20)(cid:10)(cid:11)(cid:7)(cid:8)(cid:11)(cid:21)(cid:5)(cid:31)(cid:5)(cid:20)(cid:3)(cid:25)(cid:7)(cid:8)(cid:9)(cid:11)’(cid:3)(cid:16)(cid:8)(cid:13)(cid:2)(cid:7)(cid:5)(cid:10), Bethesda, MD: NBAC. (Volume II: Commissioned Papers).

National  Bioethics  Advisory  Commission  (US)  Report:  (cid:24)(cid:13)(cid:14)(cid:7)(cid:4)(cid:18)(cid:20)(cid:11) (cid:18)(cid:8)(cid:6)(cid:11) (cid:1)(cid:3)(cid:20)(cid:7)(cid:4)(cid:23)(cid:11) (cid:30)(cid:10)(cid:10)(cid:16)(cid:5)(cid:10)(cid:11) (cid:7)(cid:8)(cid:11) (cid:30)(cid:8)(cid:13)(cid:5)(cid:2)(cid:8)(cid:18)(cid:13)(cid:7)(cid:3)(cid:8)(cid:18)(cid:20)(cid:11) (cid:15)(cid:5)(cid:10)(cid:5)(cid:18)(cid:2)(cid:4)(cid:14)*
’(cid:20)(cid:7)(cid:8)(cid:7)(cid:4)(cid:18)(cid:20)(cid:11) (cid:17)(cid:2)(cid:7)(cid:18)(cid:20)(cid:10)(cid:11)
II).  Available  at:
http://bioethics.georgetown.edu/nbac/pubs.html

(cid:7)(cid:8)(cid:11) (cid:21)(cid:5)(cid:31)(cid:5)(cid:20)(cid:3)(cid:25)(cid:7)(cid:8)(cid:9)(cid:11) ’(cid:3)(cid:16)(cid:8)(cid:13)(cid:2)(cid:7)(cid:5)(cid:10),  Bethesda,  MD:  NBAC 

(Vols 

I  & 

Nuffield Council of Bioethics (2002) (cid:17)(cid:14)(cid:5)(cid:11)(cid:24)(cid:13)(cid:14)(cid:7)(cid:4)(cid:10)(cid:11)(cid:3)(cid:12)(cid:11)(cid:15)(cid:5)(cid:10)(cid:5)(cid:18)(cid:2)(cid:4)(cid:14)(cid:11)(cid:15)(cid:5)(cid:20)(cid:18)(cid:13)(cid:5)(cid:6)(cid:11)(cid:13)(cid:3)(cid:11) (cid:5)(cid:18)(cid:20)(cid:13)(cid:14)(cid:4)(cid:18)(cid:2)(cid:5)(cid:11)(cid:7)(cid:8)(cid:11)(cid:21)(cid:5)(cid:31)(cid:5)(cid:20)(cid:3)(cid:25)(cid:7)(cid:8)(cid:9)(cid:11)’(cid:3)(cid:16)(cid:8)(cid:13)(cid:2)(cid:7)(cid:5)(cid:10):
London: NCB.

Sugarman,  J,  Pokin,  B,  Fortney,  J.  and  Rivera,  R.  (2001)  ’International  perspectives  on  protecting  human
research  subjects’  in  National  Bioethics  Advisory  Commission  (US)  Report:  (cid:24)(cid:13)(cid:14)(cid:7)(cid:4)(cid:18)(cid:20)(cid:11) (cid:18)(cid:8)(cid:6)(cid:11) (cid:1)(cid:3)(cid:20)(cid:7)(cid:4)(cid:23)(cid:11) (cid:30)(cid:10)(cid:10)(cid:16)(cid:5)(cid:10)(cid:11) (cid:7)(cid:8)
(cid:30)(cid:8)(cid:13)(cid:5)(cid:2)(cid:8)(cid:18)(cid:13)(cid:7)(cid:3)(cid:8)(cid:18)(cid:20)(cid:11) (cid:15)(cid:5)(cid:10)(cid:5)(cid:18)(cid:2)(cid:4)(cid:14)*(cid:11) ’(cid:20)(cid:7)(cid:8)(cid:7)(cid:4)(cid:18)(cid:20)(cid:11) (cid:17)(cid:2)(cid:7)(cid:18)(cid:20)(cid:10)(cid:11) (cid:7)(cid:8)(cid:11) (cid:21)(cid:5)(cid:31)(cid:5)(cid:20)(cid:3)(cid:25)(cid:7)(cid:8)(cid:9)(cid:11) ’(cid:3)(cid:16)(cid:8)(cid:13)(cid:2)(cid:7)(cid:5)(cid:10),  Bethesda,  MD:  NBAC.  (Volume  II:
Commissioned Papers).

Tröhler,  U.  &    Reiter-Theil,  S.  (1998)  (eds)  (cid:24)(cid:13)(cid:14)(cid:7)(cid:4)(cid:10)(cid:11) ’(cid:3)(cid:6)(cid:5)(cid:10)(cid:11) (cid:7)(cid:8)(cid:11) )(cid:5)(cid:6)(cid:7)(cid:4)(cid:7)(cid:8)(cid:5)*(cid:11) $(cid:3)(cid:16)(cid:8)(cid:6)(cid:18)(cid:13)(cid:7)(cid:3)(cid:8)(cid:10)(cid:11) (cid:18)(cid:8)(cid:6)(cid:11) -(cid:4)(cid:14)(cid:7)(cid:5)(cid:31)(cid:5)(cid:29)(cid:5)(cid:8)(cid:13)(cid:10)(cid:11) (cid:3)(cid:12)
’(cid:3)(cid:6)(cid:7)(cid:12)(cid:7)(cid:4)(cid:18)(cid:13)(cid:7)(cid:3)(cid:8)(cid:11)(cid:10)(cid:7)(cid:8)(cid:4)(cid:5)(cid:11)&/01, Aldershot: Ashgate.

WMA  (2000)  (cid:21)(cid:5)(cid:4)(cid:20)(cid:18)(cid:2)(cid:18)(cid:13)(cid:7)(cid:3)(cid:8)(cid:11) (cid:3)(cid:12)(cid:11)  (cid:5)(cid:20)(cid:10)(cid:7)(cid:8)+(cid:7)(cid:11) 2(cid:11) (cid:24)(cid:13)(cid:14)(cid:7)(cid:4)(cid:18)(cid:20)(cid:11) (cid:1)(cid:2)(cid:7)(cid:8)(cid:4)(cid:7)(cid:25)(cid:20)(cid:5)(cid:10)(cid:11) (cid:12)(cid:3)(cid:2)(cid:11) )(cid:5)(cid:6)(cid:7)(cid:4)(cid:18)(cid:20)(cid:11) (cid:15)(cid:5)(cid:10)(cid:5)(cid:18)(cid:2)(cid:4)(cid:14)(cid:11) (cid:30)(cid:8)(cid:31)(cid:3)(cid:20)(cid:31)(cid:7)(cid:8)(cid:9)(cid:11)  (cid:16)(cid:29)(cid:18)(cid:8)(cid:11) !(cid:16)(cid:19)"(cid:5)(cid:4)(cid:13)(cid:10),
adopted  by  the  52nd  World  Medical  Association  General  Assembly,  Edinburgh,  Scotland,  October  2000.
Available at: http://www.wma.net/e/policy/17-c_e.html

20

(cid:29)(cid:5)(cid:28)(cid:27)(cid:19)(cid:2)(cid:8)01(cid:8)"(cid:26)#(cid:7)
,1 1(cid:7)(cid:8)8$1 
University of Bergen, Norway

#(cid:11)$(cid:28)(cid:10)(cid:4)(cid:8)(cid:12)(cid:23)(cid:8)(cid:10)(cid:6)(cid:28)(cid:25)(cid:28)(cid:10)(cid:19)(cid:6)(cid:8)(cid:10)(cid:12)(cid:6)(cid:6)(cid:19)(cid:13)(cid:12)(cid:2)(cid:19)(cid:11)(cid:28)(cid:12)(cid:25)(cid:8)5(cid:28)(cid:11)$(cid:8)(cid:27)(cid:5)’(cid:5)(cid:6)(cid:12)%(cid:28)(cid:25)((cid:8)(cid:10)(cid:12)(cid:3)(cid:25)(cid:11)(cid:2)(cid:28)(cid:5)(cid:4)2
(cid:10)(cid:12)(cid:25)(cid:11)(cid:2)(cid:12)’(cid:5)(cid:2)(cid:4)(cid:28)(cid:19)(cid:6)(cid:8)(cid:28)(cid:4)(cid:4)(cid:3)(cid:5)(cid:4)

(cid:29)(cid:5)(cid:28)(cid:27)(cid:19)(cid:2)(cid:8)01(cid:8)"(cid:26)#

The  controversies  surrounding  clinical  trial  collaborations  with  developing
countries have mainly been concerned with two issues: the level of care owed to
participants in clinical trials  and  the  obligations,  if  any,  to  trial  communities  after
successful testing.

After  the  debate  surrounding  the  perinatal  HIV  transmission  studies,  there  has
been  a  controversy  whether  it  is  ever  permissible  to  use  a  lower,  local  level  of
care  in  the  control  group  than  is  available  in  resource  rich  settings.  Those  who
defended a local level of care argued that this was necessary because otherwise
the results from the trial would not be applicable to the host country. Those who
defended  a  universal  standard  of  care  argued  that  useful  results  could  be
obtained using a universal standard, even if it might involve higher costs and take
longer time. In the international literature there has been a great deal of confusion
about the issue of scientific necessity of a local standard of care. Nevertheless, it
can  easily  be  shown  that  in  cases  of  an  unknown,  variable  placebo  effect,
equivalence  trials  cannot  show  that  an  intermediate  treatment  is  better  than
placebo, if the trial results in non-equivalence between the two treatments. Thus,
there  can  be  no  question  that  there  are  real  scientific  reasons  for  wanting  to
conduct trials with a lower standard of care. The crucial issue is therefore whether
there  are  other,  overriding  moral  concerns,  which  would  make  such  trials
impermissible, in spite of the fact that they might be the only way to obtain useful
results. If one can argue that they sometimes are permissible, the second crucial
issue is under what conditions they are permissible. Can we allow different levels
of care in trials depending on different economic conditions?

The  main  criticism  has  been  that  in  allowing  studies  that  could  not  be  done  in
developed countries, we would be exploiting developing countries and  would be
allowing  an  ethical  double  standard.  And  secondly,  that  there  is  a  clinical
obligation to identifiable individuals to provide known proven treatments.

Against  this,  in  a  defence  against  these  criticisms  it  has  been  argued  that  it  is
sometimes necessary, in order  to  obtain  knowledge  necessary  in  resource  poor
settings,  to  do  trials  with  a  different  level  of  care.  Such  trials  should  be
permissible  if  one  can  introduce  safeguards  to  avoid  exploitation.  Such  trials
would have to be done in full openness and after wide consultation.

The second controversial issue concerns the obligations to trial communities after
successful  testing.  In  resource  rich  settings,  one  would  normally  expect  that  a
successful  product  would  become  available  to  those  who  need  it.  In  resource
poor settings this is often not the case. Recently, attention has also been brought

23

to a practice of conducting trials in resource poor settings, which cannot be done
for ethical reasons in resource rich settings, but where the results are known not
to be useful in the host country. One recent example is the preventive malarone
trials in African countries, resulting in licensing of this  drug for  the  prevention  of
malaria in travellers and expatriates. Because of such cases, a number of recent
international guidelines and documents have required that research can only be
morally  permitted  if  there  is  some  likelihood  that  it  will  benefit  the  community  in
which it takes place. Some have defended a stronger requirement of explicit prior
agreements  with  a  detailed  plan  for  how  the  results  will  be  useful  for  the  host
community. In spite of the current popularity of these notions, there are very few,
if  any,  examples  of  successful  prior  agreements.  There  is  a  danger  that  the
preoccupation  with  prior  agreements  will  deflect  attention  from  the  fact  that  it  is
the  size  of  the  benefit  to  the  host  population  that  is  important,  not  whether  the
benefit  concerns  availability  of  the  product  after  successful  testing.  In  addition,
one  needs  to  address  the  issue  whether  “reasonable  availability”  should  be  a
condition for approval of protocols?

There  are  many  International  Guidelines  that  address  these  issues.  Where  the
Helsinki  Declaration  establishes  a  universal  standard,  NBAC,  Nuffield  and
UNAIDS  foresee  allowable  differences;  and  the  CIOMS  guidelines  do  not  allow
for these differences (cid:17)(cid:2)(cid:6)(cid:11)(cid:14)(cid:2), but the accompanying commentary does.

Between  them  there  seems  to  be  agreement  with  respect  to  the  necessary
conditions of placebo use and reasonable availability. First, the results of the trial
should  be  relevant  to  the  study  population/country  in  which  the  study  is  carried
out  and  that  there  is  a  reasonable  likelihood  that  the  new  intervention  will  be
implemented. Unfortunately, this was not the case for the short course treatment.

And secondly, at the conclusion of the study, every patient entered into the study
should  be  assured  of  access  to  the  best  proven  prophylactic,  diagnostic,  and
therapeutic  methods  identified  by  that  study,  as  required  by  the  Helsinki
Declaration This is also reflected in other guidelines.

There is no agreement on a requirement for the availability to general community.
According to the previous version of the CIOMS guidelines, as a general rule, the
sponsoring  agency  should  ensure  that,  at  the  completion  of  successful  testing,
any product developed would be made reasonably available to the inhabitants of
the  underdeveloped  community 
the  research  was  carried  out.
in  which 
Exceptions  to  this  general  requirement  should  be  justified,  and  agreed  to  by  all
concerned  parties  before  the  research  is  begun.  Whereas,  the  current  Helsinki
Declaration  stipulates  that  medical  research  is  only  justified  if  there  is  a
reasonable  likelihood  that  the  populations  in  which  the  research  is  carried  out
stand to benefit from the results of the research.

Moreover,  there  is  consensus  and  agreement  that  this  issue  needs  to  be
addressed. The notion of “prior agreements” is gaining some popularity, however

24

one  should  not  underestimate  the  complexities  of  this  issue.  Focusing  on  prior
agreements might divert resources from more important concerns.

(cid:13)(cid:14)(cid:15)(cid:1)(cid:3)(cid:2)(cid:11)(cid:9)(cid:14)(cid:15)

Therefore, it is clear that when focusing on prior agreements, all the complexities of
prior agreements need to be addressed. Against this, one might want to maintain that
more  emphasis  needs  to  be  placed  on  the  risks  and  the  benefits  of  the  research
project  itself,  as  well  as  the  benefits  that  are  to  be  provided  immediately,  including
health benefits during the study period.

25

 (cid:2)1(cid:8)4(cid:19)(cid:4)(cid:19)(cid:25)(cid:11)$(cid:19)(cid:8),(cid:30)(cid:22)+(cid:30)/=!,>
Senior Deputy Direcor General of the Indian Council of Medical Research,
New Delhi, India

(cid:26)(cid:24),(cid:29)?(cid:4)(cid:8)(cid:19)%%(cid:2)(cid:12)(cid:19)(cid:10)$(cid:8)(cid:10)(cid:12)(cid:25)(cid:10)(cid:5)(cid:2)(cid:25)(cid:28)(cid:25)((cid:8)(cid:11)$(cid:5)(cid:8)(cid:5)(cid:11)$(cid:28)(cid:10)(cid:4)(cid:8)(cid:12)(cid:23)(cid:8)(cid:10)(cid:6)(cid:28)(cid:25)(cid:28)(cid:10)(cid:19)(cid:6)(cid:8)(cid:2)(cid:5)(cid:4)(cid:5)(cid:19)(cid:2)(cid:10)$
(cid:28)(cid:25)(cid:8)(cid:26)(cid:25)(cid:27)(cid:28)(cid:19)

4(cid:19)(cid:4)(cid:19)(cid:25)(cid:11)$(cid:19)(cid:8),(cid:30)(cid:22)+(cid:30)/=!,>

Established  in  1947,  the  Indian  Council  of  Medical  Research  (ICMR)  was  set  up  in
order  to  foster  a  research  culture  in  India,  improve  and  develop  infrastructure  and
foster community support. As one of the oldest medical research bodies in the world,
ICMR  is  the  apex  body  in  India  for  the  formulation,  co-ordination  and  promotion  of
biomedical  research.  With  an  institutional  network  incorporating  21  permanent
institutes  and  six  regional  centres,  ICMR  has  developed  into  a  formidable  funding
agency  for  supporting  medical  research  in  the  country.  It’s  primary  role  is  the
development  of  infrastructure,  capacity  building,  peer review,  monitoring,  evaluation
procedures, etc.

The  major  challenges facing the  ICMR  and  public  health  in  India  remain  the  double
burden  of  communicable  and  non-communicable  diseases.  Clinical  trials  are
therefore  oriented  towards  TB,  leprosy,  viral  diseases,  malaria,  leishmaniasis,
HIV/AIDS, as well as cancer, cardiovascular, mental health, haematological disorders.
(see graph). These health concerns are primarily due to the realities of  a  population
without access to safe water, health services and sanitation.

(cid:22)$(cid:5)(cid:8)(cid:5)(cid:4)(cid:11)(cid:19)(cid:13)(cid:6)(cid:28)(cid:4)$&(cid:5)(cid:25)(cid:11)(cid:8)(cid:12)(cid:23)(cid:8)(cid:5)(cid:11)$(cid:28)(cid:10)(cid:19)(cid:6)(cid:8)(cid:4)(cid:11)(cid:19)(cid:25)(cid:27)(cid:19)(cid:2)(cid:27)(cid:4)

In  1980,  the  #(cid:9)(cid:4)(cid:8)(cid:3)(cid:16)(cid:11) $(cid:7)(cid:5)(cid:7)(cid:2)(cid:22)(cid:2)(cid:10)(cid:7)(cid:11) (cid:9)(cid:10)(cid:11) %(cid:7)(cid:19)(cid:8)(cid:3)(cid:5)(cid:4)(cid:11) &(cid:9)(cid:10)(cid:14)(cid:8)(cid:29)(cid:2)(cid:6)(cid:5)(cid:7)(cid:8)(cid:9)(cid:10)(cid:14)(cid:11) (cid:8)(cid:10) (cid:9)(cid:4) (cid:2)(cid:29)(cid:11) (cid:8)(cid:10)(cid:11) (cid:6)(cid:2)(cid:14)(cid:2)(cid:5)(cid:6)(cid:3)(cid:19)(cid:11) (cid:9)(cid:10)
(cid:13)(cid:21)(cid:22)(cid:5)(cid:10)(cid:11) $(cid:21)(cid:25)(cid:31)(cid:2)(cid:3)(cid:7)(cid:14)(cid:0)  was  established.  However,  the  growing  demands  made  by  the
critical issues in the area of biogenetic research, as well as mandatory trials for new
drugs  have  developed  a  need  to  update  these  guidelines.  Moreover,  new
technologies  and  diagnostic  procedure  have  further  underlined  this  need  most
notably with respect to issues such as ART, organ transplants, xenotransplantation,
human genome and use of foetal tissue.

These  guidelines  were  therefore  revised  in  1996,  during  which  time  an  ethics
committee was constituted under the chairmanship of Justice Sh.M.N. Venkatachalia.
The  Central  Ethics  Committee  on  Human  Research  (CECHR)  comprised  of  27
members,  and  5  Sub-committees  of  experts,  was  set  up  for  drawing  up  the
guidelines in respective areas.

The major areas identified by the Committee were:
•  Clinical evaluation of drug/devices/diagnostics/vaccines/herbal remedies
•  Epidemiological research
•  Human Genetic Research

2 Mainly dealt with issues such as ethics committees, informed consent, clinical trials, research on children,
the mentally disadvantaged and those with disminished autonomy ; traditional medicine ; and publications.

29

                                                
•  Transplantation research including foetal tissue transplantation
•  Assisted Reproductive technologies

The final Revised guidelines were released in September 2000, entitled ’%(cid:7)(cid:19)(cid:8)(cid:3)(cid:5)(cid:4)
(cid:24)(cid:21)(cid:8)(cid:29)(cid:2)(cid:4)(cid:8)(cid:10)(cid:2)(cid:14)(cid:11)(cid:12)(cid:9)(cid:6)(cid:11)(cid:25)(cid:8)(cid:9)(cid:22)(cid:2)(cid:29)(cid:8)(cid:3)(cid:5)(cid:4)(cid:11)(cid:6)(cid:2)(cid:14)(cid:2)(cid:5)(cid:6)(cid:3)(cid:19)(cid:11)(cid:9)(cid:10)(cid:11)(cid:19)(cid:21)(cid:22)(cid:5)(cid:10)(cid:11)(cid:14)(cid:21)(cid:25)(cid:31)(cid:2)(cid:3)(cid:7)(cid:14)((cid:18)(cid:11)The general principles
outlined by these guidelines, known as the ICMR code, are as follows:
(cid:1)  Essentiality
(cid:1)  Voluntarism, Informed consent, Community Agreement
(cid:1)  Non-exploitation
(cid:1)  Privacy and Confidentiality
(cid:1)  Precaution & Risk minimisation
(cid:1)  Professional Competence
(cid:1)  Accountability and Transparency
(cid:1)  Maximisation of public interest and distributive justice
(cid:1) 
(cid:1)  Public domain
(cid:1)  Totality of responsibility
(cid:1)  Compliance.

Institutional arrangements

Unfortunately,  these  guidelines  are  not  binding.  For  example,  did  the  recent
controversial Phase I and II clinical trials for anti-cancer drug treatments done in India
not  follow  certain  procedures  laid  down  in  these  guidelines.    There  is  no  National
Biomedical  Authority  in  place  for  monitoring  which  is  now  being  suggested.    The
Ethical  Review  Procedure  is  however  mandatory  and  must  be  done  by  either  the
IEC.  It is done to ensure sound ethical & scientific decision-making and to promote
ethically viable priority research.  As well, with respect to public health, this procedure
is  put  in  place  to  provide  public  assurance,  and  to  safeguard  welfare  &  rights  of
participants.  In so doing, establish regular monitoring of clinical trials.

The main ethical issues involved in the Ethical Review Procedure are:
• 
the Informed Consent Process,
•  Compensation for participation,
•  Selection of Special Groups as research Subjects,
•  Essential Information on Confidentiality for Prospective Research Subjects,
•  Compensation for Accidental Injury,
• 
•  Relations with Media & Publication Practices.

International Collaboration,

#(cid:11)$(cid:28)(cid:10)(cid:19)(cid:6)(cid:8)(cid:10)(cid:12)(cid:25)(cid:10)(cid:5)(cid:2)(cid:25)(cid:4)(cid:8)(cid:28)(cid:25)(cid:8)(cid:10)(cid:6)(cid:28)(cid:25)(cid:28)(cid:10)(cid:19)(cid:6)(cid:8)(cid:2)(cid:5)(cid:4)(cid:5)(cid:19)(cid:2)(cid:10)$(cid:8)(cid:28)(cid:25)(cid:8)(cid:26)(cid:25)(cid:27)(cid:28)(cid:19)

There are however many concerns and issues surrounding these procedures.  First,
research  ethics  are  a  relatively  new  speciality  in  India,  which  impacts  on  ethical
review.    The  process  therefore  remains  relatively  unknown  and  rudimentary  in
general.    It  has  been  said  that  only  Ethical  Review  can  make  a  difference,  but  can
ethics committees make a difference?

30

The inherent difficulties associated with informed consent remain high illiteracy rates
and  the  existence  of  many  languages  in  India.    This  coupled  with  overburdened
health professionals leaves little time for explanation.

Moreover, bioethics education is not currently a part of the present curriculum; there
is a need for  legislation  to  regulate  human  experiments;  and  the  issues surrounding
Community  consultation  must  be  addressed.    These  issues  include  a  community
benefit  agreement,  product  availability,  and  the  ethics  of  priority  setting.    These
require  a  greater  involvement  of  those  close  to  communities,  as  well  as  that  of
voluntary agencies, and village leaders.

International  Collaboration  also  requires  greater  attention.    Community  participation
and  that  the  protection  of  vulnerable  populations  should  be  requirements  for  all
capacity  building  initiatives  done  through  international  collaboration.    The  careful
planning  of  clinical  trials  can  ensure  this.    The  discussion  on  standard  of  care
highlighted  the  necessity  to  insist  on  best  possible  care  through  the  study  of  the
situation  within  country,  according  the  best  nationally  available  health  care,  and  not
care set by international standards.  The burden and benefits of these issues should
be assessed in the framework of  equal  respect for the  rules  and  regulations  of  both
countries.

(cid:26)(cid:25)(cid:28)(cid:11)(cid:28)(cid:19)(cid:11)(cid:28)’(cid:5)(cid:4)(cid:8)(cid:19)(cid:25)(cid:27)(cid:8)(cid:4)(cid:11)(cid:2)(cid:19)(cid:11)(cid:5)((cid:28)(cid:5)(cid:4)

Some strategies being developed to address these concerns include the preparation
and dissemination of guidelines, the organising of public debates, workshops as well
as  regional  initiatives,  such  as  FERCAP  (Forum  for  Ethics  review  Committees  in
Asia-Pacific), FERCI (India), FERCIT (Thailand), FEHRIN (Nepal), etc.

Moreover, legislation has been developed in order to protect research participants in
India.    The  possibility  of  malaria  trials  at  the  Mekong  region  have  spurred  the
development  and  implementation  of  national  legislation  for  ethics  committees  over
the  last  year  at  Laos  and  Cambodia.    Currrently,  Nepal  and  Philippines  have  their
own  guidelines,  where  as  Vietnam  and  Indonesia  are  in the  process  of  developing
such  guidelines.    This  is  with  the  hope  that  all  countries  will  have  appropriately
functioning ethics committees.

More  specifically,  ICMR  has  developed  certain  specific  initiatives  in  order  to  better
address  these  issues.    These  initiatives  include  the  establishment  of  a  Central
Ethics  Committee  at  Headquarters  to  look  at  research  proposals  with  national
significance and also to help  the  Regional  IEC’s  in  various  issues.  These  include:
the  strengthening  the  increasing  demand  for  infrastructure  development,  capacity
building,  monitoring  mechanism,  safety  issues,  and  innovative  initiatives;  the
establishment  of  the  Pre-clinical  toxicology  units,  Clinical  Pharmacology  units,
Clinical Trial centres.

31

Regarding  education  and  training,  the  initiatives  include  Research  Methodology
workshops, Clinical trial training courses, biostatistics courses, and training in human
&  animal  ethics  and  in  modern  biology.   In  this,  FRCAP,  has  developed  workshops
for  ethics  review  committee  members  for  WHO  ethical  guideline  implementation,
while Industry is also getting involved by sponsoring ethics workshops.

(cid:24)(cid:12)(cid:25)(cid:10)(cid:6)(cid:3)(cid:4)(cid:28)(cid:12)(cid:25)(cid:4)

To  ensure  that  India  becomes  a  leading  nation  in  Good  Clinical  Research,  greater
attention  must  be  paid  to  promoting  clinical  research.    The  gap  between  the
developed  and  developing  worlds  needs  to  be  narrowed  in  order  to  ensure  global
justice, particularily with respect to the widespread availability of proven interventions
in developing countries.  The emphasis is to ensure that Research ethics should be
made an integral part of all biomedical research.  As such every stakeholder should
consider research participants as central players, who should be protected from any
harm for which an appropriate legislation should be in place to ensure the above.

(cid:31)(cid:5)(cid:11)5(cid:12)(cid:2)6(cid:4)(cid:8)(cid:12)(cid:23)(cid:8)(cid:24)(cid:5)(cid:25)(cid:11)(cid:2)(cid:5)(cid:4)(cid:8)(cid:12)(cid:23)(cid:8)!(cid:27)’(cid:19)(cid:25)(cid:10)(cid:5)(cid:27)(cid:8)(cid:29)(cid:5)(cid:4)(cid:5)(cid:19)(cid:2)(cid:10)$

Pre  clinical  Toxicology  Units  (PCT) :  National  Institute  of  Nutrition  (Hyderabad),
toxicology  Research  Centre
Institute  of  Pathology  (New  Delhi), 
(Lucknow),  Institute  for  Research  in  Reproduction  (Mumbai),  Post  Graduate
Institute (Chandigarh).
ICMR  Institutes  having  Animal  Facility :  RMRIMS,  NICED,  RMRC,  TRC,  RMRC,
IIH, IOP, CJIL, VCRC, NIV, NCLAS, IRR.

Industrial 

Clinical Pharmacology Units (Pahse I and Pahse II trials) : Tuberculosis Research
Centre (Chennai), KEM Hospital (Mumbai), Nizam’s Institute (Hyderabad).

Traditional  Medicine  research :  CAR  for  Natural  products,  CDRI  (Lucknow),
Clinical Pharmacology Centre for TRM – Nair Hospital (Mumbai), Standardisation
&  Quality  Control  of  Traditional  Remedies :  RRL  (Jammu)  and  NIPER
(Chandigarh)

32

 (cid:2)1(cid:8)(cid:31)(cid:28)(cid:10)(cid:12)(cid:6)(cid:19)(cid:4)(cid:8),# !(cid:8), (cid:7)(cid:8)8$ 
Chief, Department of HIV/AIDS & Reproductive Health
Centre MURAZ, MoH Biomedical Research & Training Institute,
Bobo-Dioulasso, Burkina Faso

+(cid:26)4@!(cid:26) /(cid:8)(cid:10)(cid:6)(cid:28)(cid:25)(cid:28)(cid:10)(cid:19)(cid:6)(cid:8)(cid:2)(cid:5)(cid:4)(cid:5)(cid:19)(cid:2)(cid:10)$(cid:8)(cid:28)(cid:25)(cid:8)!(cid:23)(cid:2)(cid:28)(cid:10)(cid:19)2(cid:8)(cid:5)(cid:11)$(cid:28)(cid:10)(cid:19)(cid:6)(cid:8)(cid:19)(cid:4)%(cid:5)(cid:10)(cid:11)(cid:4)

(cid:31)(cid:28)(cid:10)(cid:12)(cid:6)(cid:19)(cid:4)(cid:8),# !

It is impossible to begin to discuss this topic without giving an indication of the scale
and  the  seriousness  of  the  problem  in  the  African  region.  Nearly  30  million  people
today  live  with  the  AIDS  virus  in  Africa.  About  16  million  people  have  already
succumbed to AIDS leaving behind as many orphans.

The  total  statistics  from  around  the  world  do  not  even  approach  those  from  Africa.
Moreover,  if  AIDS  has  imposed  itself  as  the  most  serious  threat  to  public  health  in
Africa, it has also become the most serious obstacle to durable human development
in the region.

+(cid:26)4@!(cid:26) /(cid:8)(cid:4)(cid:28)(cid:11)(cid:3)(cid:19)(cid:11)(cid:28)(cid:12)(cid:25)(cid:8)(cid:28)(cid:25)(cid:8)!(cid:23)(cid:2)(cid:28)(cid:10)(cid:19)(cid:7)(cid:8)(cid:15)(cid:16)(cid:16)(cid:15)

World

Africa

Orphans

Children

Total cases 
HIV infection

0

5

10

15

20

25

30

35

40

Number of cases (million), 2002

There  is  no  question  as  to  the  necessity  of  the  need  for  clinical  research  as  a
necessary step in the advancement of medical knowledge in order to provide quality
health  care  to  the  public.  We  should  also  recognise  that  Africa  is  clearly  where
HIV/AIDS  medical  research  should  become  a  priority,  and  everyone  (national
decision-makers, development, scientific and community  partners) should  recognise
this. More than anywhere else, it is in Africa that issues such as prevention, access
to  healthcare,  treatment  and  finally  the  care  of  people  infected  are  the  most
desperate.

In  this  line,  major  advances  have  been  obtained  on  the  field  in  Africa.  With  the
principal  support  of  the  European  Commission,  research  has  shown  that  treating
sexually transmitted diseases (STD) will  significantly reduce the  incidence  of HIV  in

35

the  general  population3.  With  the  support  of  the  French  Nationale  Agency  for  AIDS
Research    (ANRS)4,  the  American  National  Institut  of  Health  and  the  Centre  for
Disease  Control  and  Prevention  (CDC),  research  has  proven  that  short-course
antiviral drugs can diminish by half mother to infant transmission of the AIDS virus.5

Moreover,  with  this  same  financial  support  from  the  ANRS  and  the  CDC,  we  now
know  that  cotimoxazole,  commonly  known  as  BACTRIM  and  very  inexpensive,
diminishes  by  almost  half  the  severe  illnesses  and  even  death  in  tuberculosis
infected and non-infected individuals living with HIV. This work was done in the Ivory
Coast.

And finally, through research done in Kenya and Tanzania, we are today convinced
that the counselling and HIV testing services provided to the individual, and what is
more, to the couple, changes sexual behaviour. Thus, reducing by 46% the incidence
of sexually transmitted disease, including HIV/AIDS.

These recent advances in medical research in Africa are already  being  applied  and
are saving lives. All the United Nations agencies as well all the development partners
have taken the examples cited as points of reference for program financing.

However, if we were to apply one of the many ethical guidelines established around
the  world  to  these  projects,  none  of  these  studies  would  have  been  conducted.
Which is why the main part of my presentation will address the following: « we want
the  research  results  in  Africa »,  « we  reject  the  research  necessary  to  obtain  the
results we need ».

This  is  why  the  foundation  of  my  presentation  will  seek  to  defend  the  following
hypothesis:  if  the  ethical  rules  dictated  by  the  dominance  of  the  western  atheism,
said to be liberated from dogmas, are imposed on all as revelations of truth, we can
therefore consider that instead of promoting  human rights, these  rules represent  an
obstacle to scientific progress in Africa. My scientific perspective on ethics has been
formed  by  culture,  the  value  system  of  a  given  society,  religion,  the  level  of
education,  of  development,  of  experience,  and  also  contains  and  an  emotional  and
an intuitive dimension.

This  is  the  reason  that  the  real  foundations  of  ethics  in  medical  research  in
developing countries must be based on the African context and the reality of North-
South  relations  today.  Outside  of  this  frame  of  reflection,  this  meeting  would  be
nothing  more  than  another  meeting  where  good  people  sat  around  a  richly
ornamented  table  to  say  good  things  but  which  would  have  no  influence  on  the
everyday reality of the African population.

3 Treating STD syndromes reduces HIV incidence by 42% in adult general population and is cost effective.
Grosskurth et al. Lancet 1995, Gilson et al. Lancet 1997.
4 L’Agence Nationale française de Recherches sur le SIDA (ANRS)
5 Using short course ARV regimens in the perinatal periode reduces MTCT of HIV by nearly 50% at 6
months and is cost-effective. Dabis et al. Lancet 1999, Gay et al. Lancet 1999, Creese et al. 2002.

36

                                                
There  are  essentially  five fundamental  principles  in  ‘universal’  ethics  that  served  as
the  basis  for  the  putting  in  place  of  different  rules,  regulations  and  laws.  My
presentation will review, one by one, these different principles and build on the reality
of these different principles in the medical research devoted to HIV/AIDS in Africa.

(cid:22)$(cid:5)(cid:8)%(cid:2)(cid:28)(cid:25)(cid:10)(cid:28)%(cid:6)(cid:5)(cid:8)(cid:12)(cid:23)(cid:8)(cid:11)$(cid:5)(cid:8)(cid:2)(cid:5)(cid:4)%(cid:5)(cid:10)(cid:11)(cid:8)(cid:12)(cid:23)(cid:8)(cid:11)$(cid:5)(cid:8)/(cid:10)(cid:28)(cid:5)(cid:25)(cid:10)(cid:5)(cid:8) (cid:28)((cid:25)(cid:28)(cid:11)(cid:20)

The  first  of  these  principles  is  for  me  the  respect  of  the  dignity  of  science.  This
respect  necessitates  that  questions  with  respect  to  public  health  are  given  priority
and  addressed  with  the  necessary  scientific  rigour.    This  includes  the  relevance  of
the  study  question  for  medical  progress  and  public  health,  the  quality  of  the  study
protocol,  the  adequacy  of  technical  facilities  and  funds,  and  the  qualifications  of
scientific investigators.

The  reality  in  Africa  is  somewhat  different.  In  Africa  good  science  is  equated  with
imported  research,  where  local  researchers  are  not  involved  in  the  scientific
protocols. Moreover, these protocols are not evaluated independently.  This therefore
leaves room for the « the kingdom of promotional studies »,  where the  low  capacity
of  local  investigators  in the  design,  conduct  and  publication  of  scientifically  relevant
studies  are  targeted  by  the  private  sector.  The  pharmaceutical  industry  is  thus
conducting  purely  promotional  research  in  collaboration  with  doctors  from  public
hospitals  in  order  to  prepare  glossy  brochures  colour  prospecti  responding  to
questions of little social value.

In  Africa,  the  best  clinical  research  is  generally  those  projects  which  are  conducted
by researchers from the North in collaboration with scientists from the South, due to
the weak methodological capacity of local researchers as well as the weak economy.
For example,  let  us  randomly  take  the  ten most  renowned  journals,  and  look at  the
first  author  of  published  AIDS  clinical  research.  The  number  of  African  researchers
will virtually tend towards zero, if it is not simply zero.

In  the  field,  the  African  media  daily  ‘reports’  rumours  and  information  on  traditional
treatments  with  miraculous  curative  powers  with  respect  to  HIV/AIDS.  Moreover,
many  traditional  practitioners  and  unscrupulous  persons  abuse  the  distress  created
by AIDS. The fact that the population is generally uninformed in regard to HIV natural
history, enables these persons to prove the absolute efficiency of traditional (or non-
traditional) products, whose efficiency and safety have never been tested. And often,
this  is  done  with  the  benediction  of  the  local  authorities,  always  ready  to  value
traditional or local medicine over the too expensive modern medicines.

37

(cid:22)$(cid:5)(cid:8)%(cid:2)(cid:28)(cid:25)(cid:10)(cid:28)%(cid:6)(cid:5)(cid:8)(cid:12)(cid:23)(cid:8)(cid:26)(cid:25)(cid:27)(cid:28)’(cid:28)(cid:27)(cid:3)(cid:19)(cid:6)(cid:8)!(cid:3)(cid:11)(cid:12)(cid:25)(cid:12)&(cid:20)

The  respect  of  human  dignity,  centred  on  enlightened  consent  is  the  principal  ethic
which has been the most valued. It is the basis for the Nuremberg code.  It is useless
to spend time on the main ideas behind this principal. Let us rather look at the reality
of the application of this principle in Africa.

Autonomy  in  the  choice  to  participate  in the study  through  a  clear  understanding  of
the  study  protocol  indicated  by  the  signature  of  informed  consent.  This  is  done  in
order  to  ensure  the  protection  of  the  confidentiality  of  collected  data  or  private
information  known  in  the  context  of  the  study.  The  situation  in  Africa,  plagued  by
poverty, has introduced vulnerability and coercion into the debate.

Can  we  speak  of  the  autonomy  of  women  in  a  precarious  social  position?  Which
autonomy of choice can exist in the context of poverty when faced with the privileges
offered by the study? How can one protect confidentiality in a social situation where
HIV/AIDS  is  highly  stigmatised?  Is  the  individualistic  approach  of  ethics  appropriate
in a context where communitarianism governs society?

In  discussing  Africa,  we  evoke  a  context  of  vulnerability  marked  by  increasing
poverty,  cumbersome  sociocultural  traditions  and  high  illiteracy.  In  an  environment
where there is little available treatment for AIDS, and where participating in a clinical
trial  may  be  considered  a  privilege  (where  participants  are  given  the  benefit  of  a
standard of care significantly better than the rest of the population) what value does
freedom of choice have?

What  freedom  of  choice  does  a  woman  have  in  this  decision  when  she  herself  is
convinced  that  only  her  partner  or  husband  can  authorise  such  and  such  act  in  life
(DITRAME  experiment)?  What  autonomy  does  individual  consent  have  in  a  rural
environment  where  the  village  chief  is  responsible  for  the  relationship  with  the
outside  world?  To  what  extent  can  notions  of  random  parallel,  crossed  or  plan
factorial  trial  double  blind  versus  placebo  be  understood  when  almost  70%  of  the
population is illiterate? At this stage we only have questions.

(cid:22)$(cid:5)(cid:8)%(cid:2)(cid:28)(cid:25)(cid:10)(cid:28)%(cid:6)(cid:5)(cid:8)(cid:12)(cid:23)(cid:8)(cid:1)(cid:5)(cid:25)(cid:5)(cid:23)(cid:28)(cid:10)(cid:5)(cid:25)(cid:10)(cid:5)

The third principal is that of beneficence. It is in the respect of this principle that the
scientist  is  subjected  to  the  most  difficult  questions  in  research:  How  to  treat  the
individual, in the form of direct benefit and evaluate long term collective benefit? If a
certain  treatment  is  evaluated  to  have  an  interesting  potential  benefit  and  is
comparable to the standard treatment in place, a priori, ambivalence is respected.

The  ethical  conflict  remains  how  to  maximise  benefits  and  minimise  harm:  how  to
treat  a  patient  (care)  and  evaluate  a  treatment  (research)?    How  does  one  respect
the equipoise between a new promising method, with good results in the preliminary

38

animal  and  Phase  I/II  studies  versus  the  established  standard  of  care? What  is  the
place of placebo?

The situation in Africa is that of poverty, one which cannot afford a high standard of
care.  As  we  saw  with  the  Harvard  MTCT trial  in  Thailand,  those  results  are  for  rich
countries.  However,  the  MTCT  and  Cotrimoxazole  clinical  trial  results  are  widely
utilised in Africa. Microbicided trials have the right to use placebo groups. However,
where  there  is  no  standard  of  care,  or  where  the  existing  standard  of  care  is
inaccessible  (culturally,  technically,  logistically,  financially,  etc.),  should  research  be
forbidden?  Is  it  ethical,  in  the  name  of  universal  moral  values,  to  prevent
downtrodden populations to fight to identify interventions that would be accessible to
them?

One  has  only  to  consider  the  short-course  trials  of  antiviral  drugs  in  Africa.  I
personally led this type of trial in Burkina Faso. The use of placebo as a standard of
comparative  treatment  was  contested  without  taking  into  account  its  social  and
scientific  value,  as  well  as  the  adaptation  of  the  study  to  the  local  context.  The
disputed studies produced scientifically irrefutable results that all the agencies across
the  world,  and  particularly  the  European  Commission,  recommend  in  AIDS
programmes in the South.

The  standard  of  care  which  we  are  discussing  with  respect  to  the  principle  of
beneficence is not a simple question of will but that of what the power to buy at the
level of the State or that of the individual can buy. The reality can not be hidden by a
declaration, a rich person and a poor person do not have the same standard of care.
To  impose  such  standards,  in  order  to  respect  ethics,  would  prevent  much  needed
clinical research, to an African would appear as unjust and immoral.

(cid:22)$(cid:5)(cid:8)%(cid:2)(cid:28)(cid:25)(cid:10)(cid:28)%(cid:6)(cid:5)(cid:8)(cid:12)(cid:23)(cid:8)A(cid:3)(cid:4)(cid:11)(cid:28)(cid:10)(cid:5)

Let us consider this principle of Justice which appears as one of the five pillars of so-
called universal ethics. There are many components to this principal, and I  will  only
cite one rule:(cid:11)%(cid:7)(cid:19)(cid:8)(cid:3)(cid:5)(cid:4)(cid:4)(cid:16))(cid:11)(cid:5)(cid:4)(cid:4)(cid:11)(cid:17)(cid:5)(cid:7)(cid:8)(cid:2)(cid:10)(cid:7)(cid:14)(cid:11)(cid:19)(cid:5) (cid:8)(cid:10)(cid:20)(cid:11)(cid:17)(cid:5)(cid:6)(cid:7)(cid:8)(cid:3)(cid:8)(cid:17)(cid:5)(cid:7)(cid:2)(cid:29)(cid:11)(cid:8)(cid:10)(cid:11)(cid:5)(cid:11)(cid:14)(cid:7)(cid:21)(cid:29)(cid:16)(cid:11)(cid:22)(cid:21)(cid:14)(cid:7)(cid:11)(cid:25)(cid:2)(cid:11)(cid:5)(cid:14)(cid:14)(cid:21)(cid:6)(cid:2)(cid:29))(cid:11)(cid:5)(cid:7)
(cid:7)(cid:19)(cid:2)(cid:11) (cid:2)(cid:10)(cid:29)(cid:11) (cid:9)(cid:12)(cid:11) (cid:7)(cid:19)(cid:2)(cid:11) (cid:14)(cid:7)(cid:21)(cid:29)(cid:16))(cid:11) (cid:9)(cid:12)(cid:11) (cid:29)(cid:8)(cid:5)(cid:20)(cid:10)(cid:9)(cid:14)(cid:7)(cid:8)(cid:3))(cid:11) (cid:7)(cid:19)(cid:2)(cid:6)(cid:5)(cid:17)(cid:2)(cid:21)(cid:7)(cid:8)(cid:3)(cid:11) (cid:5)(cid:10)(cid:29)(cid:11) (cid:17)(cid:6)(cid:2) (cid:2)(cid:10)(cid:7)(cid:8) (cid:2)(cid:11) (cid:7)(cid:6)(cid:2)(cid:5)(cid:7)(cid:22)(cid:2)(cid:10)(cid:7)(cid:11) (cid:30)(cid:19)(cid:8)(cid:3)(cid:19)(cid:11) (cid:7)(cid:19)(cid:2)
(cid:14)(cid:7)(cid:21)(cid:29)(cid:16)(cid:11)(cid:14)(cid:19)(cid:9)(cid:30)(cid:2)(cid:29)(cid:11)(cid:7)(cid:9)(cid:11)(cid:25)(cid:2)(cid:11)(cid:14)(cid:21)(cid:17)(cid:2)(cid:6)(cid:8)(cid:9)(cid:6).

This  principle  implies  the  equitable  distribution  of  the  risks,  the  burden  and  most
importantly, the benefits resulting from research. It also implies that post-trial benefits
are  seen  in  rich  and  poor  countries,  and  that  North-South  collaboration  establishes
good principles of research partnership. The reality is that the poverty at country and
population  levels  precludes  any  large  application  of  research  results  for  prevention
and care of HIV. In the case of external funding, the location of research activities or
interests  and
resulting  programmes  depends  on  political  and  economical 
geostrategy.  For  example,  which  EU  funds  will  be  allocated  to  Togo?  Which  for
Zimbabwe?

39

How many Africans have access to the positive aspects of HIV/AIDS clinical research
financed by the North? Less than 1% of those living with HIV in developing countries
who require treatment have access to ARV. Very few pregnant women benefit from
short term ARVs to save their child’s life.

The question is above all linked to the weak purchasing power of the populations and
states  in  Africa.  But  when  international  solidarity  intervenes  in  order  to  benefit  the
African population, the principle of Justice remains in this room on the rue Froissart.
Where  is  USAID  in  Africa? Will  the  European  Commission  give  even  one  penny  to
the populations of Zimbabwe, Togo or the Ivory Coast? What is the responsibility of
African  governments, 
"South"
researchers? It seems clear that without international solidarity it is quite impossible
to apply the Justice principle in the post-trial period.

funding  agencies, 

rich  countries, 

"North"  & 

(cid:22)$(cid:5)(cid:8)%(cid:2)(cid:28)(cid:25)(cid:10)(cid:28)%(cid:6)(cid:5)(cid:8)(cid:12)(cid:23)(cid:8)(cid:26)(cid:25)(cid:27)(cid:5)%(cid:5)(cid:25)(cid:27)(cid:5)(cid:25)(cid:10)(cid:5)

And finally, we will end with the fifth principle which is that of independence. It is not
easy to prove the credibility, good faith, conformity to ethical rules and the application
of standards in the good practices for clinical, biological and statistical research when
we refuse to submit to the criticism and control by external scrutiny. This is why the
role of the different ethical, scientific, regulatory and pilot committees is preponderant
in  clinical  trials.  (e.g.  Scientific  Review  Committees,  Ethical  Review  Committees,
Data  &  Safety  Monitoring  Board,  Study  Steering  Committee,  Study  Scientific
Committee)

In  Africa,  we  are  always  looking  for  this  type  of  committee,  particularly  when  only
local researchers conduct the research. Who is responsible for this void? Why is this
criticism  of  the  lack  of  ethical  committees  done  is  such  an  insidious  manner  when
researchers  from  the  North  are  implicated?  Why  is  this  same  concern  not  raised
when researchers from the South are working in their corner?

By  talking  about  ethics  in  clinical  research  in  Africa  without  taking  into  account  the
state of poverty, culture, social value systems, religion, illiteracy levels, development
levels, and local experience is to contemplate the gender of angels. In Africa, many
countries do not have committees for local or imported studies.

Without  government  awareness  of  duties  to  protect  human  rights,  it  is  difficult  to
imagine  the  creation  of  competent  ethical  committees.  The  actual  practices  have
many limitations with respect to the ethical rules  in medical research  in  Africa.  How
do  the  standards  of  ethics,  established  under  the  domination  of  the  Western  value
system  represent  a  universal  standard?  Why  are  governments  and  civil  society  in
Africa inert in the face of questions and challenges of ethical dilemmas in the field of
medical  research  in  Africa?  Why  are  the  technical  abilities  and  methodological
capacities  of  Africans,  with  respect  to  clinical  research  devoted  to  AIDS,  so

40

underdeveloped  after  decades  of  scientific  collaboration  between  the  North  and
South?  Is  there  a  real  vision  of  development  in  the  North/South  exchange  with
respect to HIV/AIDS research? What is the North  doing  to  promote  human rights  in
the HIV/AIDS research that it finances in the South?

It is almost pretentious to talk about the right answer to the ethical challenge that is
HIV/AIDS  research  in  Africa.  But  in  my  humble  opinion,  there  is  substance  in  the
results  that  we  have  today  that  will  allow  us  to  abandon  the  rhetoric  wrapped  in
dogmatism, even imperialism, to engage in a pragmatic path to the contextualisation
of medical ethics.

A principal  I  would  like  to  introduce  is the  obligation of  international  solidarity  in  the
defence of the right to health and human rights  in  the  South. International  solidarity
can amplify pressure on governments and civil society in Africa in order to take into
account ethics in HIV/AIDS research. International solidarity can also truly become a
way  to  development  in  the  formation  and  support  of  the  immense  capacity  in  the
South for medical research. Without international solidarity, I do not see how African
populations can benefit from the positive results of HIV/AIDS research conducted by
agencies  financed  by  the  North.  And  what  role,  what  leadership  can  the  European
Commission  provide  or  play  in  order  to  overcome  these  major  challenges  that  can
guarantee  African  populations,  and  what  is  more  -to  those  infected  with  AIDS,  the
power to enjoy the basic right to health?

41

 (cid:2)1(cid:8)+(cid:19)(cid:25)(cid:25)(cid:19)(cid:8)(cid:31)(cid:9)+>(cid:31)#0(cid:8), (cid:8)8$ 
Department of Vaccines
National Public Health Institute
HELSINKI - Finland

#(cid:11)$(cid:28)(cid:10)(cid:19)(cid:6)(cid:8)(cid:28)(cid:4)(cid:4)(cid:3)(cid:5)(cid:4)(cid:8)(cid:28)(cid:25)(cid:8)(cid:11)$(cid:5)(cid:8)%(cid:25)(cid:5)(cid:3)&(cid:12)(cid:10)(cid:12)(cid:10)(cid:10)(cid:19)(cid:6)(cid:8)(cid:10)(cid:12)(cid:25):(cid:3)((cid:19)(cid:11)(cid:5)(cid:8)’(cid:19)(cid:10)(cid:10)(cid:28)(cid:25)(cid:5)
(cid:10)(cid:6)(cid:28)(cid:25)(cid:28)(cid:10)(cid:19)(cid:6)(cid:8)(cid:11)(cid:2)(cid:28)(cid:19)(cid:6)(cid:4)(cid:8)(cid:28)(cid:25)(cid:8)(cid:11)$(cid:5)(cid:8)8$(cid:28)(cid:6)(cid:28)%%(cid:28)(cid:25)(cid:5)(cid:4)2(cid:8)(cid:11)$(cid:5)(cid:8)!(cid:29)(cid:26)4!(cid:24)(cid:8)(cid:5)<%(cid:5)(cid:2)(cid:28)(cid:5)(cid:25)(cid:10)(cid:5)

+(cid:19)(cid:25)(cid:25)(cid:19)(cid:8)(cid:31)(cid:9)+>(cid:31)#0

Since  July  2000,  the  ARIVAC  consortium  has  been  conducting  a  Phase  III
effectiveness  study  of  an  unlicensed  pneumococcal  (Pnc)  conjugate  vaccine  (PCV)
in the Philippines. Unlike most other PCV trials which have concentrated on invasive
Pnc disease, the main endpoint of this study is pneumonia, which kills approximately
4  million  children  annually,  and  thus  constitutes  a  major  public  health  disease
burden. An estimated cohort of 12 190 infants will be enrolled over a period of three
years. The vaccine is given according to the national immunisation programme at 6,
10, and 14 weeks, and the children are being followed up until the age of 2 years.

The study is a Phase III, randomised, double blind, controlled, clinical trial (RCT)  to
determine the effectiveness of an 11-valent  PCV  in  preventing  radiologically  proven
pneumonia in young children. It is being conducted in 6 municipalities on the island of
Bohol, the Philippines. The trial commenced in July 2000 and will last until 2005, with
a decade of preparatory work.

In  addition  to  the  main  endpoint,  the  trial  will  answer  several  other  research
questionssuch  as    overall  Pnc  disease  burden,  cost-effectiveness  of  PCV,  herd
immunity effect, vaccine type invasive disease, immunogenicity and safety of  PCV,
and the vaccine impact on the nasopharyngeal carriage of pneumococcea.

Pneumonia was chosen as the primary endpoint diagnosis because of its importance
as the major global public health disease burden in children under five years old. The
Philippines  was  chosen  as  thestudy  site  because  of  the  availability  of  data  arising
from  long-term  baseline  studies  on  ARI  case  management  and  on  the  causes  of
pneumonia,  sepsis  and  meningitis.  The  island  of  Bohol  was  chosen  because  of  its
infrastructure  supporting  the  trial  and    the  research  friendly  environment,  both  on
professional  and  political  level.  This  study  is  so  far  the  only  Phase  III  study  being
planned with any Pnc vaccine to take place in Asia. It is carried under the multiparty
international co-operation by the ARIVAC consortium, whichincludes Finland, France,
the Philippines, the United Kingdom, Australia, and the United States.

Studies  of  this  scope  and  size  tend  to  be  complex,  loaded  with  numerous  research
questions  and  expensive;there  are  many  ethical  issues  raised  during  the  course  of
the work. The main ethical points which the trial team is or has been dealing with are
the process of informed consent, the availability of care during the trial, the availability
of the product after the trial is over, the long term safety follow-up of the trial subjects,
and finally the sponsor’s responsibility for securing funding.

45

(cid:22)$(cid:5)(cid:8)%(cid:2)(cid:12)(cid:10)(cid:5)(cid:4)(cid:4)(cid:8)(cid:12)(cid:23)(cid:8)(cid:28)(cid:25)(cid:23)(cid:12)(cid:2)&(cid:5)(cid:27)(cid:8)(cid:10)(cid:12)(cid:25)(cid:4)(cid:5)(cid:25)(cid:11)

Informed consent (IC) is a PROCESS by which a subject voluntarily confirms his or
her  willingness  to  participate  in  a  trial  or  research  after  having  been  informed  of  all
aspects  of  the  trial  that  are  relevant  to  the  subject’s  decision  to  participate.  IC  is
documented by means of a written, signed and dated informed consent form.

The practical dilemma with informed consent is how to give the vast amount of new
information needed for the parents and the extended family to fully understand what
their  child  isare  getting  involved  in  when  becoming  a  trial  subject.  In  the  ARIAC
consortium,  we  see  this  informing  as  a  process  evolving  over  a  long  period  of  time
rather than just the face to face contact with the enrolling physician and the parental
signing  of  their  consent.  The  process  starts  with  educational  posters  put  up  in  the
community  on  pneumonia  and  vaccine  preventable  diseases,  and  continues  in  the
well  baby  clinic  meetings  where  the  trial  is  being  discussed.  A  leaflet  is  given  to
parents, then a study nurse pays a home visit to discuss the trial details with all those
family  members  who  need  to  know,  and  are  involved  in  making  decisions  for  the
baby,  which  in  this  Asian  setting  often  includes  the  grandmother  and  father.  Only
then  the  final  discussion  during  the  enrolment  and  signing  of  the  consent  form  will
follow.  Despite  this  extensive  process,  not  all  parents  fully  understand  and/or
remember.  We  have  evaluated  the  outcome  of  the  process  in  focus  group
discussions;it is evident that the concept of randomisation and placebo are the most
difficult ones to grasp.

It  is  most  important  to  provide  the  opportunity  to  ask  questions,  and  discuss  in
prenatal  clinics  the  trial  brochure,  and  information  sheet.  Only  through  repeated
questions  and  answers  do  the  participants  truly  understand  what  they  are  getting
into. These provisions are put in place so that all relevant information is available for
the  parents  to  make  a  fully  informed  decision.  We  also  ensure  that  there  is
opportunity for prospective participants to ask questions and discuss concerns with a
knowledgeable research team member, one to two weeks prior to the first study visit
or  during  a  postpartum  visit.  And  most  importantly,  to  allow  time  to  discuss  the
information  sheet  with  significant  others.  This  process  is  put  in  place  in  order  to
create an atmosphere allowing requests for additional information.

The international Data Safety Monitoring Committee, concerned that the process was
too long and the information sheets too complicated requested for Informed Consent
quality  checks.  In  2001,  the  IC  process  was  therefore  evaluated  through  external
interviews  with  consented  (N=536)  and  non-consented  (N=130)  mothers.  These
interviews  showed  that  few  mothers  understood  that  placebo  does  not  provide
protection. Most mothers could not have decided on participation prior to discussion,
and  that  most  mothers  sought  advice  from  family  members  or  neighbours  prior  to
consenting,  a  clear  indication  for  the  need  to  involve  community  participation  and
information.

46

(cid:22)$(cid:5)(cid:8)(cid:19)’(cid:19)(cid:28)(cid:6)(cid:19)(cid:13)(cid:28)(cid:6)(cid:28)(cid:11)(cid:20)(cid:8)(cid:12)(cid:23)(cid:8)(cid:10)(cid:19)(cid:2)(cid:5)(cid:8)(cid:27)(cid:3)(cid:2)(cid:28)(cid:25)((cid:8)(cid:11)$(cid:5)(cid:8)(cid:11)(cid:2)(cid:28)(cid:19)(cid:6)

During  the  clinical  trial  the  ARIVAC  patients  receive  free  physician’s  attention,  free
diagnostic  tests  (blood  culture,  cerebrospinal  fluid  culture  CSF,  white  blood  cell
count,  oxymeter), 
to  oxyxen,  and
radiogramsand 
antimicrobials,  but  only  if  they  attend  the  Bohol  Regional  Hospital  or  the  3  private
hospitals in charge of case evaluation for pneumonia, sepsis, and meningitis.

free  access 

free  chest 

To  avoid  discrimination  and  to  support  unforced  decision  to  participate  in  the  trial,
chest  radiograms,  blood  and  CSF  culture,  clinical  chemistry  tests  and  basic
antimicrobials  are  provided  for  all  the  children  <5  years  of  age  admitted  to  the  4
collaborating  hospitals  for  the  trial  endpoint  diseases  (i.e.  pneumonia,  sepsis,
meningitis) and living in the 6 trial municipalities regardless of their participation in the
trial. One might argue that this makes the trial more expensive, but the availability of
care to all children from the trial area has been deemed ethically a more just solution
than discriminating on the basis of trial enrolment.

This decision was made in response to  criticism that  parents  were  not  truly  given  a
free choice to participate.

(cid:22)$(cid:5)(cid:8)(cid:19)’(cid:19)(cid:28)(cid:6)(cid:19)(cid:13)(cid:28)(cid:6)(cid:28)(cid:11)(cid:20)(cid:8)(cid:12)(cid:23)(cid:8)(cid:11)$(cid:5)(cid:8)%(cid:2)(cid:12)(cid:27)(cid:3)(cid:10)(cid:11)(cid:8)(cid:19)(cid:23)(cid:11)(cid:5)(cid:2)(cid:8)(cid:11)$(cid:5)(cid:8)(cid:11)(cid:2)(cid:28)(cid:19)(cid:6)(cid:8)(cid:28)(cid:4)(cid:8)(cid:12)’(cid:5)(cid:2)

In January 2001, after less than a year of an intensive fact-finding and consultation,
the  manufacturer  decided  to  stop  the  clinical  development  of  the  study  vaccine
(11PCV)  .  The  reason  was  that  11PCV  was  shown  to  be  very  immunogenic  when
given  with  the  conventional  diphtheria  whole  cellular  pertussis  vaccine,  but  did  not
perform nearly as well when given with acellular pertussis vaccine.
In  the  light  of  the  estimated  risk  of  possibly  not  succeeding  in  the  licensure  of  the
product should the FDA requirements for immunogenic equivalence in comparison to
the presently licensed 7-valent PCV-the manufacturer in January 2002 decided not to
pursue  the  commercialization  of  the  product  .  Immediately  the  availability  of  the
product after the trial would be  over became a major concern to the trial team. This
led  to  extensive  consultative  process  with  the  Ethical  Review  Board  in  Manila,  the
provincial  and  municipal  health  officers, the  Ministry  of  Health,  and  the  Data  Safety
Monitoring  Board.  The  ARIVAC  consortium  for  its  part  agreed  that  the  trial  should
continue  as  its  main  aim  was  to  find  answers  to  relevant  public  health  questions
(vaccine effectiveness in true field conditions, burden of pneumococcal disease, cost
effectiveness, herd immunity) rather than to be a pivotal licensure study.  All research
questions  were  still  valid,  as  this  is  the  only  PCV  trial  in  Asia,  where  Pnc  disease
burden information  is  very  much  needed  and to  aid  in  the  decision making  on  PCV
implementation into national programmes.

When  the  community  advice  was  sought  by  the  consortium,  the  major  reason  why
the local municipal health officers decided that the trial should be allowed to continue

47

was  the  immediate  benefits  brought  to  the  community,  i.e.  steady  availability  of  the
EPI and study vaccines and treatment during hospitalisation.

Two ethical issues arose from this event. First, what and how to inform the ARIVAC
trial  participants,  trial  staff  and  the  community  of  the  manufacturer´s  decision?  The
informed  consent  was  changed  and  a question  answer  sheet  developed  in  order  to
standardise  the  messages  given  by  the  study  nurses  and  physicians  to  the
community on this new development. In addition, the intention was to publish a news
piece on recent developments in the Bohol Bulletin, but this initiative was given up in
fear  of  media  possibly  misunderstanding  the  course  of  events  and  their  rationale.
Second,  what  product  would  the  sponsor  (the  ARIVAC  consortium)  provide  to  the
participants and community after the trial is over ? The negotiation process to resolve
this  issue  has  started.  However,  in  my  opinion,  addressing  this  site  specific  issue
should not deviate the scientific and public health community away from  initiating the
long  term  decision  making  process  via  feasibility,  disease  burden  and  cost
effectiveness  studies  along  with  the  phase  III  studies,  so  that  by  the  time  the
effectiveness  data  of  the  product  is  available,  the  decision  makers,  funders  and
donor  community  are  better  prepared  to  implement  the  new  product  in  national
programs, provided effectiveness has been proven.

Another question on the availability of the product after the trial is over is whether the
community  as  a  whole  should  be  given  this  benefit.  How  does  one  define  the
community?  Is  it  only  those  municipalities  which  participated  in  the  trial,  is  it  the
whole island, region or possibly the nation? From the point of view of the funders of
the study, requests of this magnitude may be economically hard to come up with, and
may  in  long  run  be  counterproductive.  The  ARIVAC  consortium  has  started
negotiations over this issue , but nothing definite has as yet been decided.

"(cid:12)(cid:25)((cid:8)(cid:11)(cid:5)(cid:2)&(cid:8)(cid:4)(cid:19)(cid:23)(cid:5)(cid:11)(cid:20)(cid:8)(cid:4)(cid:3)(cid:2)’(cid:5)(cid:28)(cid:6)(cid:6)(cid:19)(cid:25)(cid:10)(cid:5)

Once the trial is over, there are two ways of dealing with the placebo group: one can
decide not to give them any further extra benefit in the form of the study vaccine or its
equivalent  or  one  can  decide  to  give  them  this  benefit.  Those  who  argue  for  the
benefit want to believe that the vaccine is safe also in long term and see no scientific
or ethical reason to extend the long-term follow up time. Those who are increasingly
weary  of  long  term  non-specific  effects  of  any  vaccine  are  strongly  against  treating
the  placebo  group,  and  advice  following  up  this  group  to  rule  out  any  deleterious
effects. For them, it is unscientific, unethical and unjust to give the placebo group the
study vaccine. Moreover, most studies do not have the power to look at rare adverse
events. In statistical terms, the power calculations demostrate that in order to detect
a  two-fold  increase  in  any    adverse  event  from    5  to  10%  incidence  ,  1000  study
subjects  are  needed.  An  increase  from  1  to  2  %  can  be  observed  with  5000  trial
subjects. And as rare event as 0.1-increasing to0.2  % will explode the sample size to
50 000, a size of a trial very few of researchers and funderscan afford..

48

The ARIVAC consortium  is not strongly for treating the placebo group also from the
epidemiologic  point  of  view  that  by  the  age  of  2  years,  most  study  children  have
passed  the  riskiest  age  for  Pnc  disease.  A  dose  of  PCV  would  thus  not  provide  so
much  preventive  benefit  that  it  would  be  justified.  Another  question  is  how  the  long
term safety follow up should be arranged by the study team provided the trial as such
no  longer  exists  and  the  trial  staff  and  enhanced  active  surveillance  usually  cannot
be supported by the local health care infrastructures.

If  the  product  is  licensed  and  thus  enters  into  phase  IV,  it  is  the  national  AEFI
surveillance system and manufacturers whose responsibility safety surveillance falls
under  .  It  becomes  a  different  issue  if  the  product  is  not  brought  to  the  markets.
Clinical  development  cost  is  already  very  high-  If  we  want  to  add  the  burden  of
extended safety follow up to the manufacturers, it could be counterproductive in the
long run.

/%(cid:12)(cid:25)(cid:4)(cid:12)(cid:2)?(cid:4)(cid:8)(cid:2)(cid:5)(cid:4)%(cid:12)(cid:25)(cid:4)(cid:28)(cid:13)(cid:28)(cid:6)(cid:28)(cid:11)(cid:20)(cid:8)(cid:23)(cid:12)(cid:2)(cid:8)(cid:4)(cid:5)(cid:10)(cid:3)(cid:2)(cid:5)(cid:8)(cid:23)(cid:3)(cid:25)(cid:27)(cid:28)(cid:25)(

In the case of this phase III trial, the ARIVAC consortium which consists of different
academic institutions and the manufacturer jointly sponsors the study . According to
the ICH guidelines, the sponsor takes responsibility of the initiative, monitoring and/or
financing  of  a  clinical  trial.  Thus,  it  is  the  sponsor´s  responsibility  to  secure  the
funding basis of the trial, preferably already prior to the start of the trial. If the sponsor
is  the  manufacturer  alone,  often  times  there  is  enough  venture  capital  to  provide
thefundingbasis.  However,if  the  sponsor  is  from  the  public  domain,  and  relies  on
funding  agencies,  the  situation  becomes  more  complex.  This  is  the  case  with  the
ARIVAC study where EU DG Research is the main funder . The EU funding contracts
usually  allowonly  2-3  year  funding  periods  .  These  funding  periods  are  in  striking
contrast  to  the  mean  durations  of  clinical  trials.  Discovery  to  development  alone
represents an average of 7 to 13 years. Baseline studies, finding the facts and phase
I and II trials were started in 1990. The ARIVAC consortium has had 5 separate EU
contracts  in  place.  The  amount  of  insecurity  arising  from  the  evaluation  and
negotiations  in  the  middle  of  an  ongoing  trial  is  in  striking  contrast  to  the  general
requirements of planning ahead and  the good conduct  of clinical  trials. The  present
EU funding reality raises the last ethical dilemma the ARIVAC consortium has had to
deal  with:  is  it  ethical  even  to  start  a  study  with  a  contract  from  a  public  domain
funder if there is no guarantee for further funds to take the trial to its planned end?

(cid:24)(cid:9)(cid:31)(cid:24)"(cid:30)/(cid:26)(cid:9)(cid:31)/

RCT is the gold standard to test vaccine efficacy and effectiveness on ethically sound
ground.  In order to successfully undertake clinical trials, and especially in developing
countries, a 3 dimension interphase, i.e. public – private - regulatory is essential in
most advanced vaccine development.

49

From the nature of any  product  development  it follows  that the  developmental  work
will  take  more  time,  will  be  increasingly  more  costly,  and  professionally  more
demanding  if  we  want  to  maintain  high  ethical  standards.  Also,  if  we  want  to  keep
clinical  product  development  in  the  public  domain  and  maintain  independence  from
private industry, we need to practice creative thinking. .

50

 (cid:2)1(cid:8)(cid:31)(cid:19)(cid:27)(cid:28)(cid:19)(cid:8)(cid:22)(cid:9)(cid:29)(cid:31)(cid:26)#8(cid:9)(cid:29)(cid:22)+(cid:7)(cid:8), (cid:7)(cid:8) (cid:22),B+
Director, Clinical Development,
GlaxoSmithKline Biologicals,
Rixensart, Belgium

#(cid:11)$(cid:28)(cid:10)(cid:19)(cid:6)(cid:8)(cid:19)(cid:4)%(cid:5)(cid:10)(cid:11)(cid:4)(cid:8)(cid:12)(cid:23)(cid:8)(cid:10)(cid:12)(cid:25)(cid:27)(cid:3)(cid:10)(cid:11)(cid:28)(cid:25)((cid:8)(cid:10)(cid:6)(cid:28)(cid:25)(cid:28)(cid:10)(cid:19)(cid:6)(cid:8)(cid:11)(cid:2)(cid:28)(cid:19)(cid:6)(cid:4)(cid:8)(cid:28)(cid:25)(cid:8)(cid:27)(cid:5)’(cid:5)(cid:6)(cid:12)%(cid:28)(cid:25)(
(cid:10)(cid:12)(cid:3)(cid:25)(cid:11)(cid:2)(cid:28)(cid:5)(cid:4)2(cid:8)#<%(cid:5)(cid:2)(cid:28)(cid:5)(cid:25)(cid:10)(cid:5)(cid:4)(cid:8)(cid:12)(cid:23)(cid:8))(cid:6)(cid:19)<(cid:12)/&(cid:28)(cid:11)$0(cid:6)(cid:28)(cid:25)(cid:5)(cid:8)C)/0D1

(cid:31)(cid:19)(cid:27)(cid:28)(cid:19)(cid:8)(cid:22)(cid:9)(cid:29)(cid:31)(cid:26)#8(cid:9)(cid:29)(cid:22)+

This  presentation  will  highlight  some  of  my  practical  experiences  while  conducting
clinical trials in developing countries. GSK has ongoing active collaborative research
programs into diseases of the developing world. Personally, I have been involved in
research concerning the  development  of  vaccines  against malaria,  tuberculosis  and
pneumococcal  infections.  Although  I  am  not  here  to  speak  on  behalf  of  industry,  I
would like to share with you the specific product development perspective that I have
gained during this period.

It  should  be  strongly  emphasised  that  any    research,  regardless  of  locale,  should
always  be  conducted  according  to  recognised  ethical  standards.  Clinical  research
must  be  conducted  according  to  principles  of  the  International  Conference  on
Harmonisation  Good  Clinical  Practice  (ICH-GCP),  and  national  and  international
guidelines  to  safeguard  the  rights  and  safety  of  trial  participants  worldwide.  The
research  should take  into  account  local  laws  and  regulations  as  well  as  ethical  and
cultural practices.

Clinical  research  in  developing  countries  is  conducted  for  a  number  of  different
reasons, foremost to respond to local health needs of disease endemic countries. It
can  also  be  translational  research  to  test  the  effectiveness  or  implementability  of
interventions,  to  respond  to  national  regulatory  requirements,  which  may  require
clinical  trial  experience  in  different  ethnic  groups  or  in  a  number  of  different  health
care settings.  

Whatever  the  reason,  conducting  clinical  trials  in  developing  countries  is  never  an
easy  or  inexpensive    option.  The  lack  of  infrastructure  and  complex  ethical  and
regulatory  requirements  can  make  conducting  clinical  research  in  developing
countries    a  formidable  challenge.  Therefore,  it  is  necessary  to  pay  particular
attention to the local context in which research will  take  place,  and  obtain guidance
from local experts, committees and institutions as necessary. This must be done as
part  of  an  interactive  learning  experience  if  the  research  is  to  be  implemented
successfully.

(cid:22)$(cid:5)(cid:8)(cid:6)(cid:12)(cid:10)(cid:19)(cid:6)(cid:8)(cid:10)(cid:12)(cid:25)(cid:11)(cid:5)<(cid:11)

In  the  developing  world  in  particular,  local  experts,  community  leaders  and  ethics
committees  have  an  important  role  in  advising  on  the  social,  economic  and  cultural
context  in  which  the  research  will  be  carried  out.  This  includes  guidance  on  the
appropriate  reimbursement  to  be  offered  to  trial  participants.  Independent  ethics

53

committees  should  play  an  active  part  in  the  review  and  oversight  of  the  informed
consent  process  that  may  include  consultations  at  several  community  levels  but
should ultimately result in informed individual consent.

This  can  represent  quite  a  challenge  to  sponsors  and  researchers  who  need  to
comply  with  regulatory  requirements  according  to  “Western  standards”  in  complex
local settings, for instance in poorly educated or illiterate populations.

The  social,  economic  and  cultural  context  in  the  host  community  must  therefore  be
considered.  Guidance  must  be  sought  and  dialogue  established  with  the  lay  and
scientific  community,  the  ethical  review  committees,  governmental  and  non-
governmental organisations in a continuous and mutual learning process.

(cid:22)$(cid:5)(cid:8)(cid:2)(cid:12)(cid:6)(cid:5)(cid:8)(cid:12)(cid:23)(cid:8)(cid:11)$(cid:5)(cid:8)#(cid:11)$(cid:28)(cid:10)(cid:19)(cid:6)(cid:8)(cid:29)(cid:5)’(cid:28)(cid:5)5(cid:8)(cid:24)(cid:12)&&(cid:28)(cid:11)(cid:11)(cid:5)(cid:5)(cid:8)C#(cid:29)(cid:24)D

Appropriately  constituted  and  competent  ethics  committees  do  not  always  exist
where  disease  burden  is  highest.  Independent  international  co-operative  projects
dedicated to developing best practices in the ethical review of biomedical research by
strengthening regional and in-country capacity are welcomed by industry as they are
essential in ensuring competent guidance by local ethics committees.

The ethical review committee should be a competent and independent review board
with  knowledge  of  the  local  context  and  would  ideally  even  conduct  site  visits  to
oversee procedures. The reality can look different. A worldwide survey has identified
frequently  encountered  issues  that  would  affect  the  quality  of  ethical  review.  These
include:

(cid:2)  The  inadequate  representation  of  the  scientific  and  lay  communities  on  ethical
review  committees  in  particular  with  respect  to  their  composition  by  gender  or
religion.

(cid:2)  Without standard operating procedures there may be a lack of transparency.
(cid:2)  Conflict  of  interest  or  interdependence  between  the  members  of  the  ethics
committee may be a problem. If you are familiar with the importance of authority,
for  instance  in  some  African  countries,  and  see  that  some  ethics  committees
have the head of the hospital on the board but also his subordinates,  then  you
can understand what issues may arise from this.
Inadequate documentation is the most frequent problem we as sponsors have to
deal with.

(cid:2) 

(cid:2)  The  lack  of  resources,  time,  and  space.  This  frequently  results  in  inadequate

ethics committee monitoring of study conduct and follow-up systems.

(cid:2)  The inadequate training of ERC members: new members are expected to learn
on the job and often receive little or no specific training on important issues.

In  addition  the  increasing  complexity  of  collaborative  research  involving  multiple
institutions  and  sponsors  can  challenge  the  ethical  review  system.  Currently,  this

54

represents  a  complex  process  of  multiple  reviews,  which  should  be  facilitated  by
dialogue between external and host country ERCs. In a project we recently initiated
between partners in Africa, the US and Europe, multiple rounds of ethical review took
several  months  to  complete.    While  the  requirements  and  decision  making  of  the
local  ERCs  were  relatively  clear,  it  took  a  major  educational  effort  to  familiarise
external  institutional  review  boards  ("IRBs")  with  the  ethical  aspects  of  conducting
clinical trials in developing countries. This process really needs to be simplified.

(cid:24)(cid:19)%(cid:19)(cid:10)(cid:28)(cid:11)(cid:20)(cid:8)(cid:13)(cid:3)(cid:28)(cid:6)(cid:27)(cid:28)(cid:25)((cid:8)(cid:23)(cid:12)(cid:2)(cid:8)(cid:5)(cid:11)$(cid:28)(cid:10)(cid:19)(cid:6)(cid:8)(cid:2)(cid:5)’(cid:28)(cid:5)5

Effective  capacity  building  should  be  measured  by  its  sustainability  and  as  such
should be developed in close partnership with the various stakeholders in any given
research  program.  Capacity  building  for  ethical  review  must  not  only  focus  on
strengthening  the  local  ethics  committee  but  also  must  encourage  and  foster  the
interactive  and  mutual  learning  process  between  developed  and  developing
countries.

Standard  operating  procedures  (SOP)  for  ethics  committees  are  available,  and
should  be  used 
review  procedures.
to  ensure  harmonisation  of  ethical 
Harmonisation  can  save  time  with  respect  to  much  needed  research  to  reduce
disease  burden.  Currently,  quality  assurance  systems,  auditing  and  accreditation  of
ERCs  are  being  developed  and  cautiously  put  in  place  to  ensure  transparency.
However,  responsibilities  and  the  authority  of  this  quality  assurance  need  to  be
defined.

(cid:13)(cid:9)(cid:30)(cid:11)(cid:3)(cid:5)(cid:10)(cid:11)(cid:7)(cid:19)(cid:2)(cid:11)(cid:14)(cid:17)(cid:9)(cid:10)(cid:14)(cid:9)(cid:6)(cid:11)(cid:2)(cid:10)(cid:14)(cid:21)(cid:6)(cid:2)(cid:11)(cid:5)(cid:29)(cid:2)!(cid:21)(cid:5)(cid:7)(cid:2)(cid:11)(cid:2)(cid:7)(cid:19)(cid:8)(cid:3)(cid:5)(cid:4)(cid:11)(cid:6)(cid:2) (cid:8)(cid:2)(cid:30)*

CIOMS clearly indicates the increased responsibility of the sponsor to build capacity
in  ethical  review.  However,  in  order  to  maintain  the  independence  of  ERCs,  the
mechanisms to do so may actually be limited, as there is limited interaction between
the sponsor and the ERC.

Providing dedicated funding for local governments as some have suggested may not
necessarily be the ideal solution. So what mechanisms are available if  quality ethical
review is to be established in developing countries? ERC training needs may not be
communicated  to  the  sponsors  -  should  the  assessment  of  ERC  performance  be
done through external review?

In  one  situation  we  encountered  recently,  we  solved  this  problem  by  asking  the
chairman  of  the  independent  data  safety  monitoring  board  to  talk  to  the  ERC  to
assess  possible  training  needs.  So  in  my  view,  the  initiatives  mentioned  by  the
$(cid:7)(cid:6)(cid:5)(cid:7)(cid:2)(cid:20)(cid:8)(cid:3)(cid:11)+(cid:10)(cid:8)(cid:7)(cid:8)(cid:5)(cid:7)(cid:8) (cid:2)(cid:11)(cid:12)(cid:9)(cid:6)(cid:11)(cid:1)(cid:2) (cid:2)(cid:4)(cid:9)(cid:17)(cid:8)(cid:10)(cid:20)(cid:11)&(cid:5)(cid:17)(cid:5)(cid:3)(cid:8)(cid:7)(cid:16)(cid:11)(cid:12)(cid:9)(cid:6)(cid:11)%(cid:7)(cid:19)(cid:8)(cid:3)(cid:5)(cid:4)(cid:11)(cid:28)(cid:2) (cid:8)(cid:2)(cid:30)(cid:11)(SIDCER - WHO) are
extremely  important  and  welcomed  to  support,  strengthen  and  allow  independent
review  and  assessment  of  ERCs.  Independent  initiatives  &  training  to  strengthen
ethical review capacity should therefore be encouraged and supported.

55

(cid:24)(cid:19)%(cid:19)(cid:10)(cid:28)(cid:11)(cid:20)(cid:8)(cid:13)(cid:3)(cid:28)(cid:6)(cid:27)(cid:28)(cid:25)((cid:8)(cid:23)(cid:12)(cid:2)(cid:8)(cid:10)(cid:6)(cid:28)(cid:25)(cid:28)(cid:10)(cid:19)(cid:6)(cid:8)(cid:2)(cid:5)(cid:4)(cid:5)(cid:19)(cid:2)(cid:10)$

Training  of  local  investigators  and  the  strengthening  of  local  expertise  and
infrastructure for the conduct of clinical trials according to ICH Good Clinical Practice
(GCP)  and  regulatory  requirements  are  a  pre-requisite  for  clinical  research  in
developing countries and are an important capacity building measure.

Clinical  research  capability  determines  the  quality  and  ultimately  the  regulatory
acceptance  of  data,  so  where  the  capability  does  not  exist,  targeted  development
should  be  implemented  to  ensure  that  these  standards  are  put  in  place.  However,
active participation of the local community and the local government are  paramount
to  ensure  that  such  measures  will  remain  sustainable.  It  is  extremely  important  for
local research institutions to establish career development plans for their staff so that
qualified staff can be retained and the learning is not lost.

(cid:26)(cid:25)(cid:23)(cid:12)(cid:2)&(cid:5)(cid:27)(cid:8)(cid:10)(cid:12)(cid:25)(cid:4)(cid:5)(cid:25)(cid:11)2

In  compliance  with  ICH  GCP,  legal  and  regulatory  requirements,  informed  consent
must be based on an understanding of the society in which the study takes place but
should adhere to universal principles.

We  should  remember  to  consider  the  very  specific  local  requirements  within  a
broader framework. The ethical issues surrounding the use of appropriate language,
community  versus  individual  consent,  as  well  as  illiteracy,  oral  consent  and  the
impartial  witness  should  all  be  considered.  Moreover,  any  reimbursement    provided
must be consistent with the principle of voluntary consent.
The community itself can teach us valuable lessons. The informed consent  process
will  –  in  some  cultures  –  need  to  involve  the  larger  community,  local  village  chiefs,
family  members…  Sufficient  time  and  flexibility  should  be  built  into  the  process  to
accommodate  the  local  customs.  However,  this  can  only  complement  and  never
replace individual informed consent.

Legal  requirements  can  lead  to  a  lengthy  and  complicated  informed  consent
document  difficult  to  comprehend  for  any  person.  Local  ethics  committees  have
repeatedly complained that value of and understanding by study populations may be
limited, which led to the other extreme: the request for a one page informed consent,
simplifying  the  language, taking  out  what the  population might  not  have  understood
anyway.

Given  the  real  difficulties  to  ensure  informed  consent  I  do  agree  that  all  attempts
should be made to simplify the language in the informed consent - without however
applying  a  double  standard.  All  relevant  elements  according  to ICH-GCP  should  be
provided  to  study  participants  in  their  information.  It  is  our  challenge  to  find  the
appropriate  wording  to  communicate  this  information.  When  dealing  with  illiterate

56

populations,  oral  consent  or  thumb  printed  consent  in  the  presence  of  an  impartial
witness  may  be  obtained.    In  practice  there    may  be  issues:  how  impartial  is  the
impartial witness, if he is reimbursed for  the  time  spent  supporting  the  study  on  the
time  spent  on  the  study?  And  can  he  really  assess  whether  the  information  was
understood?
But  paramount  for  any  clinical  research,  any    recompense  provided  must  be
consistent with the principal of voluntary consent. Again, this raises questions – does
the  provision  of  free  medical  care  for  a  participant  during  a  clinical  trial  constitute
appropriate clinical care? In areas where medical supplies are scarce this may be an
established practice, approved by the local ERC and yet constitute a strong incentive
for  participation.  There  is  no  definitive    answer,  we  must  always  challenge
established practices and  confer  with  the  local  ethics committee  on  a  case  by  case
basis  while  applying 
legislative
requirements  and  following  the  research  methodologies  outlined  in  ICH-GCP
guidelines.

international  and  national 

regulatory  and 

(cid:22)$(cid:5)(cid:8)(cid:4)(cid:11)(cid:19)(cid:25)(cid:27)(cid:19)(cid:2)(cid:27)(cid:8)(cid:12)(cid:23)(cid:8)(cid:10)(cid:19)(cid:2)(cid:5)

This applies similarly to  decisions taken  regarding  standard  of  care  provided  to  trial
participants  that  need  to  be  aligned  with  sustainable  health  care  practice  in  the
respective country and must not constitute undue inducement for participation.

The design of a clinical trial protocol is not necessarily an issue specific to developing
countries.  Scientific  considerations  have  to  be  taken  into  account  irrespective  of
where  a  study  will  be  performed.    However,  the  standard  of  care  in  a  particular
context  is  the  subject  of  much  debate  today,  in  particular  since  the  Declaration  of
Helsinki  was  last  revised.  I  think  we  can  all  agree  that  sound  scientific  ethical  and
clinical  judgement  must  guide  the  design  of  clinical  trials.  Moreover,  clinical  trials
’(cid:3)(cid:5)(cid:10)(cid:10)(cid:9)(cid:7)(cid:11)(cid:25)(cid:2)(cid:11)(cid:31)(cid:21)(cid:14)(cid:7)(cid:8)(cid:12)(cid:8)(cid:2)(cid:29)(cid:11)(cid:2)(cid:7)(cid:19)(cid:8)(cid:3)(cid:5)(cid:4)(cid:4)(cid:16)(cid:11)(cid:21)(cid:10)(cid:4)(cid:2)(cid:14)(cid:14)(cid:11)(cid:3)(cid:5)(cid:17)(cid:5)(cid:25)(cid:4)(cid:2)(cid:11)(cid:9)(cid:12)(cid:11)(cid:17)(cid:6)(cid:9)(cid:29)(cid:21)(cid:3)(cid:8)(cid:10)(cid:20)(cid:11)(cid:14)(cid:3)(cid:8)(cid:2)(cid:10)(cid:7)(cid:8)(cid:12)(cid:8)(cid:3)(cid:5)(cid:4)(cid:4)(cid:16)(cid:11)(cid:6)(cid:2)(cid:4)(cid:8)(cid:5)(cid:25)(cid:4)(cid:2)(cid:11)(cid:6)(cid:2)(cid:14)(cid:21)(cid:4)(cid:7)(cid:14)(
,&+-.$(cid:11)/00/1(cid:18)

Difficulties are often encountered with respect to the understanding of concepts such
as  randomisation  and  placebo.  Regulatory  agencies  such  as  the  European
Committee for Proprietary Medicinal Products (CPMP) and the U.S. Food and  Drug
Administration and the scientific community maintain that randomised controlled trials
remain the gold standard when demonstrating the efficacy and tolerability  of a new
product.

Randomised,  controlled  trials  are  designed  to  generate  scientifically  reliable  results
while avoiding a distribution bias of risks/benefits:

’(cid:23)(cid:19)(cid:2)(cid:11) (cid:31)(cid:21)(cid:29)(cid:8)(cid:3)(cid:8)(cid:9)(cid:21)(cid:14)(cid:11) (cid:21)(cid:14)(cid:2)(cid:11) (cid:9)(cid:12)(cid:11) (cid:17)(cid:4)(cid:5)(cid:3)(cid:2)(cid:25)(cid:9)(cid:11) (cid:6)(cid:2)(cid:22)(cid:5)(cid:8)(cid:10)(cid:14)(cid:11) (cid:2)(cid:14)(cid:14)(cid:2)(cid:10)(cid:7)(cid:8)(cid:5)(cid:4)(cid:11) (cid:7)(cid:9)(cid:11) (cid:29)(cid:2)(cid:22)(cid:9)(cid:10)(cid:14)(cid:7)(cid:6)(cid:5)(cid:7)(cid:2)(cid:11) (cid:7)(cid:19)(cid:2)(cid:11)  (cid:5)(cid:4)(cid:21)(cid:2)(cid:11) (cid:9)(cid:12)(cid:11) (cid:10)(cid:2)(cid:30)
(cid:22)(cid:2)(cid:29)(cid:8)(cid:3)(cid:8)(cid:10)(cid:5)(cid:4)(cid:11)(cid:17)(cid:6)(cid:9)(cid:29)(cid:21)(cid:3)(cid:7)(cid:14)((cid:11),&#.#(cid:11)/0021

57

The choice of active control or placebo/escape treatment as comparator will depend
principally  on  the  level  of  risk  to  participants,  and  whether  the  design  will  yield
scientifically reliable results. Any choice of comparator, especially within the context
of  developing  countries  must  be  determined  in  close  consultation  with  local  experts
and  health  authorities  and  ideally  be  aligned  with  locally  sustainable  health  care
practice.

8(cid:12)(cid:4)(cid:11)(cid:8)(cid:11)(cid:2)(cid:28)(cid:19)(cid:6)(cid:8)(cid:10)(cid:12)(cid:25)(cid:4)(cid:28)(cid:27)(cid:5)(cid:2)(cid:19)(cid:11)(cid:28)(cid:12)(cid:25)(cid:4)

All  post-trial  considerations  must  be  determined  before  a  study  takes  place.  Early
dialogue  with  representatives  of  the  scientific  and  lay  communities  as  well  as  local
governments  will  be  essential  to  manage  expectations  as  to  possible  trial  outcome
and the provision of any post-trial medications. Currently, however, deliberations may
take more than a year. A transparent and more efficient process must be established.
We must keep in mind that it is a long road to product licensure – the fact that  one
trial shows a research intervention to have merit does not necessarily mean that the
specific intervention has been proven successful.

The shared responsibilities must be defined  upfront.  A reasonable  balance  must be
found which does not jeopardise clinical research in developing countries but shows
a  positive  way  forward  –  exemplified  by  an  increasing  number  of  public-private
partnerships for the development of products against developing world diseases.

(cid:24)(cid:12)(cid:25)(cid:10)(cid:6)(cid:3)(cid:4)(cid:28)(cid:12)(cid:25)(cid:4)(cid:8)(cid:19)(cid:25)(cid:27)(cid:8)(cid:29)(cid:5)(cid:10)(cid:12)&&(cid:5)(cid:25)(cid:27)(cid:19)(cid:11)(cid:28)(cid:12)(cid:25)(cid:4)

Clinical  research  in  developing  countries  requires  special  consideration  of  ethical
aspects  to  safeguard  the  rights  and  safety  of  research  participants.  I    believe  that
strengthening  ethical  review  capacity  is  critical  in  this  process.  I    further  strongly
believe that dialogue and the sharing of experiences between stakeholders should be
encouraged to ensure research priorities in the developing world are addressed.

58

(cid:31)(cid:5)(cid:9)(cid:6)(cid:20)(cid:9)(cid:9)(cid:5)(cid:11)(cid:17)

/(cid:3)&&(cid:19)(cid:2)(cid:20)(cid:8)(cid:12)(cid:23)(cid:8)(cid:11)$(cid:5)(cid:8) (cid:28)(cid:4)(cid:10)(cid:3)(cid:4)(cid:4)(cid:28)(cid:12)(cid:25)(cid:8)∗

The  Round  Table  discussion  was  characterised  by  a  dynamic  exchange  of  ideas,
which  sought to  put forward,  some  of  the  more  complicated  issues  surrounding  the
ethics of clinical trials in developing countries. Inspired by the morning and afternoon
panel,  the  discussion  focused  on  issues  ranging  from  negotiation  and  moral
pluralism,  to  capacity  building  and  placebo  control  trials.  The  essential  themes
evoked during these discussions are presented below.

(cid:24)(cid:3)(cid:6)(cid:11)(cid:3)(cid:2)(cid:19)(cid:6)(cid:8)(cid:2)(cid:5)(cid:6)(cid:19)(cid:11)(cid:28)’(cid:28)(cid:4)&(cid:8)(cid:19)(cid:25)(cid:27)(cid:8)(cid:11)$(cid:5)(cid:8)(cid:25)(cid:5)(cid:5)(cid:27)(cid:8)(cid:23)(cid:12)(cid:2)(cid:8)(cid:25)(cid:5)((cid:12)(cid:11)(cid:28)(cid:19)(cid:11)(cid:28)(cid:12)(cid:25)

When  conducting  biomedical  research  in  developing  countries,  the  question  of
differing values was raised in light of cultural relativism. Are there universal values in
research  or  does  research  need  to  be  adapted  to  the  existing  value  systems  and
cultures locally? This question needs to be addressed both from the point of view of
the  researchers  and  the  local  community.  Moreover,  issues  such  as  the  impact  of
research on culture lead to other lines of thought: what possibility is there for cultures
to  be  enriched  by  Science?  And  on  the  other  hand,  in  what  way  could  Science
benefit from local culture?

In  order  to  better  address these  issues,  a  need for  sociological  and  cultural  studies
was expressed in order to examine the relationship between research and the local
community.  This  would  in  fact  introduce  direct  input  from  the  developing  countries
into the debate and expose the disparities between international standards and local
realities. We  must,  however,  also  note  that  there  is  very  little  empirical  evidence  to
show the existence of cultural differences in a medical research context. To support
this argument, a study conducted  on  South  East  Asian  countries showed  that  more
differences existed between these countries than between Asia and the West.

The differing interpretations and perceptions, within the context of cultural relativism,
of concepts and beliefs render negotiation an essential tool in the interaction between
the  researchers  and  the  community.  As  we  cannot  proceed  only  on  the  basis  of
established  guidelines,  input  from  cultural  anthropologists  would  be  extremely
beneficial.  Researchers  must  familiarise  themselves  with  the  culture  they  will  be
working  with:  discuss  with  people,  understand  the  traditions,  etc. This  also  includes
confrontation  and  dilemma,  nuanced  with  the  intricacies  of  different  points  of  view.
There  are  so  many  different  ways  of  meeting  different  groups  or  communities,  and
there  is  a  need  to  use  all  the  levels  of  encounter:  confrontation,  sharing  stories,
histories  and  really  establishing  a  living  community  or  conduct  with  the  societies.
These  differences  in  values,  as  well  as  the  ‘(cid:3)(cid:5)(cid:17)(cid:5)(cid:3)(cid:8)(cid:7)(cid:16)(cid:11) (cid:9)(cid:12)(cid:11) (cid:3)(cid:21)(cid:4)(cid:7)(cid:21)(cid:6)(cid:2)(cid:14)(cid:11) (cid:7)(cid:9)(cid:11) (cid:6)(cid:2)(cid:14)(cid:8)(cid:14)(cid:7)(cid:11) (cid:7)(cid:9)
(cid:7)(cid:2)(cid:3)(cid:19)(cid:10)(cid:9)(cid:14)(cid:3)(cid:8)(cid:2)(cid:10)(cid:3)(cid:2)’ are the main arguments for the need for negotiation.

∗

 The summary of the discussion has been prepared by Katerina Sukovski, Trainee within the
Secretariat of the European Group on Ethics in Science and New Technologies.

61

                                                
The emphasis must be on the negotiation(cid:7)process between all concerned parties. In
a  conference  room,  the  framework  for  that  process  can  be  set  up,  establishing  the
means  for  capacity  building  in  developing  countries  and  for  the  acquisition  of  value
knowledge. In this respect, negotiation will be a continual process, which must be left
to  a  certain  extent  to  researchers  and  the  developing  countries  (government,  local
researchers  and  the  community).  Moreover,  this  means  that  all  actors  will  come
around  the  table  with  a  set  of  values  and  not  consider  universal  values.  However,
although  an  interesting  venue  to  explore,  while  each  actor  tries  to  promote  his/her
own values and trying to come to an agreement, the obstacle becomes the balance
of power between all these actors. This process could help solve such questions as
for example, what would be considered the conditions for a fair  negotiation  process
between the funding agency and a developing country in which a trial is supposed to
take place?

Any negotiation that is developed is going to go beyond anything that is agreed upon
in  a  conference  room.  One  must  keep  in  mind  that  requiring  scientists  to  conduct
research  according  to  standards  established  by  Northern  countries  may  be  a  quick
and easy political strategy, but this will not be effective for global health for a number
of reasons. First, it will exclude developing countries from access to this research, a
benefit  in  and  of  itself.  Secondly,  it  will  promote  ‘unethical’  behaviour,  where
researchers  will  shop  around  for  an  ethical  committee,  which  will  approve  their
protocols.  This  is  well-documented  common  practice  in  some  places.  And  finally,  it
assumes  that  guidelines  established  by  Northern  countries  are  always  relevant,
which  is  often  not  necessarily  the  case.  These  are  reasons  that  negotiation  is
necessary.  However,  there  are  many  critical  questions  with  respect  to  negotiation,
which need to be addressed. How will this negotiation process meet the standards of
procedural justice?

And finally, the issue of what has been referred to as cultural imperialism needs to be
addressed  in  this  process.  Emphasis  must  be  put  on  the  process,  based  in  North-
South dialogue, and not a Northern top-down approach. One must consider what are
the ethical issues and what are  the  needs  of  the  population  and  their  point  of  view.
This dialogue must not degrade into a form of  paternalism. Often,  researchers from
developing  countries,  and  specifically,  local  researchers  feel  that  they  are  passive
recipients of protocols, which is most often the case. They receive finalised protocols
from Europe, which are submitted to them for administrative approval. They feel that
they are cosmetic partners. This concern needs to be addressed within the context of
the negotiation process.

Therefore,  the  importance  of  cultural  relativism  may  not  simply  lie  in  identifying
cultural  differences,  but  in  interpreting  these  differences.  Perhaps  through  their
interpretation,  these  differences  will  diminish,  allowing  space  for  partnership  and
participation through common values and common rules.

62

(cid:26)(cid:25)(cid:23)(cid:12)(cid:2)&(cid:5)(cid:27)(cid:8)(cid:10)(cid:12)(cid:25)(cid:4)(cid:5)(cid:25)(cid:11)

The ethical aspects of ‘informed consent’ can be considered from the point of view of
the  individual,  as  well  as  that  of  the  community.  Again  here,  the  importance  of  the
role  of  the  community  can  be  seen.  First,  considerations  of  how  ‘informed’  consent
actually is with respect to language and cultural barriers must be taken into account.
If there is no word for ‘gene’ or ‘informed consent’ in the local language, how can one
explain  the  process?  It  must  be  kept  in  mind  that  issues  surrounding  the
understanding  of  informed  consent  are  not  proper  to  developing  countries,  and  are
often associated with studies done in industrialised countries as well. However, it has
been  suggested  that  given  the  relationship  between  North  and  South,  the  lack  of
understanding with respect to scientific research and  principles  of  informed  consent
may be exploited in developing countries, at the expense of local communities. What
safeguards, if any, need to be put in place?

Moreover,  when  personal  consent  is  requested  from  one  member  in  one  tribe  or  in
one village, we’re putting forth a cultural question: we’re asking if this person has the
authority  to  actually  answer,  on  their  behalf  and  that  of  the  community.  The
relationships between members of the community, as well as differing conceptions of
autonomy  therefore  require  a  better  understanding  of  the  local  context  so  that  the
principles  underlying  informed  consent  are  respected.  Moreover,  given  the  greater
role  of  the  community,  we  cannot  ignore  the  possibility  of  segregation  or
discrimination that may exist within the community between the participants and the
rest  of  the  community?  What  criteria  must  be  established  in  order  to  evaluate  this
positive or negative community influence?

In these negotiations, with respect to the community, could interested consent play a
greater role than informed consent? Considering the expected advantages, could this
concept  of  interested consent  be  useful?(cid:7)Considering  the  socio-economic  divide,  to
what  extent  does  inducement  play  a  role  in  informed  consent?(cid:7) What  impact  would
the promise of financial gain or improved health care have on the participants and the
community as a whole?(cid:7)Is inducement actually wrong and is it equally  wrong for  all
kinds  of  trials? We  pay  doctors  to  do  trials,  and  research  methodologists  to  design
them. Is inducement therefore always wrong?

Given the context, could more standards or monitoring be required in order to ensure
that the requirements for informed consent are upheld? The danger of introducing a
double-standard  raises  concern  when  considering  extensive  monitoring  of  informed
consent  procedures  as  a  requirement  in  developing  country  research,  when  not
routinely  done  in  Northern  settings.  Currently,  research  ethics  committees  review
protocols,  but  they  do  not  monitor  the  research,  don’t  do  site  visits,  don’t  review
consent.  If  this  is  to  be  made  a  requirement,  it  should  be  universal.  However,  the
infrastructure  and  resources  required  to  do  this  properly  are  almost  impossible  to
achieve.  This  may  be  a  good  idea  in  certain  types  of  trials,  but  impossible  as  a
universal rule, as it would require an enormous amount of resources.  In the following
section we will take a closer look at the challenges and obstacles facing local ethical

63

review  committees,  and  therefore  better  understand  the  difficulty  in  implementing
such requirements.

#(cid:11)$(cid:28)(cid:10)(cid:19)(cid:6)(cid:8)(cid:29)(cid:5)’(cid:28)(cid:5)5(cid:8)(cid:24)(cid:12)&&(cid:28)(cid:11)(cid:11)(cid:5)(cid:5)(cid:4)(cid:8)C#(cid:29)(cid:24)D

The  nature  and  role  of  local  Ethical  Review  Committees  evoked  much  discussion.
First the role of the local ERC is to evaluate ethical considerations with respect to the
study and its impact in the community.

Unfortunately, due to the limited resources available to implement and maintain local
ERCs in developing countries, these bodies are often non-existent or limited in their
capacity  to  effectively  carry  out  evaluations.  It  is  in  this  light  that  the  question  with
respect to the  competence  of  local  ERC  was  evoked. Often,  clinical  trials  are given
great  importance  whereas  other  issues  such  as  control  by  health  authorities,
adequate study design, and its interpretation in practises are inadequately discussed.

However,  there  was  a  suggestion  put  forward  on  the  possibility  of  having  a  type  of
DSMB  (Data  and  Safety  Monitoring  Board)  extended to  more than  data  and  safety,
which would deal with ethical problems and post trial considerations. This committee
could  be  composed  of  people from the  North  and  South,  including  lay  persons  and
ethicists.

Many low-income countries do not have the resources for ethical considerations and
community participation. If these systems are not in place, what needs to be done in
order  to  conduct  these  trials?  Do  we  wait  for  a  system  to  be  put  in  place  before
initiating  any  trials?  Or  do  we  negotiate  a  working  model  with  all  stakeholders
involved?

The central role of ERC in clinical research in developing countries lies specifically in
the  nature  of  their  function.  As  an  intermediary  between  the  scientific  and  local
community  with  respect  to  ethical  concerns,  the  increasing  number  of  guidelines
requiring ethical review have accorded more and more importance to ERCs. It is for
these  reasons  that  the  strengthening  of  ethical  review  has  become  an  important
aspect of capacity building, the subject of the following section.

(cid:24)(cid:19)%(cid:19)(cid:10)(cid:28)(cid:11)(cid:20)(cid:8)(cid:1)(cid:3)(cid:28)(cid:6)(cid:27)(cid:28)(cid:25)(2(cid:8)5$(cid:12)(cid:8)(cid:10)(cid:19)(cid:25)(cid:8)(cid:13)(cid:3)(cid:28)(cid:6)(cid:27)(cid:8)(cid:10)(cid:19)%(cid:19)(cid:10)(cid:28)(cid:11)(cid:20)9(cid:8)5$(cid:19)(cid:11)(cid:8)6(cid:28)(cid:25)(cid:27)(cid:8)(cid:12)(cid:23)(cid:8)(cid:10)(cid:19)%(cid:19)(cid:10)(cid:28)(cid:11)(cid:20)(cid:8)(cid:28)(cid:4)(cid:8)(cid:25)(cid:5)(cid:5)(cid:27)(cid:5)(cid:27)9

The question of ‘who can build capacity?’ is closely linked to that of ‘who is funding
capacity building?’. Many debates during the discussion centred on the ethics of who
should be involved in this process.

It  was  suggested  that  the  sponsoring  agency  should  be  responsible,  there  is
therefore  a  need  to  define  the  ‘sponsoring  agency’.  If  defined  by  the  private  sector,
such  as  the  pharmaceutical  industry,  is  it  ethically  sound  for  industry  to  be  funding

64

capacity  building  and  ethics  in  developing  countries?  On  the  other  hand,  funds  for
capacity  building  are  scarce,  and  more  than  just  workshops  and  conferences  are
needed,  such  as  the  ability  to  maintain  infrastructure  in  the  long  term.  Therefore,  if
the  public  sector  is  going  to  take  on  the  responsibility  of  ‘sponsoring’,  it  needs  to
clearly identify and define its level of participation and commitment.

The  industry  perspective  maintains  that  it  provides  a  good  partner  for  capacity
building,  highlighting  that  there  is  a  lot  of  skill  there.  The  question  is  rather  what
capacity  is  being  built?  In  addition  to  the  need  to  work  jointly,  the  point  was  raised
that often, once the training is completed, the individuals often go to work in Western
countries  (i.e.  USA),  and  that  this  too  is  a  form  of  capacity  building  which  is
continually  being  depleted.  In  what  way  can  the  training  and  skills  targeting
developing countries be maintained in the long term?

Moreover,  there  are  many  levels  to  capacity  building  in  research  with  respect  to
developing countries. Although fundamentally due to the socio-economic  divide,  the
gap  between  developed  and  developing  countries  in  scientific  research  and  health
care  standards  is  growing  exponentially  in  the  face  of  diseases  such  as  HIV/AIDS,
which  have  exploded  on  the  African  continent.  Before  discussing  these  levels,  we
must first illustrate the context in which this capacity is necessary. For this, the case
of HIV/AIDS in Africa can best demonstrate the complete market mismatch between
the needs of developing countries and the economic reality of vaccine development.
The  pharmaceutical  industry  has  had  an  important  role  in  the  development  and
research of vaccines with respect to HIV/AIDS. If, however, the industry is demanded
to  make  vaccines  available  at  their  own  cost  in  all  the  countries  where  the  clinical
trials  take  place,  the  pharmaceutical  industry  will  withdraw  from  these  markets.
However, vaccines are only made available to the poorest countries  15  to  20  years
after their introduction to the West. What measures need to be taken to ensure that
the few pharmaceutical companies that are investing in AIDS vaccines or others do
not  withdraw  from  the  markets  because  the  sets  of  rules  and  regulations  have
become  too  strict?  We  should  not  forget  that  we  are  working  in  a  globalised
economy, and as such, take into account the multiple levels and degrees involved.

Moreover,  when  discussing  developing  countries,  there  is  a  tendency  to  mainly
discuss  Africa.  However,  countries  in  transition  are  also  developing  countries:  low
brut  national  product  (less  than  $5000),  very  small  public  funds  for  research,  less
than  1%  of  this  sum.  The  very  strong  influence  of  the  manufacturers  on  research-
whether the pharmaceutical industry, medical devices or equipment- is mainly due to
the fact that they are the main or sometimes the only source of funding.

This  creates  a  conflict  of  interest  on  the  side  of  researchers,  because  the  main
source  of  their  research  funding  comes  from  the  manufacturers. What  is  more,  the
competence and the power of ERCs, if they exist at all, are often unsatisfactory, and
the implementation of the legislation is insufficient.

65

Therefore,  when  discussing  capacity  building,  we  should  consider  the  government
(legislation), local researchers as well as the local community. It should be noted that
some of the national guidelines, such as in South Africa, mention the explicit need for
capacity building and what they refer to as community consultation. This includes the
involvement of the local community health workers, a stress on  local  education  and
training,  and  the  need  for  the  presence  of  local  independent  witnesses  or  an
ombudsperson,  in  specific  clinical  situations.  This,  however,  raises  questions  as  to
what  actually  is  happening  on  the  ground?  Who  is  documenting  this?  Who  is
recording  this?  What  verification,  what  procedural  mechanisms  are  in  place  to
document all the negotiation that is happening?

The  capacity  needs  of  local  researchers,  although  evoked,  were  discussed  to  a
lesser  extent.  With  respect  to  research  protocols,  there  has  been  a  tendency  to
involve local researchers in only Phase III and IV trials. This exclusion from Phase I
and  II  trials  needs  to  be  addressed,  as  well  as  the  need  to  ensure  that  local
researchers participate in all stages of the clinical trial process. This is necessary not
only  from  a  capacity  building  perspective,  but  from  an  ethical  point  of  view  which
stresses partnership.

While  discussing  the  needs  of  developing  countries,  the  type  of  research  needs  of
the  population  of  the  country  must  also  be  considered.  If  we  look  at  the  global
pharmaceutical research budget, tropical diseases have a small insignificant share of
that  budget.  We  also  know  that  diseases  of  developing  countries  are  not  given
enough attention. This should be a major concern. No ethical guidelines will change
this. For instance, Sweden has a traditional window for research co-operation, which
includes  budgets,  capacity  building,  trying  to  promote  building  domestic  capacity  in
research  (i.e.  tropical  diseases).  More  attention  must  therefore  be  accorded  to
developing co-operation with respect to these needs.

In discussing the issue of ethics of research in developing  countries,  attention must
be  given  to  the  definition  of  priorities,  and  the  place  of  capacity  building  in  this
discussion. Too often the advantages to industrialised countries are stressed, rather
than the interests of the developing country.

/(cid:11)(cid:19)(cid:25)(cid:27)(cid:19)(cid:2)(cid:27)(cid:8)(cid:12)(cid:23)(cid:8)(cid:24)(cid:19)(cid:2)(cid:5)2(cid:8)(cid:28)(cid:4)(cid:8)(cid:23)(cid:28)(cid:2)(cid:4)(cid:11)(cid:8)(cid:10)(cid:6)(cid:19)(cid:4)(cid:4)(cid:8)$(cid:5)(cid:19)(cid:6)(cid:11)$(cid:8)(cid:10)(cid:19)(cid:2)(cid:5)(cid:8)(cid:3)(cid:25)(cid:27)(cid:3)(cid:5)(cid:8)(cid:28)(cid:25)(cid:27)(cid:3)(cid:10)(cid:5)&(cid:5)(cid:25)(cid:11)9

Although, all would agree that it is extremely important to insist upon well-being when
providing  health  care  and  referring  to  health  care  standards,  the  ethical  concerns
stemming  from  the  impact  of  this  standard  of  care  with  respect  to  the  clinical  trials
has  sparked  debate.  Some  would  argue  that  when  there  is  research  between  the
North  and  the  South  in  a  partnership  situation, then the standard  used  in  the  North
should be used in the South. Some would argue that this is not a decision that should
be made by Northern researchers or ethicists, but by the developing country.

66

Still  others  would  argue  that this  level  of  standard  of  care  would  impact  on  the  trial
results,  and  constitute  undue  inducement.  In  resource  poor  settings,  there  can  be
many  forms  of  inducement.  For  example,  during  an  HIV  vaccine  trial  in  Bangkok,
participants received 10 Euro for transportation. This is a very small amount, and can
not be considered inducement, although the transportation cost was actually 10% of
that amount. The argument made was that this induced drug users in the study, but
in reality, much more is needed to maintain a drug habit. In fact, the real inducement
lied  in  the  entitlement  to  health  care  clinics.  It  appears  that  the  main  motivation  for
participants  was  the  promise  of  being  taken  care  of  if  they  got  sick,  which  was
perceived as something much greater than its actual cost.

Although  the  debate  with  respect  to  the  standard  of  care  continues,  the  danger  of
establishing  a  double  standard  remains  in  the  background.  Would  it  be  a  form  of
paternalism  to  enforce  such  standards  of  care  on  research  coming  from  the  North
when  there  same  standards  are  not  applied  to  local  researchers  conducting  clinical
trials?

There  is,  however,  general  agreement  that  the  health  needs  of  local  community
should be taken into account. One would hope that in developed countries there is an
awareness  of  the  health  needs  of  developing  countries  and  the  desire  to  develop
these needs.

The  standard  of  care  is  a  particularly  difficult  issue  in  that  it  involves  not  only  the
scientific community and the advancement of Science, but also the  health care  and
health  needs  of  the  community.  In  this  context,  the  obvious  benefits  of  improved
standards of health care in certain trial communities can quickly become the topic of
political  debate  when  national  health  care  standards  are  insufficient  to  meet  the
health needs of the general population. Given the discrepancy between the standard
of  care  between  the  North  and  the  South,  there  were  questions  raised  during  the
discussion as to the obligations and the nature of these obligations to improve global
health in general.

And finally, the cost of such improved standards of care can not be neglected. Given
that current  conditions  in  developing  countries  offer  obvious financial  advantages  in
the  research  and  development  of  vaccines,  would  standards  imposing  universal
standards of care be a deterrent to further research and development?

8(cid:6)(cid:19)(cid:10)(cid:5)(cid:13)(cid:12)(cid:8)(cid:24)(cid:12)(cid:25)(cid:11)(cid:2)(cid:12)(cid:6)(cid:8)(cid:22)(cid:2)(cid:28)(cid:19)(cid:6)(cid:4)2(cid:8)(cid:13)(cid:5)(cid:4)(cid:11)(cid:8)(cid:19)’(cid:19)(cid:28)(cid:6)(cid:19)(cid:13)(cid:6)(cid:5)(cid:8)(cid:12)(cid:2)(cid:8)(cid:13)(cid:5)(cid:4)(cid:11)(cid:17)%(cid:2)(cid:12)’(cid:5)(cid:25)(cid:8)(cid:11)(cid:2)(cid:5)(cid:19)(cid:11)&(cid:5)(cid:25)(cid:11)9

The ethical concerns raised by the use of placebo control trials emanate from the fact
that placebo control trials are used in order to establish standard treatment. However,
given the controversy surrounding the Helsinki Declaration revisions the debate over
best proven and best available treatment remains at the core of clinical trial design in
developing  countries,  where,  for  the  most  part,  the  best  proven  treatment  is  not

67

available to the population. The best illustration of this would be the HIV transmission
trials done in Africa and Thailand.

The  Clarification  Note  of  the  WMA6  (cid:16)(cid:8)(cid:1)(cid:3)(cid:6)(cid:5)(cid:6)(cid:4)(cid:9)(cid:14)(cid:15)(cid:7) (cid:14)(cid:17)(cid:7) (cid:18)(cid:8)(cid:3)(cid:11)(cid:9)(cid:15)(cid:19)(cid:9)  states:  “(cid:2)"(cid:7)(cid:6)(cid:2)(cid:22)(cid:2)(cid:11) (cid:3)(cid:5)(cid:6)(cid:2)
(cid:22)(cid:21)(cid:14)(cid:7)(cid:11) (cid:25)(cid:2)(cid:11) (cid:7)(cid:5)(cid:15)(cid:2)(cid:10)(cid:11) (cid:8)(cid:10)(cid:11) (cid:22)(cid:5)(cid:15)(cid:8)(cid:10)(cid:20)(cid:11) (cid:21)(cid:14)(cid:2)(cid:11) (cid:9)(cid:12)(cid:11) (cid:5)(cid:11) (cid:17)(cid:4)(cid:5)(cid:3)(cid:2)(cid:25)(cid:9)3(cid:3)(cid:9)(cid:10)(cid:7)(cid:6)(cid:9)(cid:4)(cid:4)(cid:2)(cid:29)(cid:11) (cid:7)(cid:6)(cid:8)(cid:5)(cid:4)(cid:11) (cid:5)(cid:10)(cid:29)(cid:11) (cid:7)(cid:19)(cid:5)(cid:7)(cid:11) (cid:8)(cid:10)(cid:11) (cid:20)(cid:2)(cid:10)(cid:2)(cid:6)(cid:5)(cid:4)(cid:11) (cid:7)(cid:19)(cid:8)(cid:14)
(cid:22)(cid:2)(cid:7)(cid:19)(cid:9)(cid:29)(cid:9)(cid:4)(cid:9)(cid:20)(cid:16)(cid:11)(cid:14)(cid:19)(cid:9)(cid:21)(cid:4)(cid:29)(cid:11)(cid:9)(cid:10)(cid:4)(cid:16)(cid:11)(cid:25)(cid:2)(cid:11)(cid:21)(cid:14)(cid:2)(cid:29)(cid:11)(cid:8)(cid:10)(cid:11)(cid:7)(cid:19)(cid:2)(cid:11)(cid:5)(cid:25)(cid:14)(cid:2)(cid:10)(cid:3)(cid:2)(cid:11)(cid:9)(cid:12)(cid:11)(cid:7)(cid:19)(cid:2)(cid:11)(cid:2)"(cid:8)(cid:14)(cid:7)(cid:8)(cid:10)(cid:20)(cid:11)(cid:17)(cid:6)(cid:9) (cid:2)(cid:10)(cid:11)(cid:7)(cid:19)(cid:2)(cid:6)(cid:5)(cid:17)(cid:16)”.

This  (cid:2)"(cid:8)(cid:14)(cid:7)(cid:8)(cid:10)(cid:20)(cid:11) (cid:17)(cid:6)(cid:9) (cid:2)(cid:10)(cid:11) (cid:7)(cid:19)(cid:2)(cid:6)(cid:5)(cid:17)(cid:16)  may  not  however  be  available  to  the  populations  in
need; can placebo trials then be justified? Very often, the placebo control trials done
in  these  countries  are  very  difficult  to  defend,  such  as  placebo  controls  on
schizophrenic  or  major  depression  patients.  It  is  clear  from  an  ethical  point  of  view
that the local context in terms of treatment availability and access to health care has
an important place in this debate.

Moreover, the requirements of the American FDA are often cited as reasons for the
continuation of this practise, because it does not permit any new drug that does not
have  such  a  control.  The  role  of  regulatory  bodies  with  respect  to  drug  licensing
needs to be elucidated and also taken into account in this debate.

When  discussing  developing  countries  we  should  keep 
that
underdevelopment has several levels. Placebo control trials are a scientific tool used
in research, but it is the reality of the impact of this research on trial communities, as
well  as  the  relevance  of  these  trials  to  the  local  community  which  are  taken  into
account  when  discussing  ethical  concerns.  The  debate  did  however  echo  general
agreement that treatment availability at a local or regional level should be taken into
account.

in  mind 

8(cid:19)(cid:11)(cid:5)(cid:25)(cid:11)(cid:8)(cid:28)(cid:4)(cid:4)(cid:3)(cid:5)(cid:4)

Patent issues, although highly technical and legal in nature, have made their way into
the ethical debate with respect to their place in prior agreements, and as obstacles to
access to treatment, and the development of new treatment in developing countries.

The International AIDS Vaccine Initiative (IAVI) Price Agreements were put in  place
under certain conditions for the co-funding of HIV vaccine development. If a vaccine
were  found  to  be  effective,  the  company  would  agree  to  make  it  available  to
developing countries at production costs plus a 10% profit. If IAVI disagrees with the
estimate,  it  can then  ask  another  company  to  produce  the  vaccine.  IAVI  claimed  to
have  solved  the  problem  of  intellectual  property  rights,  the  following  two  examples
will show that this is in fact not the case.

IAVI was set up to try to get passed the standard kind of paradigm: that something is
licensed  to  Europe  or  the  US,  and  after  one  or  more  decades  it  might  become
available in developing countries, and for HIV vaccines, this is unacceptable. Hence,

6 World Medical Association.

68

                                                
there  are  attempts  to  change  that  paradigm,  by  working  directly  in  developing
countries. These attempts are however facing many obstacles.

In the first case, in IAVI vs. Kenya, the UK researchers submitted a patent application
without involving the Kenyan researchers. When faced with the anger and frustration
of  the  Kenyan  researchers,  IAVI  was  ill  equipped  to  deal  with  the  situation.
Eventually, IAVI recognised that the memorandum of understanding was inadequate
and apparently now there is a new agreement in place that does involve intellectual
property rights, but the content is still unknown. This highlights the complexity of prior
agreements and the importance of property rights in research.

In the  second  case,  IAVI  and  a  North  Carolina  (NC)  company,  there  was  a  dispute
about the ownership of the patent rights of a vaccine candidate, and it is not certain
that  the  NC  company  had  the  patent  right  over  this  vaccine.  If  the  company  that
develops  the  vaccine  does  not  have  the  intellectual  property  rights  it  would  have  to
pay a license fee, which would become part of the ‘production costs’, again showing
the possible deficiency of this type of agreement.

However, with respect to patents, it is important to keep in mind who owns patents -
and  someone  will  ultimately  own  a  patent  -and  it  may  not  be  clear  until  years  of
litigation and counter  claims  who  really  owns  the  various  patents. It’s  not  an  ethical
issue of whether someone owns a patent. The issue is what is done with the patent
and whether the development of a vaccine is allowed in the most cost-effective way
for these countries or whether the patent is used to block that development?

The  intellectual  property  issues  are  complex,  but  it  is  thought  that  the  eventual
outcome should be that there is no profiteering or just simple obstructiveness that will
block  the  availability  of  the  vaccines  in  the  countries  where  they  are  most  acutely
needed.  However,  looking  at  how  patents  are  going  to  be  controlled  and  how  to
prevent them from being a block to distribution is not a substitute for looking at ethical
issues within a trial, including benefits to participants.

(cid:22)(cid:2)(cid:19)(cid:27)(cid:28)(cid:11)(cid:28)(cid:12)(cid:25)(cid:19)(cid:6)(cid:8)&(cid:5)(cid:27)(cid:28)(cid:10)(cid:28)(cid:25)(cid:5)

With respect to the cultural dimension, the role of traditional medicine was evoked in
order to understand its impact on the ethical considerations discussed.

To what extent is traditional medicine, including traditions stemming from Buddhism
and  Hinduism  incorporated  into  education  and  ethics  in  these  countries?  Are  there
any contradictions in theory and in practice of these teachings?

In India, for example, when discussing bioethics, it is modern bioethics. There are no
theologians  except  those  based  in  Christianity.  Bioethical  teachings  are  mostly
dominated by Western influence.

69

In  Africa,  traditional  practices  are  transmitted  from  one  generation  to  another,  one
family  to  another,  based  on  non-referenced  practises.  For  example,  in  the  village
they  say  that  eating  a  certain  form  of  bark  is  good  for  you.  This,  of  course,  is  not
published in a  medical journal. In  a given  context,  the  importance  of  spirituality  and
its relationship to health through traditional medicine, is also considered an important
aspect of treatment.

Issues  with  respect  to  forms  of  treatment  were  also  discussed:  Are  there  criteria  to
distinguish  between  traditional  forms  of  treatment  and  the  non-traditional  forms  of
treatment?  The  referral  to  non-traditional  implies  that  there  is  a  different  treatment
model,  and  what  is  the  hierarchy  between  these  models?  Can  traditional  forms  of
treatment actually be made subject to scientific investigations?

In India, there are five systems of traditional medicine, and there are more traditional
medical  practitioners  than  non-traditional  practitioners.  Where  quality  checks  have
been  done,  modern  practises  have  not  necessarily  been  shown  to  be  superior  to
traditional practices. What is more, a number of cases have shown the equality if not
the superiority of traditional medicine. Especially in cases involving chronic illness or
illnesses  related  to  ageing,  traditional  medicines  are  shown  to  be  as  effective  with
less  or  no  side  effects.  Specific  medicines  used  for  ageing  are  now  undergoing
modern techniques of evaluation, to prove that traditional medicine has value.

It  should  be  noted  that  traditional  medicine  is  a  community-based  practise,  and
therefore  has  an  important  role  in  any  medical  practise  and  should  be  taken  into
account, not only with respect to clinical trials, but to capacity building as well.

(cid:24)(cid:12)(cid:25)(cid:10)(cid:6)(cid:3)(cid:4)(cid:28)(cid:12)(cid:25)

In general, the discussion provided many lines of thought and reflection with respect
to  ethical  considerations  in  research  in  developing  countries.  The  main  themes,
outlined  here,  have  been  summarised  in  order  to  provide  a  foundation  for  further
thought and reflection in this area. The end comments of participants and panellists
focused  primarily  on  the  need  for  practical  solutions,  and  pragmatism.  Although
ethical principles are at the centre of these discussions, it is their transformation into
policy that is most significant in the field, and for the participants of the clinical trials.

The role of International Guidelines were also evoked with respect to many of these
issues,  but  the  inconsistencies  and  divergence  in  these  have  often  further
complicated ethical discussions. Moreover, post-trial considerations must also not be
neglected, as they also constitute a part of the clinical trial, and although mentioned,
were not extensively discussed.

The general sentiment emerging from the discussion can be summarised as follows:
there  are  many  difficulties  associated  with  working  in  development,  the  most
important is that the intervention does not create more problems than those already
existing, and secondly it generate a positive impact.

70

 (cid:20)(cid:16)(cid:16)(cid:5)(cid:6)(cid:20)(cid:8)(cid:20)(cid:14)(cid:4)!(cid:5)(cid:1)(cid:7)(cid:3)

(cid:24)(cid:3)(cid:2)(cid:2)(cid:28)(cid:10)(cid:3)(cid:6)(cid:3)&(cid:8)4(cid:28)(cid:11)(cid:19)(cid:5)

/7(cid:2)(cid:5)(cid:25)(cid:8)+(cid:9)",

8(cid:2)(cid:12)(cid:23)(cid:5)(cid:4)(cid:4)(cid:12)(cid:2)
(cid:30)(cid:25)(cid:28)’(cid:5)(cid:2)(cid:4)(cid:28)(cid:11)(cid:20)(cid:8)(cid:12)(cid:23)(cid:8),(cid:19)(cid:25)(cid:10)$(cid:5)(cid:4)(cid:11)(cid:5)(cid:2)(cid:8)B(cid:8)(cid:30)(cid:25)(cid:28)’(cid:5)(cid:2)(cid:4)(cid:28)(cid:11)(cid:20)(cid:8)(cid:12)(cid:23)(cid:8)(cid:9)(cid:4)(cid:6)(cid:12)

Søren Holm is Professor of Clinical Bioethics at the University of Manchester and Professor of
Medical Ethics at the University of Oslo. He holds degrees in medicine, philosophy and health
care ethics and works clinically as a doctor one day a week treating patients with ovarian
cancer.

His doctoral thesis was concerned with the question whether American biomedical ethics could
be transferred to Europe without modification.

He has written over 100 papers and several books on various issues in bioethics.

73

(cid:24)(cid:3)(cid:2)(cid:2)(cid:28)(cid:10)(cid:3)(cid:6)(cid:3)&(cid:8)4(cid:28)(cid:11)(cid:19)(cid:5)

 (cid:2)1(cid:8),(cid:12)(cid:25)(cid:28)(cid:10)(cid:19)(cid:8)0(cid:9)(cid:31)(cid:29)! 

(cid:24)(cid:19)&(cid:13)(cid:2)(cid:28)(cid:27)((cid:5)(cid:7)(cid:8)(cid:30)(cid:25)(cid:28)(cid:11)(cid:5)(cid:27)(cid:8)0(cid:28)(cid:25)((cid:27)(cid:12)&

,(cid:12)(cid:25)(cid:28)(cid:10)(cid:19)(cid:8)0(cid:12)(cid:25)(cid:2)(cid:19)(cid:27) is a medical anthropologist and active researcher in the life sciences. She has
carried out field-based research projects since the early 1990s linked to the cultural and ethical
implications of the new reproductive and genetic technologies.

She  has  an  interdisciplinary  training  in  the  social  sciences  with  degrees  in  politics,  sociology
and social anthropology and gained her Ph.D. from the London School of Economics & Political
Science (1996). Her doctoral thesis addressed the subject of anonymous egg donation and the
kinship  of  IVF  transplantation  cultures  between  British  donors  and  recipients.  She  has  held
teaching  and  research  posts  at  the  University  of  Sussex,  Goldsmiths  College,  University  of
London,  and  is  currently  Associate  Fellow  at  the  School  of  Advanced  Study,  University  of
London. Recent publications explore the interface between culture, biotechnology and bioethics
in  relation  to  predictive  genetic  testing  technologies.  (Konrad,  M.  (2002)  ’Pre-symptomatic
networks:  tracking  experts  across  medical  science  and  the  new  genetics’.  In  C.  Shore  &  S.
Nugent (eds) (cid:24)(cid:20)(cid:7)(cid:13)(cid:5)(cid:11)’(cid:16)(cid:20)(cid:13)(cid:16)(cid:2)(cid:5)(cid:10)*(cid:11)-(cid:8)(cid:13)(cid:14)(cid:2)(cid:3)(cid:25)(cid:3)(cid:20)(cid:3)(cid:9)(cid:7)(cid:4)(cid:18)(cid:20)(cid:11)(cid:1)(cid:5)(cid:2)(cid:10)(cid:25)(cid:5)(cid:4)(cid:13)(cid:7)(cid:31)(cid:5)(cid:10), London: Routledge, pp.227-48).

Forthcoming publications in the journals -(cid:8)(cid:13)(cid:14)(cid:2)(cid:3)(cid:25)(cid:3)(cid:20)(cid:3)(cid:9)(cid:23)(cid:11)3(cid:11))(cid:5)(cid:6)(cid:7)(cid:4)(cid:7)(cid:8)(cid:5) and the ,(cid:3)(cid:16)(cid:2)(cid:8)(cid:18)(cid:20)(cid:11)(cid:3)(cid:12)(cid:11)(cid:13)(cid:14)(cid:5)(cid:11)(cid:15)(cid:3)(cid:23)(cid:18)(cid:20)
-(cid:8)(cid:13)(cid:14)(cid:2)(cid:3)(cid:25)(cid:3)(cid:20)(cid:3)(cid:9)(cid:7)(cid:4)(cid:18)(cid:20)(cid:11) (cid:30)(cid:8)(cid:10)(cid:13)(cid:7)(cid:13)(cid:16)(cid:13)(cid:5)  explore  the  relationship  between  new  diagnostic  and  prognostic
knowledge  in  clinical  genetics,  and  moralities  of  information  disclosure  at  the  familial  level.
Monica  Konrad  is  currently  researching  transcultural  medical  ethics  and  comparative  medical
moralities relating to the new genetics, planning future research collaborations in this area, and
developing new teaching materials addressing the ’anthropology of genetics’. She contributed a
written  submission  to  the  UK  Nuffield  Council  on  Bioethics  Consultation  Paper  informing  the
final Report (2002) on (cid:17)(cid:14)(cid:5)(cid:11)(cid:24)(cid:13)(cid:14)(cid:7)(cid:4)(cid:10)(cid:11)(cid:3)(cid:12)(cid:11)(cid:15)(cid:5)(cid:10)(cid:5)(cid:18)(cid:2)(cid:4)(cid:14)(cid:11)(cid:15)(cid:5)(cid:20)(cid:18)(cid:13)(cid:5)(cid:6)(cid:11)(cid:13)(cid:3)(cid:11) (cid:5)(cid:18)(cid:20)(cid:13)(cid:14)(cid:4)(cid:18)(cid:2)(cid:5)(cid:11)(cid:7)(cid:8)(cid:11)(cid:21)(cid:5)(cid:31)(cid:5)(cid:20)(cid:3)(cid:25)(cid:7)(cid:8)(cid:9)(cid:11)’(cid:3)(cid:16)(cid:8)(cid:13)(cid:2)(cid:7)(cid:5)(cid:10).
Memberships  of  professional  bodies:  International  Network  on  Feminist  Approaches  to
Bioethics; the British Association for Advancement of Science; Genetic Interest Group; Human
Genetics Alert; British Fertility Society; London Forum for Arts in Health; Royal Anthropological
Institute; Association of Social Anthropologists of the Commonwealth; European Association of
Social Anthropologists; Anthropology in Action.

75

(cid:24)(cid:3)(cid:2)(cid:2)(cid:28)(cid:10)(cid:3)(cid:6)(cid:3)&(cid:8)4(cid:28)(cid:11)(cid:19)(cid:5)

(cid:29)(cid:5)(cid:28)(cid:27)(cid:19)(cid:2)(cid:8)01(cid:8)"(cid:26)#

,1 1(cid:7)(cid:8)8$1 
(cid:30)(cid:25)(cid:28)’(cid:5)(cid:2)(cid:4)(cid:28)(cid:11)(cid:20)(cid:8)(cid:12)(cid:23)(cid:8)(cid:1)(cid:5)(cid:2)((cid:5)(cid:25)(cid:7)(cid:8)(cid:31)(cid:12)(cid:2)5(cid:19)(cid:20)

Mag.art. (Philosophy), University of Bergen, 1982
M.D., University of Bergen 1983
Ph.D. (Philosophy), University of Minnesota, Minneapolis, 1987

Born November 26, 1954

# (cid:30)(cid:24)!(cid:22)(cid:26)(cid:9)(cid:31)

University of Bergen, Mag.art. (Philosophy),  September 1982. 
University of Bergen, M.D. June 1983.
University of Minnesota, Minneapolis, Department of Philosophy.  Ph.D. July 1987.

8(cid:29)(cid:9)(cid:18)#//(cid:26)(cid:9)(cid:31)!"(cid:8) #4#"(cid:9)8,#(cid:31)(cid:22)

Assistant professor, Department of Medical Humanities, School of Medicine, East Carolina
University, Greenville, North Carolina, 1987 - 1989
Director, Centre for Medical Ethics, University of Oslo 1989 - 1995
Professor of Medical Ethics, University of Oslo, 1992 - 1995
Professor of Philosophy, University of Bergen, 1995 -
Adjunct Professor, Thammasat University, Bangkok, Thailand, 2000-

,!A(cid:9)(cid:29)(cid:8)(cid:18)(cid:30)(cid:31) # (cid:8)(cid:29)#/#!(cid:29)(cid:24)+(cid:8)8(cid:29)(cid:9)A#(cid:24)(cid:22)/

(cid:1)  Director of a 5 year research and competence building project in Medical Ethics, funded by
the Norwegian Research Council, 1989-1994.  A total of 7 Ph.D. students were associated
with this project, all of whom have successfully defended their dissertations. Funded by the
Norwegian Research Council, US$ 1,000,000

(cid:1)  ETHICA - Ethics and Health: An International and Comparative Arena.  Core project is a
collaboration between the University of Colombo, Sri Lanka and the University of Bergen,
Norway  in  ethics  and  health  policy.    Funded  from1996-2006.  Co-director.  Funded  from
Norwegian  Council  for  Higher  Education(cid:1)s  Programme  for  Development  Research  and
Education, US$ 500,000

(cid:1)  SEAHEN - South East Asian Health Ethics Network.  Consultant on a WHO-SEARO region
project  with  the  aim  of  creating  a  network  in  the  region  as  well  as  initiating  research
projects.  Funded  from  1997  -  1998  by  World  Health  Organisation,  South  East  Asian
Regional Office, New Delhi, US$ 200,000

(cid:1)  EUROPEAN ETHICS NETWORK - EU funded Socrates project with the aim of producing
European textbooks in applied ethics as well as preparing a European Mastersprogram in
ethics.  Co-coordinator of the Bioethics part of this project. Funded from 1997 - 1999, by
European Commission, Brussels US$ 3,000 (Bergen part).

77

(cid:1)  EURO  ELSAV  -  BIOMED  project  on  ethical,  legal  and  social  issues  in  vaccine
development, coordinated from Rome.  Responsible for a sub-project on ethical issues in
international  collaborative  vaccine  trials  within  this  general  project.  Funded  from  1998  -
2000, by European Commission, Brussels. US$ 60,000 (Bergen part)

(cid:1)  HUMAN RIGHTS, EQUITY AND HEALTH SECTOR REFORM. TDR/WHO funded project
involving  three  countries,  Bangladesh,  Sri  Lanka  and  Thailand.  Funded  1998-1999.
Funded by World Health Organization, Geneva, US$100,000

(cid:1)  CTC-ETHICS - Ethical issues in clinical trial collaborations with developing countries. EU
funded, 2000-2002. Director. Funded by European Commission, Brussels, US$ 300,000
(cid:1)  EVIBASE.  Ethical  issues  in  evidence  based  medicine.  EU  funded  project  2001-2002.

Funded by European Commission, Brussels, US$ 50,000

/#(cid:29)4(cid:26)(cid:24)#

(cid:30)(cid:8)(cid:13)(cid:5)(cid:2)(cid:8)(cid:18)(cid:13)(cid:7)(cid:3)(cid:8)(cid:18)(cid:20)(cid:11)(cid:4)(cid:3)(cid:8)(cid:10)(cid:16)(cid:20)(cid:13)(cid:18)(cid:8)(cid:4)(cid:7)(cid:5)(cid:10)

•  Member of drafting group for UNAIDS Guidance Document on Ethics and HIV

vaccine 

trials, 1999

•  Member of UNAIDS team to assess plan for HIV vaccine development in Kenya,

South 

Africa and Zambia, 1999-2000

•  Member of UNAIDS team to do an ethical review of phase III HIV vaccine trial in 

Bangkok, Thailand, 2001

(cid:30)(cid:8)(cid:13)(cid:5)(cid:2)(cid:8)(cid:18)(cid:13)(cid:7)(cid:3)(cid:8)(cid:18)(cid:20)(cid:11)(cid:15)(cid:5)(cid:10)(cid:5)(cid:18)(cid:2)(cid:4)(cid:14)(cid:11)(cid:15)(cid:5)(cid:31)(cid:7)(cid:5)4(cid:11)’(cid:3)(cid:29)(cid:29)(cid:7)(cid:13)(cid:13)(cid:5)(cid:5)(cid:10)

•  Review of research proposals for funding under the Quality of Life Programme,

European Commission, 1999-2001

•  Ethics review of funded research, European Commission, 1998-2001
•  Review of research proposals for funding, Belgian Research Council, 2001

((cid:18)(cid:13)(cid:7)(cid:3)(cid:8)(cid:18)(cid:20)(cid:11)’(cid:3)(cid:29)(cid:29)(cid:7)(cid:13)(cid:13)(cid:5)(cid:5)(cid:10)

•  Member of a Commission of the Ministry of Health on Psychiatry and Lobotomy in 

Norway, 1991-1992

•  Member of a Commission appointed by the Social Security Court on definition of

disease 

for the purpose of sickness certification. 1994

5(cid:13)(cid:14)(cid:5)(cid:2)(cid:11)6 5(cid:11)(cid:4)(cid:3)(cid:8)(cid:10)(cid:16)(cid:20)(cid:13)(cid:18)(cid:8)(cid:4)(cid:7)(cid:5)(cid:10)

•  Organised one-week training workshops for faculty of medical and nursing schools

funded by WHO-SEARO in Sri Lanka and Nepal. A total of five workshops
between 1996 and 1998

•  Organised three day training workshops for members of research ethics

committees in Geneva, Brazil, South Africa and India 1998-1999, funded by
UNAIDS

•  Organised one week training workshops in Thailand and Indonesia, 2000-2001

78

(cid:24)(cid:3)(cid:2)(cid:2)(cid:28)(cid:10)(cid:3)(cid:6)(cid:3)&(cid:8)4(cid:28)(cid:11)(cid:19)(cid:5)

 (cid:2)1(cid:8)4(cid:19)(cid:4)(cid:19)(cid:25)(cid:11)$(cid:19)(cid:8),(cid:30)(cid:22)+(cid:30)/=!,>

 (cid:5)%(cid:3)(cid:11)(cid:20)(cid:8) (cid:28)(cid:2)(cid:5)(cid:10)(cid:11)(cid:12)(cid:2)(cid:8))(cid:5)(cid:25)(cid:5)(cid:2)(cid:19)(cid:6)(cid:8)(cid:12)(cid:23)(cid:8)(cid:11)$(cid:5)(cid:8)(cid:26)(cid:25)(cid:27)(cid:28)(cid:19)(cid:25)(cid:8)(cid:24)(cid:12)(cid:3)(cid:25)(cid:10)(cid:28)(cid:6)(cid:8)(cid:12)(cid:23)(cid:8),(cid:5)(cid:27)(cid:28)(cid:10)(cid:19)(cid:6)(cid:8)(cid:29)(cid:5)(cid:4)(cid:5)(cid:19)(cid:2)(cid:10)$(cid:7)(cid:8)(cid:31)(cid:5)5
 (cid:5)(cid:6)$(cid:28)(cid:7)(cid:8)(cid:26)(cid:25)(cid:27)(cid:28)(cid:19)

Dr (Ms) Vasantha Muthuswamy,MD,DGO,
Senior Deputy Director General and Chief,
Division of Basic Medical Sciences
Indian Council of Medical research (ICMR), New Delhi

Dr. Muthuswamy is a trained gynaecologist and obstetrician from Madras, India. After pursuing
a research career in the area of Maternal and Child health and Contraception at Bangalore and
Mumbai, she is now in Charge of research in Basic Medical Sciences for the past 20 years at
the  ICMR  headquarters,  New  Delhi.  Her  areas  of  activity  include  genetics,  genomics,  drug
development including traditional medicine etc.

For  the  last  6  years  she  has  been  deeply  involved  in  the  area  of  biomedical  ethics  both  for
animal  and  human  experimentation.  A  visiting  Fellow  at  the  Kennedy  Institute  of  Ethics  at
Georgetown  University,  Washington  DC  Dr.Muthuswamy  is  responsible  for  revising  the
E#(cid:11)$(cid:28)(cid:10)(cid:19)(cid:6)(cid:8)((cid:3)(cid:28)(cid:27)(cid:5)(cid:6)(cid:28)(cid:25)(cid:5)(cid:4)(cid:8)(cid:23)(cid:12)(cid:2)(cid:8)(cid:13)(cid:28)(cid:12)&(cid:5)(cid:27)(cid:28)(cid:10)(cid:19)(cid:6)(cid:8)(cid:2)(cid:5)(cid:4)(cid:5)(cid:19)(cid:2)(cid:10)$(cid:8)(cid:12)(cid:25)(cid:8)$(cid:3)&(cid:19)(cid:25)(cid:8)(cid:4)(cid:3)(cid:13):(cid:5)(cid:10)(cid:11)(cid:4)E brought out by the ICMR
in 2000 after four years of intense deliberations by the Justice Venkatachaliah committee.

She has been member of ethics committees of various national and international organisations
such  as  UNAIDS,  HPTN,  EC,  AIIMS,  VP  Chest  Institute,  ICMR  Central  ethics  committee,
National Brain Research
Centre  etc.  Since  January  2000,  she  has  become  the  Secretary  General  of  the  Forum  for
ethical review committees in the Asia-Pacific region (FERCAP) and conducted workshops on
research  ethics  at  India,  Thailand,  Nepal,  Pakistan,  Indonesia,  Philippines,  Laos  and
Cambodia. She is currently visiting faculty at the Thammasat University, Bangkok and involved
in introducing teaching of bioethics at medical colleges and Universities all over the country and
capacity building of ethics committee members all over India.

She has been associated with development of various national and international guidelines on
Ethical issues.

As Chief of the Basic medical Sciences, she is involved in funding, infrastructure development
and  capacity  building  in  all  areas  of  Drug  development  including  Traditional  medicine
Research. As Secretary of the Toxicology Review Panel of the Council, she is closely involved
in all regulatory requirements of drug research in the country.

79

(cid:24)(cid:3)(cid:2)(cid:2)(cid:28)(cid:10)(cid:3)(cid:6)(cid:3)&(cid:8)4(cid:28)(cid:11)(cid:19)(cid:5)

, (cid:7)(cid:8)8$ 

 (cid:2)1(cid:8)(cid:31)(cid:28)(cid:10)(cid:12)(cid:6)(cid:19)(cid:4)(cid:8),# !

Dr.  MEDA,  medical  epidemiologist  and  senior  researcher,  is  the  Director  of  Centre  MURAZ  (Burkina
Faso  Ministry  of  Health  Institute  of  Training  and  Biomedical  Research)  Department  of  HIV/AIDS  and
Reproductive  Health.  He  is  also  the  field  coordinator  of  French  National  Agency  for  AIDS  Research
activities in Burkina Faso. He has extensively conducted multicentre clinical trials in the area of Mother-
to-Child  Transmission  of  HIV.  He  is  the  author  of  more  than  50  articles  published  in  international
journals.

8#(cid:29)/(cid:9)(cid:31)!"(cid:8)(cid:26)(cid:31)(cid:18)(cid:9)(cid:29),!(cid:22)(cid:26)(cid:9)(cid:31):

Date of birth:
Place of birth:
Nationality:

December 7, 1962
Dissin, Burkina Faso
Burkinabe

8(cid:29)(cid:9)(cid:18)#//(cid:26)(cid:9)(cid:31)!"(cid:8)#F8#(cid:29)(cid:26)#(cid:31)(cid:24)#2

Assistant Director of Research and Head of
Centre MURAZ Department of HIV/AIDS

Short-term Consultant / Professional, Regional Programme on AIDS
Regional Office for Africa, World Health Organization, Harare, Zimbabwe

Senior Research Scientist, Centre MURAZ,
Burkina Faso Training and Biomedical Research Institute

Assistant Research Scientist, Centre MURAZ,
Burkina Faso Training and Biomedical Research Institute

Clinician, Gynaecology & Obstetrics Department
Ministry of Health Sourô Sanou National Hospital,
Bobo-Dioulasso, Burkina Faso

(cid:9)(cid:22)+#(cid:29)(cid:8)=(cid:9)(cid:29)0(cid:26)(cid:31))(cid:8)#F8#(cid:29)(cid:26)(cid:31)(cid:24)#

Participation and scientific contribution to more than fifty workshops, seminars, international
conferences, focusing on Reproductive Health, HIV/AIDS and Health systems development.

!(cid:24)! #,(cid:26)(cid:24)(cid:8)(cid:22)(cid:29)!(cid:26)(cid:31)(cid:26)(cid:31))2

Doctorat d'Université (Ph.D.) en Epidémiologie
Université de Bordeaux II, Bordeaux

Diplôme d'Etudes Approfondies (DEA)
"Epidemiology and Public Health"

81

March 2002-
present

April 2001
February 2002

since July
1997

October 1994 to
June 1997

October 1989 to
September 1994

June 1997

October 1993

Université de Bordeaux II, Bordeaux
B.A. in Statistics and epidemiology
Institute of Statistics, University of Paris VI

Doctorat d'Etat en Médecine (Medical Degree)
Université de Ouagadougou, Burkina Faso

(cid:24)(cid:9)(cid:31)(cid:22)(cid:26)(cid:31)(cid:30)(cid:26)(cid:31))(cid:8)# (cid:30)(cid:24)!(cid:22)(cid:26)(cid:9)(cid:31)

June 1991

June 1990

May 1994 – June 1994
Diploma of the International Course on STDS & AIDS, Main topics: detection and management
of STDs and HIV infection focusing in developing countries. Alfred Fournier Institute, Paris,
France, WHO Collaborative Centre on STDs.

September 1995
Certificate on Data analysis in Epidemiological Research. Main topics: Advanced methods in data
analysis in epidemiology. Free University of Brussels, School of Public Health, Belgium.

!(cid:30)(cid:22)+(cid:9)(cid:29)2

Publications  mainly  on  reproductive  health  and  HIV  infection  in  children  and  adults  in  peer  reviewed
medical journals (52) and book’s chapters (3). More than 60 oral communications.

,!A(cid:9)(cid:29)(cid:8)!(cid:29)#!/(cid:8)(cid:9)(cid:18)(cid:8)(cid:26)(cid:31)(cid:22)#(cid:29)#/(cid:22):

Epidemiology, ethics and public health interventions on maternal and child health
Epidemiology, ethics and control of human immunodeficiency virus (HIV) infection
Health information systems and monitoring of primary health care programs
Epidemiologic surveillance and monitoring and evaluation of public health programmes

(cid:24)(cid:9)(cid:31)/(cid:30)"(cid:22)!(cid:31)(cid:24)(cid:26)#/2

Around twenty expertises and missions in different African countries in area of HIV/AIDS, Reproductive Health and
Health systems development requested by French Ministry of Cooperation, World Bank, UNAIDS and WHO.

82

(cid:24)(cid:3)(cid:2)(cid:2)(cid:28)(cid:10)(cid:3)(cid:6)(cid:3)&(cid:8)4(cid:28)(cid:11)(cid:19)(cid:5)

 (cid:2)1(cid:8)+(cid:19)(cid:25)(cid:25)(cid:19)(cid:8)(cid:31)(cid:9)+>(cid:31)#0

 (cid:5)%(cid:19)(cid:2)(cid:11)&(cid:5)(cid:25)(cid:11)(cid:8)(cid:12)(cid:23)(cid:8)4(cid:19)(cid:10)(cid:10)(cid:28)(cid:25)(cid:5)(cid:4)
(cid:31)(cid:19)(cid:11)(cid:28)(cid:12)(cid:25)(cid:19)(cid:6)(cid:8)8(cid:3)(cid:13)(cid:6)(cid:28)(cid:10)(cid:8)+(cid:5)(cid:19)(cid:6)(cid:11)$(cid:8)(cid:26)(cid:25)(cid:4)(cid:11)(cid:28)(cid:11)(cid:3)(cid:11)(cid:5)
+#"/(cid:26)(cid:31)0(cid:26)(cid:8)(cid:17)(cid:8)(cid:18)(cid:28)(cid:25)(cid:6)(cid:19)(cid:25)(cid:27)

Hanna Nohynek completed her medical studies in Helsinki, Finland, and is presently working
as a Senior Scientist at the Department of Vaccines for the National Public Health Institute. She
is  the  scientific  project  coordinator  of  the  ARIVAC  trial,  a  phase  III  study  of  an  11-valent
pneumococcal conjugate vaccine being conducted by the international ARIVAC consortium on
the island of Bohol in the Philippines. The study is funded by  the  European  Commission  DG
Research INCO programme, Bill and Melinda Gates Children’s Vaccine Programme at PATH,
the Finnish Academy and the Finnish Foreign Ministry, and WHO Vaccines and Biologicals. For
more details, visit www.sph.uq.edu.au/arivac/

Hanna  Nohynek did  her  PhD  work  on  the  serodiagnosis  of  childhood  pneumonia,  which  she
has studied in Finland, Russia, and the Philippines.  In collaboration with the Research Institute
of Tropical Medicine in the Philippines, she has coordinated 6 phase II trials  on  a  number  of
vaccines  ( (cid:18)(cid:5)(cid:29)(cid:3)(cid:25)(cid:14)(cid:7)(cid:20)(cid:16)(cid:10)(cid:11) (cid:7)(cid:8)(cid:12)(cid:20)(cid:16)(cid:5)(cid:8)(cid:22)(cid:18)(cid:5)  type  b,  meningococcal  conjugate,  and  pneumococcal
conjugate  among  infants,  and  pneumococcal  polysaccharide  among  pregnant  mothers  and
infants).    She  is  also  a  member  of  the  National  Public  Health  Institute  Advisory  Board  for
Vaccines,  Editor  in  Chief  of  the  Finnish  Vaccinators  Manual  (www.ktl.fi),  a  founding  member
and chairman of the Steering Committee of the Finnish Global Health Course initiated in 1999,
a  partner  in  the  DG  Research  funded  project  CTC-Ethics,  a  Working  Group  member  of  the
European Developing Country Clinical Trial Platform (EDCTP), a Steering Committee member
of  the  EU  DG  SanCo  funded  European  Programme  on  Intervention  Epidemiology  Training
(EPIET), and has served as technical advisor to the EU, WHO, GAVI and the Finnish Ministry
of Foreign Affairs. She has taught on several vaccinology and infectious disease epidemiology
related courses in Finland, Sweden, Russia, Estonia, France, Thailand and the Philippines and
belongs  to  the  scientific  faculty  of  the  Fondation  Merieux  initiated  Advanced  Course  on
Vaccinology, in France, since 1999. She has published 21 original scientific communications in
peer  reviewed  journals,  presented  original  data  in  68  international  scientific  meetings,  edited
several manuals and textbooks both in Finnish and English languages, and serves as a peer
reviewer to several international scientific journals.

83

(cid:24)(cid:3)(cid:2)(cid:2)(cid:28)(cid:10)(cid:3)(cid:6)(cid:3)&(cid:8)4(cid:28)(cid:11)(cid:19)(cid:5)

 (cid:2)1(cid:8)(cid:31)(cid:19)(cid:27)(cid:28)(cid:19)(cid:8)(cid:22)(cid:9)(cid:29)(cid:31)(cid:26)#8(cid:9)(cid:29)(cid:22)+

 (cid:28)(cid:2)(cid:5)(cid:10)(cid:11)(cid:12)(cid:2)(cid:7)(cid:8)(cid:24)(cid:6)(cid:28)(cid:25)(cid:28)(cid:10)(cid:19)(cid:6)(cid:8) (cid:5)’(cid:5)(cid:6)(cid:12)%&(cid:5)(cid:25)(cid:11)(cid:7)
)(cid:6)(cid:19)<(cid:12)/&(cid:28)(cid:11)$0(cid:6)(cid:28)(cid:25)(cid:5)(cid:8)(cid:1)(cid:28)(cid:12)(cid:6)(cid:12)((cid:28)(cid:10)(cid:19)(cid:6)(cid:4)(cid:7)
(cid:29)(cid:28)<(cid:5)(cid:25)(cid:4)(cid:19)(cid:2)(cid:11)(cid:7)(cid:8)(cid:1)(cid:5)(cid:6)((cid:28)(cid:3)&

8(cid:29)(cid:9)(cid:18)#//(cid:26)(cid:9)(cid:31)!"(cid:8)#F8#(cid:29)(cid:26)#(cid:31)(cid:24)#

&//12%77%(cid:11)’(cid:20)(cid:7)(cid:8)(cid:7)(cid:4)(cid:18)(cid:20)(cid:11)(cid:15)3(cid:21)8(cid:11)(cid:25)(cid:2)(cid:3)(cid:25)(cid:14)(cid:23)(cid:20)(cid:18)(cid:4)(cid:13)(cid:7)(cid:4)(cid:11)(cid:31)(cid:18)(cid:4)(cid:4)(cid:7)(cid:8)(cid:5)(cid:10)8(cid:11)!(cid:29)(cid:7)(cid:13)(cid:14)9(cid:20)(cid:7)(cid:8)(cid:5)(cid:11)(cid:28)(cid:5)(cid:5)(cid:4)(cid:14)(cid:18)(cid:29):(cid:26)(cid:20)(cid:18);(cid:3)!(cid:29)(cid:7)(cid:13)(cid:14)9(cid:20)(cid:7)(cid:8)(cid:5)
(cid:28)(cid:7)(cid:3)(cid:20)(cid:3)(cid:9)(cid:7)(cid:4)(cid:18)(cid:20)(cid:10)*

 (cid:28)(cid:2)(cid:5)(cid:10)(cid:11)(cid:12)(cid:2)(cid:7)(cid:8)(cid:24)(cid:6)(cid:28)(cid:25)(cid:28)(cid:10)(cid:19)(cid:6)(cid:8) (cid:5)’(cid:5)(cid:6)(cid:12)%&(cid:5)(cid:25)(cid:11)(cid:7)(cid:8)Pediatric Pneumococcal

!%(cid:2)(cid:8)(cid:15)(cid:16)(cid:16)(cid:15)(cid:17)%(cid:2)(cid:5)(cid:4)(cid:5)(cid:25)(cid:11)
Vaccines and Emerging Diseases,(cid:8)GlaxoSmithKline Biologicals,(cid:8)Rixensart, Belgium:
(cid:1)(cid:2)(cid:3)"(cid:5)(cid:4)(cid:13)(cid:11)(cid:21)(cid:7)(cid:2)(cid:5)(cid:4)(cid:13)(cid:3)(cid:2)8(cid:11))<(cid:30):(cid:26)!9(cid:11)(cid:25)(cid:16)(cid:19)(cid:20)(cid:7)(cid:4)2(cid:25)(cid:2)(cid:7)(cid:31)(cid:18)(cid:13)(cid:5)(cid:11)(cid:25)(cid:18)(cid:2)(cid:13)(cid:8)(cid:5)(cid:2)(cid:10)(cid:14)(cid:7)(cid:25)(cid:11)(cid:12)(cid:3)(cid:2)(cid:11)(cid:25)(cid:5)(cid:6)(cid:7)(cid:18)(cid:13)(cid:2)(cid:7)(cid:4)(cid:11)(cid:6)(cid:5)(cid:31)(cid:5)(cid:20)(cid:3)(cid:25)(cid:29)(cid:5)(cid:8)(cid:13)(cid:11)(cid:29)(cid:18)(cid:20)(cid:18)(cid:2)(cid:7)(cid:18)(cid:11)(cid:31)(cid:18)(cid:4)(cid:4)(cid:7)(cid:8)(cid:5)=
(cid:4)(cid:20)(cid:7)(cid:8)(cid:7)(cid:4)(cid:18)(cid:20)(cid:11)(cid:6)(cid:5)(cid:31)(cid:5)(cid:20)(cid:3)(cid:25)(cid:29)(cid:5)(cid:8)(cid:13)(cid:11)(cid:13)(cid:16)(cid:19)(cid:5)(cid:2)(cid:4)(cid:16)(cid:20)(cid:3)(cid:10)(cid:7)(cid:10)(cid:11)(cid:31)(cid:18)(cid:4)(cid:4)(cid:7)(cid:8)(cid:5)=(cid:11)(cid:25)(cid:8)(cid:5)(cid:16)(cid:29)(cid:3)(cid:4)(cid:3)(cid:4)(cid:4)(cid:18)(cid:20)(cid:11)(cid:4)(cid:3)(cid:8)"(cid:16)(cid:9)(cid:18)(cid:13)(cid:5)(cid:11)(cid:31)(cid:18)(cid:4)(cid:4)(cid:7)(cid:8)(cid:5)(cid:11)(cid:6)(cid:5)(cid:31)(cid:5)(cid:20)(cid:3)(cid:25)(cid:29)(cid:5)(cid:8)(cid:13)=(cid:11)(cid:8)(cid:5)4
(cid:13)(cid:5)(cid:4)(cid:14)(cid:8)(cid:3)(cid:20)(cid:3)(cid:9)(cid:7)(cid:5)(cid:10)(cid:11)>(cid:18)(cid:6)"(cid:16)(cid:31)(cid:18)(cid:8)(cid:13)(cid:10)8(cid:11)(cid:25)(cid:2)(cid:7)(cid:29)(cid:5)2(cid:19)(cid:3)(cid:3)(cid:10)(cid:13)?#
Since 2001: GSK Biologicals representative, IFPMA contact group on ethics in biomedical
research

A(cid:19)(cid:25)(cid:8)(cid:15)(cid:16)(cid:16)(cid:14)(cid:17),(cid:19)(cid:2)(cid:8)(cid:15)(cid:16)(cid:16)(cid:15)
Emerging Diseases: (cid:1)(cid:2)(cid:3)"(cid:5)(cid:4)(cid:13)(cid:11)(cid:21)(cid:7)(cid:2)(cid:5)(cid:4)(cid:13)(cid:3)(cid:2)8(cid:11))<(cid:30):(cid:26)!9(cid:11)(cid:25)(cid:16)(cid:19)(cid:20)(cid:7)(cid:4)2(cid:25)(cid:2)(cid:7)(cid:31)(cid:18)(cid:13)(cid:5)(cid:11)(cid:25)(cid:18)(cid:2)(cid:13)(cid:8)(cid:5)(cid:2)(cid:10)(cid:14)(cid:7)(cid:25)(cid:11)(cid:12)(cid:3)(cid:2)(cid:11)(cid:25)(cid:5)(cid:6)(cid:7)(cid:18)(cid:13)(cid:2)(cid:7)(cid:4)
(cid:6)(cid:5)(cid:31)(cid:5)(cid:20)(cid:3)(cid:25)(cid:29)(cid:5)(cid:8)(cid:13)(cid:11)(cid:29)(cid:18)(cid:20)(cid:18)(cid:2)(cid:7)(cid:18)(cid:11)(cid:31)(cid:18)(cid:4)(cid:4)(cid:7)(cid:8)(cid:5)?=(cid:11)(cid:4)(cid:20)(cid:7)(cid:8)(cid:7)(cid:4)(cid:18)(cid:20)(cid:11)(cid:6)(cid:5)(cid:31)(cid:5)(cid:20)(cid:3)(cid:25)(cid:29)(cid:5)(cid:8)(cid:13)(cid:11)(cid:13)(cid:16)(cid:19)(cid:5)(cid:2)(cid:4)(cid:16)(cid:20)(cid:3)(cid:10)(cid:7)(cid:10)(cid:11)(cid:31)(cid:18)(cid:4)(cid:4)(cid:7)(cid:8)(cid:5)=(cid:11)((cid:5)4(cid:11)(cid:13)(cid:5)(cid:4)(cid:14)(cid:8)(cid:3)(cid:20)(cid:3)(cid:9)(cid:7)(cid:5)(cid:10)
>(cid:18)(cid:6)"(cid:16)(cid:31)(cid:18)(cid:8)(cid:13)(cid:10)8(cid:11)(cid:25)(cid:2)(cid:7)(cid:29)(cid:5)2(cid:19)(cid:3)(cid:3)(cid:10)(cid:13)?

!(cid:4)(cid:4)(cid:12)(cid:10)(cid:28)(cid:19)(cid:11)(cid:5)(cid:8) (cid:28)(cid:2)(cid:5)(cid:10)(cid:11)(cid:12)(cid:2)(cid:8)B(cid:8) (cid:28)(cid:2)(cid:5)(cid:10)(cid:11)(cid:12)(cid:2)(cid:7)(cid:8)(cid:24)(cid:6)(cid:28)(cid:25)(cid:28)(cid:10)(cid:19)(cid:6)(cid:8) (cid:5)’(cid:5)(cid:6)(cid:12)%&(cid:5)(cid:25)(cid:11)(cid:7)

A(cid:19)(cid:25)(cid:8)(cid:15)(cid:16)(cid:16)(cid:16)(cid:17) (cid:5)(cid:10)(cid:8)(cid:15)(cid:16)(cid:16)(cid:16)
Hepatitis Vaccines, Adult Development Unit:(cid:11)(cid:5)(cid:18)(cid:2)(cid:20)(cid:23)(cid:11)(cid:4)(cid:20)(cid:7)(cid:8)(cid:7)(cid:4)(cid:18)(cid:20)(cid:11)(cid:6)(cid:5)(cid:31)(cid:5)(cid:20)(cid:3)(cid:25)(cid:29)(cid:5)(cid:8)(cid:13)(cid:11)(cid:29)(cid:18)(cid:20)(cid:18)(cid:2)(cid:7)(cid:18)(cid:11)(cid:31)(cid:18)(cid:4)(cid:4)(cid:7)(cid:8)(cid:5)8(cid:11)(cid:1)(cid:14)(cid:18)(cid:10)(cid:5)
(cid:30)(cid:30)(cid:30)(cid:11)@(cid:11)(cid:30)<(cid:11)(cid:6)(cid:5)(cid:31)(cid:5)(cid:20)(cid:3)(cid:25)(cid:29)(cid:5)(cid:8)(cid:13)(cid:11)(cid:3)(cid:12)(cid:11)(cid:13)(cid:2)(cid:18)(cid:31)(cid:5)(cid:20)(cid:5)(cid:2)(cid:10)(cid:11)(cid:18)(cid:8)(cid:6)(cid:11)(cid:14)(cid:5)(cid:25)(cid:18)(cid:13)(cid:7)(cid:13)(cid:7)(cid:10)(cid:11)(cid:31)(cid:18)(cid:4)(cid:4)(cid:7)(cid:8)(cid:5)(cid:10)(cid:11)>(cid:18)(cid:6)(cid:16)(cid:20)(cid:13)(cid:11)(cid:18)(cid:8)(cid:6)(cid:11)(cid:25)(cid:18)(cid:5)(cid:6)(cid:7)(cid:18)(cid:13)(cid:2)(cid:7)(cid:4)(cid:11)(cid:10)(cid:13)(cid:16)(cid:6)(cid:7)(cid:5)(cid:10)?#

!(cid:4)(cid:4)(cid:12)(cid:10)(cid:28)(cid:19)(cid:11)(cid:5)(cid:8) (cid:28)(cid:2)(cid:5)(cid:10)(cid:11)(cid:12)(cid:2)(cid:7)(cid:8)(cid:24)(cid:6)(cid:28)(cid:25)(cid:28)(cid:10)(cid:19)(cid:6)(cid:8) (cid:5)’(cid:5)(cid:6)(cid:12)%&(cid:5)(cid:25)(cid:11), Travelers’ &

,(cid:19)(cid:25)(cid:19)((cid:5)(cid:2)(cid:8)B(cid:8)/(cid:5)(cid:25)(cid:28)(cid:12)(cid:2)(cid:8),(cid:19)(cid:25)(cid:19)((cid:5)(cid:2)(cid:7)(cid:8)(cid:24)(cid:6)(cid:28)(cid:25)(cid:28)(cid:10)(cid:19)(cid:6)(cid:8) (cid:5)’(cid:5)(cid:6)(cid:12)%&(cid:5)(cid:25)(cid:11),

A(cid:3)(cid:25)(cid:5)(cid:8)(cid:14)GGH(cid:17) (cid:5)(cid:10)(cid:8)(cid:14)GGG
Travelers’ Vaccines, Adult Development Unit, SmithKline Beecham Biologicals, Rixensart,
Belgium,:(cid:11)(cid:1)(cid:14)(cid:18)(cid:10)(cid:5)(cid:11)(cid:30)2(cid:30)(cid:30)(cid:11)(cid:4)(cid:20)(cid:7)(cid:8)(cid:7)(cid:4)(cid:18)(cid:20)(cid:11)(cid:6)(cid:5)(cid:31)(cid:5)(cid:20)(cid:3)(cid:25)(cid:29)(cid:5)(cid:8)(cid:13)(cid:11)(cid:29)(cid:18)(cid:20)(cid:18)(cid:2)(cid:7)(cid:18)(cid:11)(cid:31)(cid:18)(cid:4)(cid:4)(cid:7)(cid:8)(cid:5)8(cid:11)(cid:1)(cid:14)(cid:18)(cid:10)(cid:5)(cid:11)(cid:30)(cid:30)(cid:30)(cid:11)@(cid:11)(cid:30)<(cid:11)(cid:6)(cid:5)(cid:31)(cid:5)(cid:20)(cid:3)(cid:25)(cid:29)(cid:5)(cid:8)(cid:13)(cid:11)(cid:3)(cid:12)
(cid:13)(cid:2)(cid:18)(cid:31)(cid:5)(cid:20)(cid:5)(cid:2)(cid:10)(cid:11)(cid:31)(cid:18)(cid:4)(cid:4)(cid:7)(cid:8)(cid:5)(cid:10)(cid:11)>(cid:2)(cid:5)(cid:9)(cid:7)(cid:10)(cid:13)(cid:2)(cid:18)(cid:13)(cid:7)(cid:3)(cid:8)(cid:11)(cid:3)(cid:12)(cid:11) (cid:5)(cid:25)(cid:18)(cid:13)(cid:23)(cid:2)(cid:7);?=(cid:11)(cid:24)(cid:17)(cid:24)’(cid:11)(cid:5)(cid:25)(cid:7)(cid:6)(cid:5)(cid:29)(cid:7)(cid:3)(cid:20)(cid:3)(cid:9)(cid:23)(cid:11)>(cid:17)(cid:2)(cid:18)(cid:31)(cid:5)(cid:20)(cid:5)(cid:2)(cid:10)A(cid:11)(cid:21)(cid:7)(cid:18)(cid:2)(cid:2)(cid:14)(cid:3)(cid:5)(cid:18)
6(cid:3)(cid:2)(cid:20)(cid:6)4(cid:7)(cid:6)(cid:5)?#(cid:11)Additional responsibilities for Clinical Development of Travelers’ & Hepatitis
Vaccines, Adult Development Unit, September – December 1999: (cid:1)(cid:14)(cid:18)(cid:10)(cid:5)(cid:11)(cid:30)(cid:30)(cid:30)(cid:11)(cid:4)(cid:20)(cid:7)(cid:8)(cid:7)(cid:4)(cid:18)(cid:20)
(cid:6)(cid:5)(cid:31)(cid:5)(cid:20)(cid:3)(cid:25)(cid:29)(cid:5)(cid:8)(cid:13)(cid:11)(cid:14)(cid:5)(cid:25)(cid:18)(cid:13)(cid:7)(cid:13)(cid:7)(cid:10)(cid:11)(cid:31)(cid:18)(cid:4)(cid:4)(cid:7)(cid:8)(cid:5)(cid:10)#

"##$%"##&(cid:4)’(cid:6)(cid:7)(cid:15)(cid:3)(cid:14)(cid:5)(cid:6)(cid:4)(cid:7)(cid:17)(cid:15)(cid:4)(cid:12)(cid:5)(cid:3)(cid:8)(cid:15)(cid:4)(cid:16)(cid:3)(cid:9)(cid:3)(cid:7)(cid:16)(cid:6)(cid:2)(cid:4)(cid:5)(cid:17)(cid:4)(cid:5)(cid:17)(cid:12)(cid:3)(cid:6)(cid:1)(cid:5)(cid:11)(cid:20)(cid:9)(cid:4)(cid:15)(cid:5)(cid:9)(cid:3)(cid:7)(cid:9)(cid:3)(cid:9)((cid:1)(cid:16)(cid:11)(cid:10)(cid:5)(cid:6)(cid:7)(cid:8)(cid:4)(cid:14)(cid:3)(cid:15)(cid:5)(cid:6)(cid:5)(cid:17)(cid:3))

!(cid:4)(cid:4)(cid:28)(cid:4)(cid:11)(cid:19)(cid:25)(cid:11)(cid:8)8(cid:2)(cid:12)(cid:23)(cid:5)(cid:4)(cid:4)(cid:12)(cid:2), Overseas Staff, Section International Medicine

,(cid:19)(cid:20)(cid:8)(cid:14)GGI(cid:17),(cid:19)(cid:20)(cid:8)(cid:14)GGH
and Public Health, Dept. of Infectious Diseases and Tropical Medicine, University of Munich,
Germany:(cid:11)(cid:15)(cid:5)(cid:10)(cid:7)(cid:6)(cid:5)(cid:8)(cid:13)(cid:11)(cid:25)(cid:14)(cid:23)(cid:10)(cid:7)(cid:4)(cid:7)(cid:18)(cid:8)8(cid:11)(cid:30)(cid:8)(cid:13)(cid:5)(cid:2)(cid:8)(cid:18)(cid:13)(cid:7)(cid:3)(cid:8)(cid:18)(cid:20)(cid:11)’(cid:3)(cid:20)(cid:20)(cid:18)(cid:19)(cid:3)(cid:2)(cid:18)(cid:13)(cid:7)(cid:31)(cid:5)(cid:11)!(cid:13)(cid:16)(cid:6)(cid:23)(cid:11)(cid:3)(cid:8)(cid:11)(cid:17)(cid:2)(cid:18)(cid:31)(cid:5)(cid:20)(cid:5)(cid:2)(cid:10)A(cid:11) (cid:5)(cid:18)(cid:20)(cid:13)(cid:14)8(cid:11))(cid:3)(cid:8)(cid:13)(cid:5)(cid:9)(cid:3)
(cid:28)(cid:18)(cid:23)8(cid:11),(cid:18)(cid:29)(cid:18)(cid:7)(cid:4)(cid:18):6#(cid:30)(cid:11)>(cid:14)(cid:5)(cid:18)(cid:20)(cid:13)(cid:14)(cid:4)(cid:18)(cid:2)(cid:5)8(cid:11)8(cid:12)(cid:3)(cid:3)(cid:6)(cid:11)(cid:10)(cid:18)(cid:12)(cid:5)(cid:13)(cid:23)(cid:11)(cid:10)(cid:16)(cid:2)(cid:31)(cid:5)(cid:7)(cid:20)(cid:20)(cid:18)(cid:8)(cid:4)(cid:5)8(cid:11)(cid:13)(cid:2)(cid:18)(cid:7)(cid:8)(cid:7)(cid:8)(cid:9)(cid:11)(cid:18)(cid:8)(cid:6)(cid:11)(cid:6)(cid:18)(cid:13)(cid:18)(cid:11)(cid:29)(cid:18)(cid:8)(cid:18)(cid:9)(cid:5)(cid:29)(cid:5)(cid:8)(cid:13)?

85

(cid:26)(cid:25)(cid:4)(cid:11)(cid:2)(cid:3)(cid:10)(cid:11)(cid:12)(cid:2)(cid:8)(cid:28)(cid:25)(cid:8),(cid:5)(cid:27)(cid:28)(cid:10)(cid:28)(cid:25)(cid:5), Division of International Medicine and Infectious

(cid:14)GGJ(cid:17)GI
Diseases, Cornell University Medical College, New York, NY: (cid:17)(cid:28)((cid:5)(cid:13)4(cid:3)(cid:2)+(cid:11)’(cid:3)(cid:3)(cid:2)(cid:6)(cid:7)(cid:8)(cid:18)(cid:13)(cid:3)(cid:2)*
B(cid:18)(cid:19)(cid:3)(cid:2)(cid:18)(cid:13)(cid:3)(cid:2)(cid:23)2(cid:28)(cid:18)(cid:10)(cid:5)(cid:6)(cid:11)!(cid:16)(cid:2)(cid:31)(cid:5)(cid:7)(cid:20)(cid:20)(cid:18)(cid:8)(cid:4)(cid:5)(cid:11)(cid:3)(cid:12)(cid:11)(cid:17)(cid:16)(cid:19)(cid:5)(cid:2)(cid:4)(cid:16)(cid:20)(cid:3)(cid:10)(cid:7)(cid:10)(cid:11)(cid:17)(cid:2)(cid:18)(cid:8)(cid:10)(cid:29)(cid:7)(cid:10)(cid:10)(cid:7)(cid:3)(cid:8)(cid:11)(cid:7)(cid:8)(cid:11)((cid:5)4(cid:11)C(cid:3)(cid:2)+(cid:11)’(cid:7)(cid:13)(cid:23)=(cid:11)(cid:24)(cid:25)(cid:7)(cid:6)(cid:5)(cid:29)(cid:7)(cid:3)(cid:20)(cid:3)(cid:9)(cid:23)
(cid:3)(cid:12)(cid:11)((cid:3)(cid:10)(cid:3)(cid:4)(cid:3)(cid:29)(cid:7)(cid:18)(cid:20)(cid:11)(cid:30)(cid:8)(cid:12)(cid:5)(cid:4)(cid:13)(cid:7)(cid:3)(cid:8)(cid:10)#

(cid:29)(cid:5)(cid:4)(cid:5)(cid:19)(cid:2)(cid:10)$(cid:8)(cid:18)(cid:5)(cid:6)(cid:6)(cid:12)5(cid:8)C,(cid:12)(cid:6)(cid:5)(cid:10)(cid:3)(cid:6)(cid:19)(cid:2)(cid:8)(cid:1)(cid:28)(cid:12)(cid:6)(cid:12)((cid:20)D, Division of International Medicine,

(cid:14)GG(cid:15)(cid:17)GK
Cornell University Medical College, New York, NY: )(cid:3)(cid:20)(cid:5)(cid:4)(cid:16)(cid:20)(cid:18)(cid:2)(cid:11)(cid:1)(cid:18)(cid:13)(cid:14)(cid:3)(cid:9)(cid:5)(cid:8)(cid:5)(cid:10)(cid:7)(cid:10)(cid:11)(cid:3)(cid:12)
(cid:24)(cid:8)(cid:13)(cid:5)(cid:2)(cid:3)(cid:25)(cid:18)(cid:13)(cid:14)(cid:3)(cid:9)(cid:5)(cid:8)(cid:7)(cid:4)(cid:11)(cid:24)(cid:10)(cid:4)(cid:14)(cid:5)(cid:2)(cid:7)(cid:4)(cid:14)(cid:7)(cid:18)(cid:11)(cid:4)(cid:3)(cid:20)(cid:7)=(cid:11))(cid:3)(cid:20)(cid:5)(cid:4)(cid:16)(cid:20)(cid:18)(cid:2)(cid:11)(cid:24)(cid:25)(cid:7)(cid:6)(cid:5)(cid:29)(cid:7)(cid:3)(cid:20)(cid:3)(cid:9)(cid:23)(cid:11)(cid:3)(cid:12)(cid:11)(cid:1)(cid:18)(cid:13)(cid:14)(cid:3)(cid:9)(cid:5)(cid:8)(cid:7)(cid:4)(cid:11)(cid:24)(cid:10)(cid:4)(cid:14)(cid:5)(cid:2)(cid:7)(cid:4)(cid:14)(cid:7)(cid:18)(cid:11)(cid:4)(cid:3)(cid:20)(cid:7)
(cid:30)(cid:8)(cid:12)(cid:5)(cid:4)(cid:13)(cid:7)(cid:3)(cid:8)(cid:10)(cid:11)(cid:7)(cid:8)(cid:11)(cid:28)(cid:2)(cid:18)(cid:22)(cid:7)(cid:20)(cid:7)(cid:18)(cid:8)(cid:11)’(cid:14)(cid:7)(cid:20)(cid:6)(cid:2)(cid:5)(cid:8)#

(cid:14)GLL(cid:17)G(cid:14)
University Hospital, Munich, Germany

(cid:29)(cid:5)(cid:4)(cid:28)(cid:27)(cid:5)(cid:25)(cid:11)(cid:8)(cid:28)(cid:25)(cid:8)(cid:26)(cid:25)(cid:11)(cid:5)(cid:2)(cid:25)(cid:19)(cid:6)(cid:8),(cid:5)(cid:27)(cid:28)(cid:10)(cid:28)(cid:25)(cid:5), University Hospital of Ulm, and Technical

8(cid:9)/(cid:22))(cid:29)! (cid:30)!(cid:22)#(cid:8)(cid:22)(cid:29)!(cid:26)(cid:31)(cid:26)(cid:31))

 (cid:28)%(cid:6)(cid:12)&(cid:19)(cid:8)(cid:28)(cid:25)(cid:8)(cid:22)(cid:2)(cid:12)%(cid:28)(cid:10)(cid:19)(cid:6)(cid:8),(cid:5)(cid:27)(cid:28)(cid:10)(cid:28)(cid:25)(cid:5)(cid:8)(cid:19)(cid:25)(cid:27)(cid:8)+(cid:20)((cid:28)(cid:5)(cid:25)(cid:5)(cid:8)C 1(cid:22)1,1B+1D, London School of Hygiene and
Tropical Medicine, London, United Kingdom, 1987
,(cid:5)(cid:27)(cid:28)(cid:10)(cid:19)(cid:6)(cid:8),(cid:20)(cid:10)(cid:12)(cid:6)(cid:12)((cid:20), "Centraalbureau voor Schimmelcultures", Baarn, The Netherlands, 1990
!(cid:27)’(cid:19)(cid:25)(cid:10)(cid:5)(cid:4)(cid:8)(cid:28)(cid:25)(cid:8)+(cid:3)&(cid:19)(cid:25)(cid:8))(cid:5)(cid:25)(cid:5)(cid:11)(cid:28)(cid:10)(cid:4), Cornell University Medical College, New York, NY, 1993
8(cid:2)(cid:28)(cid:25)(cid:10)(cid:28)%(cid:6)(cid:5)(cid:4)(cid:8)(cid:12)(cid:23)(cid:8)#%(cid:28)(cid:27)(cid:5)&(cid:28)(cid:12)(cid:6)(cid:12)((cid:20)(cid:8)@(cid:8)(cid:26)(cid:25)(cid:11)(cid:2)(cid:12)(cid:27)(cid:3)(cid:10)(cid:11)(cid:28)(cid:12)(cid:25)(cid:8)(cid:11)(cid:12)(cid:8)(cid:1)(cid:28)(cid:12)(cid:4)(cid:11)(cid:19)(cid:11)(cid:28)(cid:4)(cid:11)(cid:28)(cid:10)(cid:4), Graduate Summer Program in
Epidemiology, Johns Hopkins School of Hygiene and Public Health, Baltimore, MD, 1994
/(cid:3)(cid:13)(cid:17)(cid:4)%(cid:5)(cid:10)(cid:28)(cid:19)(cid:6)(cid:28)(cid:4)(cid:19)(cid:11)(cid:28)(cid:12)(cid:25)(cid:8)*(cid:29)(cid:16)(cid:11)(cid:10)(cid:5)(cid:6)(cid:7)(cid:8)(cid:4)+(cid:3)(cid:15)(cid:5)(cid:6)(cid:5)(cid:17)(cid:3)(cid:21),(cid:8)Bavarian(cid:8)College of Physicians, Munich, Germany,
1997

# (cid:30)(cid:24)!(cid:22)(cid:26)(cid:9)(cid:31)

(cid:14)GLH  (cid:12)(cid:10)(cid:11)(cid:12)(cid:2)(cid:19)(cid:6)(cid:8) (cid:28)(cid:4)(cid:4)(cid:5)(cid:2)(cid:11)(cid:19)(cid:11)(cid:28)(cid:12)(cid:25)(cid:8)C"(cid:29)(cid:18)(cid:9)(cid:8)(cid:18)(cid:11)(cid:4)(cid:16)(cid:29)(cid:11)(cid:20)(cid:18)(cid:16)(cid:6)(cid:5)")
and Tropical Medicine of the University of Munich, Germany
(cid:14)GLI ,1 1, Medical School of the Ludwig-Maximilians-University, Munich, Germany
(cid:14)GHG (cid:1)(cid:19)(cid:10)(cid:10)(cid:19)(cid:6)(cid:19)(cid:3)(cid:2)M(cid:19)(cid:11)(cid:8)#(cid:3)(cid:2)(cid:12)%M(cid:5)(cid:25), European School, Bergen, The Netherlands

, Department of Infectious Diseases

"!(cid:31))(cid:30)!)#(cid:8)/0(cid:26)""/*

 German (mother tongue), English, Dutch, French (fluent)

86

(cid:30)(cid:7)(cid:16)(cid:1)(cid:5)(cid:6)(cid:5)(cid:10)(cid:7)(cid:17)(cid:1)(cid:9)

,(cid:5)&(cid:13)(cid:5)(cid:2)(cid:4)(cid:8)(cid:12)(cid:23)(cid:8)(cid:11)$(cid:5)(cid:8)#(cid:3)(cid:2)(cid:12)%(cid:5)(cid:19)(cid:25)(cid:8))(cid:2)(cid:12)(cid:3)%(cid:8)(cid:12)(cid:25)(cid:8)#(cid:11)$(cid:28)(cid:10)(cid:4)(cid:8)C#)#D

Prof. Catherine LABRUSSE – RIOU
Centre de Recherche en Droit Privé
Université de Paris I Panthéon-Sorbonne
Paris, France

Dr Nicos C. ALIVIZATOS
Professor of Public Law
University of Athens
Athens, Greece

Prof. Göran HERMERÉN, President
Philosopher, Professor of Medical Ethics
Faculty of medicine, Lund University
Sweden

Prof. Rafael CAPURRO
Professor of Information Management and
Information Ethics at Fachhochschule
Stuttgart, Hochschule der Medien
University of Applied Sciences
Germany

Dr. Yvon ENGLERT
Head of Fertility Clinic, Free University of
Brussels (ULB), Professor of Medical
Ethics and Deontology
Brussels, Belgium

Prof. Anne McLAREN
Geneticist, Research Associate at
Wellcome CRC Institute
Cambridge – United Kingdom

Dr. Linda NIELSEN
University of Copenhagen
Faculty of Law, Institute of Legal Science
Copenhagen, Denmark

Dr. Pere PUIGDOMÈNECH ROSELL
Research Professor, Department for
Molecular Genetics, Director of Institut de
Biologia Molecular de Barcelona, CSIC
Barcelona – Spain

Dr. Stefano RODOTA
Professor of Civil Law, University of Rome
Chairman of the Italian Data Protection

Authority, Chairman of the European
Group of the Data Protection Authorities
Roma - Italy

Dr. Günter VIRT
Professor of Theology, Institut of Catholic
Moral Theology
University of Vienna
Vienna - Austria

Dr. Peter WHITTAKER
Biologist, Professor of Biology, Head of the
Biology Department
National University of Ireland
Maynooth - Ireland

/(cid:5)(cid:10)(cid:2)(cid:5)(cid:11)(cid:19)(cid:2)(cid:28)(cid:19)(cid:11)(cid:8)(cid:12)(cid:23)(cid:8)(cid:11)$(cid:5)(cid:8)#)#

Ms Christiane BARDOUX

Ms Joëlle BEZZAN

Ms Anne-Sophie COIFFET

Ms Brigitte GRATTON (stagiaire)

Ms Agueda OLLERO MONTIEL

/%(cid:5)(cid:19)6(cid:5)(cid:2)(cid:4)

Dr. Soren HOLM
Philosopher
Institute of Medecine, Law and Bioethics
University of Manchester - UK

Dr. Monica KONRAD
Doctor
Institute of Commonwealth Studies
School of Advanced Study
University of London – UK

Dr. Reidar K. LEI
Philosopher
M.D., Ph.D
Department of Philosophy
University of Bergen - Norway

89

(cid:21)(cid:26)(cid:11)(cid:21)(cid:5)(cid:31)(cid:5)(cid:20)(cid:3)(cid:25)(cid:29)(cid:5)(cid:8)(cid:13)*

Ms Lieve FRANSEN
Unit Human & Social Development

Mr Juan GARAY AMORES
Unit Health, AIDS and Population

(cid:21)(cid:26)(cid:11)(cid:24)(cid:8)(cid:13)(cid:2)(cid:5)(cid:25)(cid:2)(cid:7)(cid:10)(cid:5)*

Dr Birka LEHMANN
Pharmaceutical Unit

(cid:21)(cid:26)(cid:11)!-(’5(cid:11)> (cid:5)(cid:18)(cid:20)(cid:13)(cid:14)(cid:11)3(cid:11)’(cid:3)(cid:8)(cid:10)(cid:16)(cid:29)(cid:5)(cid:2)(cid:11)(cid:1)(cid:2)(cid:3)(cid:13)(cid:5)(cid:4)(cid:13)(cid:7)(cid:3)(cid:8)?*

Mr Jean-Jacques RATEAU
Advisor on Consumer Information

#(cid:3)(cid:2)(cid:12)%(cid:5)(cid:19)(cid:25)(cid:8)8(cid:19)(cid:2)(cid:6)(cid:28)(cid:19)&(cid:5)(cid:25)(cid:11)

’(cid:3)(cid:29)(cid:29)(cid:7)(cid:13)(cid:13)(cid:5)(cid:5)(cid:11)(cid:3)(cid:8)(cid:11)(cid:21)(cid:5)(cid:31)(cid:5)(cid:20)(cid:3)(cid:25)(cid:29)(cid:5)(cid:8)(cid:13)(cid:11)3(cid:11)’(cid:3)(cid:3)(cid:25)(cid:5)(cid:2)(cid:18)(cid:13)(cid:7)(cid:3)(cid:8)*

Mr. Paul LANNOYE
MEP

Ms Christina PLATZER
Assistant to Ms Karin SCHEELE
MEP

Mevr. Marieke SANDERS-TEN HOLTE
2ème vice-Président
MEP

’(cid:3)(cid:29)(cid:29)(cid:7)(cid:13)(cid:13)(cid:5)(cid:5)(cid:11)(cid:3)(cid:8)(cid:11)(cid:30)(cid:8)(cid:6)(cid:16)(cid:10)(cid:13)(cid:2)(cid:23)8(cid:11)(cid:24);(cid:13)(cid:5)(cid:2)(cid:8)(cid:18)(cid:20)(cid:11)(cid:17)(cid:2)(cid:18)(cid:6)(cid:5)8(cid:11)(cid:15)(cid:5)(cid:10)(cid:5)(cid:18)(cid:2)(cid:4)(cid:14)
(cid:18)(cid:8)(cid:6)(cid:11)(cid:24)(cid:8)(cid:5)(cid:2)(cid:9)(cid:23)*

Ms Erika MANN
MEP

Dr. Elly PLOOIJ – VAN GORSEL
MEP

Mr John PURVIS
MEP
and his Assistant : Ms Sally TAYLOR

Dr MUTHUSWAMY
Senior Deputy Director General
Indian Council of Medical Research
New Delhi – India

Dr. Nicolas MEDA
Head, Department of HIV/AIDS
Centre Muraz/Ministry of Health
Burkina Faso, West Africa

Dr. Hanna NOHYNEK
MD PhD Project coordinator
National Public Health Institute, Dept
Vaccines
Helsinki - Finland

Dr Nadia TORNIEPORTH
M.D., D.T.M. & H.
Director
Clinical Development - Emerging Diseases
GlaxoSmithKline Biologicals s.a. (GSK)
Rixensart - Belgium

#(cid:3)(cid:2)(cid:12)%(cid:5)(cid:19)(cid:25)(cid:8)(cid:24)(cid:12)&&(cid:28)(cid:4)(cid:4)(cid:28)(cid:12)(cid:25)

(cid:21)(cid:26)(cid:11)(cid:15)(cid:5)(cid:10)(cid:5)(cid:18)(cid:2)(cid:4)(cid:14)(cid:11)>(cid:15)(cid:17)(cid:21)?*

Mr. Octavi QUINTANA TRIAS
Director - Health

Mme Laurence CORDIER
Scientific Officer

Dr. Anne DEGRAND-GUILLAUD
Directorate Ageing/Poverty Diseases

Prof. Arnd HOEVELER
Chef d’Unité – Poverty Related Diseases

Ms Anna KARAOGLOU
Principle Administrator

Ms Line Gertrud MATTHIESSEN-GUYADER
Directorate Biotechnology,
Agriculture & food, Strategy & policy

Dr. Barbara RHODE
Head of Unit - Ethics & Science

90

(cid:26)(cid:25)(cid:11)(cid:5)(cid:2)(cid:25)(cid:19)(cid:11)(cid:28)(cid:12)(cid:25)(cid:19)(cid:6)(cid:8)(cid:9)(cid:2)((cid:19)(cid:25)(cid:28)N(cid:19)(cid:11)(cid:28)(cid:12)(cid:25)(cid:4)

Prof. Juhana E. IDANPAAN-HEIKKILA
Secretary-General
Council for International Organizations of
Medical Sciences (CIOMS)
C/o WHO
Geneva, Switzerland

Ms Laurence LWOFF
Council of Europe
Bioethics Division
Strasbourg, France

Ms Zara MERALI
Technical Officer
World Health Organization – WHO
Geneva, Switzerland

(cid:31)(cid:19)(cid:11)(cid:28)(cid:12)(cid:25)(cid:19)(cid:6)(cid:8)(cid:26)(cid:25)(cid:4)(cid:11)(cid:19)(cid:25)(cid:10)(cid:5)(cid:4)

Mr André BEAUCHAMP
Membre de la Commission de l’Ethique de la
Science & de la Technologie
Quebec - Canada

Dr. Matthias BECK
Dr. Med. Dr. Theol.
Institut für Ethik und Recht in des Medizin
Wien, Austria

Prof. Sadek BELOUCIF
Professeur d’Anesthésie-Réanimation
Membre du CCNE
Comité Consultatif National
D’Ethique pour les Sciences de la Vie
et de la Santé
Paris, France

Mr Christian BYK
Secretary General
International Association of Law,
Ethics and Science
Paris, France

Prof. Francesco D’AGOSTINO
Comitato Nazionale per la Bioetica
Roma, Italy

Mme Edith DELEURY
Membre de la Commission de l’Ethique de la
Science & de la Technologie
Quebec - Canada

Mme Diane DUQUET
Membre de la Commission de l’Ethique de la
Science & de la Technologie
Quebec - Canada

M. Jean-Claude MILMEISTER
Chargé d’Etudes de la C.N.E.
Commission Nationale d’Ethique – C.N.E.
Luxembourg – Grand-Duché-de-Luxembourg

Mme Michèle JEAN
Membre de la Commission de l’Ethique de la
Science & de la Technologie
Quebec - Canada

M. Jean-Philippe LAVOIE
Conseiller en Ethique
Ministère de la Recherche, de la Science
Et de la Technologie
Quebec - Canada

Mr Harald SCHMIDT
Assistant Director
Nuffield Council on Bioethics
London - UK

Prof. Maxime SELIGMANN
Professeur Emérite – Membre du CCNE
Comité Consultatif National d’Ethique pour
Les Sciences de la Vie et de la Santé
Paris, France

Prof. Daniel TARSCHYS
National Council on Medical Ethics
Ministry of Health & Social Affairs
Stockholm – Sweden

(cid:29)(cid:5)%(cid:2)(cid:5)(cid:4)(cid:5)(cid:25)(cid:11)(cid:19)(cid:11)(cid:28)’(cid:5)(cid:4)(cid:8)(cid:12)(cid:23)(cid:8)(cid:26)(cid:25)(cid:27)(cid:3)(cid:4)(cid:11)(cid:2)(cid:20)

Ms Rebecca DOWNING
Consultant
Weber Shandwick – Adamson
Brussels, Belgium

91

Mr Jean-Pascal DUCRET
Directeur Impact Malaria
Sanoti - Synthelabo
Gentilly, France

Mr Thomas GALLACHER
Member of IFPMA Ethics Group
International Federation of Pharmaceutical
Manufacturers Associations
Global Head, Medical Policy
& Standards Dept
GlaxoSmithKline R & D
Middlesex, UK

Mr Benjamin GANNON
EU Affairs Advisor
GlaxoSmithKline
Brussels, Belgium

Mr Joachim HOMBACH
Director Government Affairs
GSK Biologicals
Rixensart, Belgium

Mrs Magdalena RODRIGUEZ DE AZERO
Manager
European Vaccines Manufacturers
Brussels, Belgium

Dr. Henrietta UKWU
Member of IFPMA Ethics Group
International Federation of Pharmaceutical
Manufacturers Associations
Pensylvania, USA

(cid:29)(cid:5)%(cid:2)(cid:5)(cid:4)(cid:5)(cid:25)(cid:11)(cid:19)(cid:11)(cid:28)’(cid:5)(cid:4)(cid:8)(cid:12)(cid:23)(cid:8)(cid:19)(cid:4)(cid:4)(cid:12)(cid:10)(cid:28)(cid:19)(cid:11)(cid:28)(cid:12)(cid:25)(cid:4)

Mr Georges BINAME
Président
Association belge de Bioéthique
Brussels - Belgium

Dr Pat FAST
Medical Director
International AIDS Vaccine Initiative
New York, U.S.A.

Dr. Georges LIENARD
Secretary General
European Humanist Federation – EHF
Brussels, Belgium

Mr Adrian C. VAN BELLEN
Board Member
Dutch Genetic Alliance of Parent / Patient
Organizations – VSOP
Bennebroek – The Netherlands

Dr Frans VAN DEN BOOM
European Director
International AIDS Vaccine Initiative
Amsterdam, The Netherlands

Ms Kamau WANJIKU
STOP AIDS ALLIANCE
Brussels, Belgium

(cid:29)(cid:5)%(cid:2)(cid:5)(cid:4)(cid:5)(cid:25)(cid:11)(cid:19)(cid:11)(cid:28)’(cid:5)(cid:4)(cid:8)(cid:12)(cid:23)(cid:8)(cid:2)(cid:5)(cid:6)(cid:28)((cid:28)(cid:12)(cid:25)

Rev. P. Edouard BONE
COMECE – Commission of the Bishops’
Conferences of the European Community
Brussels, Belgium

Mgr. Athanase CHATZOPOULOS
Evêque d’Achate
Représentation de l’Eglise de Grèce
Auprès de l’Union Européenne
Brussels, Belgium

Mr Albert GUIGUI
Conférence des Rabbins Européens
Brussels - Belgium

Pr. DETILLEUX
CPME Ethics Subcommittee President
Standing Committee of European Doctors
Brussels, Belgium

Mr Faustino SAINZ-MUNOZ
Nonce Apostolique auprès des CE
298 Avenue Brugmann
B – 1180 Bruxelles

92

Ms Sujatha RAMAN
Institute for the Study of Genetics, Biorisks
And Society – IGBIS
Nottingham – United Kingdom

Dr. Monique VERON
Médecin du Travail - Coordonnateur National
Centre National de Recherches Scientifiques
et A.P.  – H.P.
CNRS
Paris, France

Dr. Heather WIDDOWS
Centre for the Study of Global Ethics
The University of Birmingham
Birmingham, United Kingdom

Ms Katharina SCHAUER
Secretariat of the COMECE
Commission of the Bishops’
Conferences of the European Community
Brussels, Belgium

Ms Monica LÜCKE
EVANGELISCHE KIRCHE in Deutschland
Brussels - Belgium

!(cid:10)(cid:19)(cid:27)(cid:5)&(cid:28)(cid:10)(cid:4)

Professor Donna DICKENSON
Centre for the Study of Global Ethics
The University of Birmingham
Birmingham, United Kingdom

Prof. Michel DUPUIS
Responsable de l’Unité d’Ethique Biomédicale
Faculté de Médecine UCL
Brussels, Belgium

Prof. Guy LEBEER
Université Libre de Bruxelles – ULB
Brussels, Belgium

Prof. Freddy MORTIER
University of Ghent
Ghent, Belgium

Prof. Didier MOULIN
Faculty of Medecine
Université Catholique de Louvain
Cliniques Universitaires Saint Luc
Brussels , Belgium

Dr. Claude Michèle POISSONNET
Médecin de Prévention
Coordinateur de la Préfecture de Police de Paris
Service de Médecine de Prévention
Hopital des Gardiens de la Paix
Paris, France

Prof. John Alexander RAEBURN
University of Nottingham
Centre for Medical Genetics
Nottingham City Hospital NHS Trust
Nottingham, United Kingdom

93

(cid:26)(cid:3)(cid:6)(cid:16)(cid:3)(cid:1)(cid:7)(cid:16)(cid:5)(cid:7)(cid:1)(cid:4)(cid:11)(cid:12)(cid:4)(cid:1)(cid:2)(cid:3)(cid:4)(cid:24)(cid:25)(cid:24)

(cid:1)(cid:2)(cid:3)(cid:4)(cid:2)(cid:5)(cid:6)(cid:4)(cid:7)(cid:6)(cid:5)(cid:8)(cid:9)(cid:10)(cid:8)(cid:5)(cid:11)(cid:2)(cid:8)(cid:12)(cid:13)(cid:4)(cid:9)(cid:14)(cid:2)(cid:6)(cid:15)(cid:8)(cid:16)(cid:4)(cid:9)(cid:13)(cid:14)(cid:8)(cid:9)(cid:15)(cid:8)(cid:12)(cid:5)(cid:11)(cid:7)(cid:3)(cid:17)

(cid:18)(cid:17)(cid:8)(cid:19)(cid:11)(cid:4)(cid:7)(cid:17)(cid:5)(cid:7)(cid:6)(cid:15)(cid:2)(cid:8)(cid:20)(cid:6)(cid:4)(cid:21)(cid:9)(cid:13)(cid:22)

(cid:1)(cid:2)(cid:3)(cid:4)(cid:5)(cid:6)(cid:7)(cid:5)(cid:8)(cid:9)(cid:10)(cid:5)(cid:7)(cid:5)(cid:7)(cid:11)(cid:12)(cid:5)(cid:13)(cid:12)(cid:5)(cid:13)(cid:14)
(cid:15)(cid:16)(cid:17)(cid:4)(cid:5)(cid:6)(cid:7)(cid:5)(cid:8)(cid:9)(cid:10)(cid:5)(cid:7)(cid:5)(cid:7)(cid:11)(cid:11)(cid:5)(cid:13)(cid:12)(cid:5)(cid:18)(cid:12)
(cid:19)(cid:20)(cid:21)(cid:16)(cid:22)(cid:3)(cid:4)(cid:5)christiane.bardoux@cec.eu.int

(cid:18)(cid:17)(cid:8)(cid:23)(cid:9)(cid:2)(cid:24)(cid:24)(cid:2)(cid:8)(cid:20)(cid:2)(cid:25)(cid:25)(cid:6)(cid:15)

(cid:1)(cid:2)(cid:3)(cid:4)(cid:5)(cid:6)(cid:7)(cid:5)(cid:8)(cid:9)(cid:10)(cid:5)(cid:7)(cid:5)(cid:7)(cid:11)(cid:18)(cid:5)(cid:23)(cid:11)(cid:5)(cid:13)(cid:24)
(cid:15)(cid:16)(cid:17)(cid:4)(cid:5)(cid:6)(cid:7)(cid:5)(cid:8)(cid:9)(cid:10)(cid:5)(cid:7)(cid:5)(cid:7)(cid:11)(cid:11)(cid:5)(cid:13)(cid:12)(cid:5)(cid:18)(cid:12)
(cid:19)(cid:20)(cid:21)(cid:16)(cid:22)(cid:3)(cid:4)(cid:5)joelle.bezzan@cec.eu.int

(cid:18)(cid:17)(cid:8)(cid:18)(cid:6)(cid:4)(cid:7)(cid:2)(cid:8)(cid:19)(cid:11)(cid:7)(cid:4)(cid:9)(cid:24)

(cid:1)(cid:2)(cid:3)(cid:4)(cid:5)(cid:6)(cid:7)(cid:5)(cid:8)(cid:9)(cid:10)(cid:5)(cid:7)(cid:5)(cid:7)(cid:11)(cid:18)(cid:5)(cid:7)(cid:12)(cid:5)(cid:24)(cid:13)
(cid:15)(cid:16)(cid:17)(cid:4)(cid:5)(cid:6)(cid:7)(cid:5)(cid:8)(cid:9)(cid:10)(cid:5)(cid:7)(cid:5)(cid:7)(cid:11)(cid:11)(cid:5)(cid:13)(cid:12)(cid:5)(cid:18)(cid:12)
(cid:19)(cid:20)(cid:21)(cid:16)(cid:22)(cid:3)(cid:4)(cid:5)marie.chirol@cec.eu.int

(cid:18)(cid:17)(cid:8)(cid:26)(cid:6)(cid:5)(cid:4)(cid:7)(cid:3)(cid:7)(cid:6)(cid:8)(cid:18)(cid:9)(cid:27)(cid:27)(cid:2)(cid:15)(cid:17)

(cid:1)(cid:2)(cid:3)(cid:4)(cid:5)(cid:6)(cid:7)(cid:5)(cid:8)(cid:9)(cid:10)(cid:5)(cid:7)(cid:5)(cid:7)(cid:11)(cid:18)(cid:5)(cid:24)(cid:13)(cid:5)(cid:14)(cid:13)
(cid:15)(cid:16)(cid:17)(cid:4)(cid:5)(cid:6)(cid:7)(cid:5)(cid:8)(cid:9)(cid:10)(cid:5)(cid:7)(cid:5)(cid:7)(cid:11)(cid:11)(cid:5)(cid:13)(cid:12)(cid:5)(cid:18)(cid:12)
(cid:19)(cid:20)(cid:21)(cid:16)(cid:22)(cid:3)(cid:4)(cid:5)patricia@mommens@cec.eu.int

(cid:18)(cid:6)(cid:7)(cid:24)(cid:7)(cid:15)(cid:28)(cid:8)(cid:6)(cid:21)(cid:21)(cid:4)(cid:2)(cid:17)(cid:17)

(cid:19)(cid:25)(cid:26)(cid:27)(cid:28)(cid:2)(cid:16)(cid:29)(cid:5)(cid:30)(cid:27)(cid:21)(cid:21)(cid:22)(cid:31)(cid:31)(cid:22)(cid:27)(cid:29)
 (cid:26)(cid:27)(cid:25)(cid:28)(cid:5)(cid:27)!(cid:5)"(cid:27)(cid:3)(cid:22)#$(cid:5)%&’(cid:22)(cid:31)(cid:2)(cid:26)(cid:31)
()(cid:19)*(cid:5)(cid:23)(cid:9)+(cid:23)(cid:7)(cid:24)
((cid:5),(cid:5)(cid:23)(cid:9)(cid:13)(cid:11)(cid:5),(cid:5)((cid:26)(cid:25)(cid:31)(cid:31)(cid:2)(cid:3)(cid:31)(cid:5)(cid:20)(cid:5)((cid:2)(cid:3)-(cid:22)(cid:25)(cid:21)

(cid:29)(cid:10)(cid:10)(cid:7)(cid:3)(cid:2)

(cid:19)(cid:25)(cid:26)(cid:27)(cid:28)(cid:2)(cid:16)(cid:29)(cid:5)(cid:30)(cid:27)(cid:21)(cid:21)(cid:22)(cid:31)(cid:31)(cid:22)(cid:27)(cid:29)
%’(cid:2)(cid:29)(cid:25)(cid:2)(cid:5)&.%(cid:25)&(cid:2)(cid:26)-/(cid:2)(cid:21)(cid:5)(cid:13)(cid:12)
((cid:5),(cid:5)(cid:23)(cid:9)(cid:13)(cid:11)(cid:5),(cid:5)((cid:26)(cid:25)(cid:31)(cid:31)(cid:2)(cid:3)(cid:31)(cid:5)(cid:20)(cid:5)((cid:2)(cid:3)-(cid:22)(cid:25)(cid:21)

(cid:30)(cid:2)(cid:31)(cid:8)(cid:17)(cid:7)(cid:5)(cid:2)

http://europa.eu.int/comm/european_group_ethics

97

European Commission

(cid:1)(cid:2)(cid:3)(cid:4)(cid:3)(cid:5)(cid:2)(cid:6)(cid:7)(cid:8)(cid:9)(cid:4)(cid:8)(cid:10)(cid:11)(cid:3)(cid:7)(cid:5)(cid:10)(cid:4)(cid:12)(cid:13)(cid:4)(cid:14)(cid:6)(cid:12)(cid:15)(cid:3)(cid:16)(cid:6)(cid:7)(cid:8)(cid:9)(cid:4)(cid:17)(cid:3)(cid:10)(cid:3)(cid:8)(cid:17)(cid:7)(cid:2)(cid:4)(cid:6)(cid:18)(cid:4)(cid:16)(cid:3)(cid:19)(cid:3)(cid:9)(cid:12)(cid:11)(cid:6)(cid:18)(cid:20)(cid:4)(cid:7)(cid:12)(cid:21)(cid:18)(cid:5)(cid:17)(cid:6)(cid:3)(cid:10)

(cid:22)(cid:17)(cid:12)(cid:7)(cid:3)(cid:3)(cid:16)(cid:6)(cid:18)(cid:20)(cid:10)(cid:4)(cid:12)(cid:13)(cid:4)(cid:5)(cid:2)(cid:3)(cid:4)(cid:23)(cid:12)(cid:21)(cid:18)(cid:16)(cid:4)(cid:1)(cid:8)(cid:14)(cid:9)(cid:3)(cid:4)(cid:24)(cid:3)(cid:14)(cid:8)(cid:5)(cid:3)

Luxembourg: Office for Official Publications of the European Communities

2003 — vi, 97 pp. — 21 x 29.7 cm

ISBN 92-894-5064-9

